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Detection and Management of Colorectal Neoplasia in the 
NHS Bowel Cancer Screening Programme 
 
Abstract 
Background 
Screening for colorectal cancer aims to reduce mortality by detecting cancer at an 
earlier stage. The NHS Bowel Cancer Screening Programme (BCSP) offers faecal 
occult blood testing (FOBt) followed by colonoscopy for those with a positive FOBt. 
This thesis examines the detection and management of colorectal neoplasia in the 
BCSP. 
 
Aims and Methods 
1. Explore adenoma detection rate (ADR) as a measure of colonoscopic 
performance and examine which factors influence adenoma detection rate by 
analysing data gathered from the BCSP. 
2. Describe the findings at 12 month surveillance colonoscopy in high risk 
individuals (according to adenoma surveillance guidelines in the BCSP) and 
explore factors which may predict findings at surveillance. 
3. Describe the management of large sessile colonic polyps (LSCP) in the 
BCSP and explore factors which influence the choice of treatment modality 
(surgical or endoscopic) and subsequent outcome. A national study of LSCP 
management was undertaken. 
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Results 
ADR correlated positively with other performance indicators including withdrawal 
time and caecal intubation rate.  
The yield of advanced colonic neoplasia (ACN) at surveillance colonoscopy was 
6.6%. The presence of right sided or villous lesions at baseline may predict the 
presence of ACN at surveillance.  
121/557 LSCP (21.7%) were managed surgically, 436/557 (78.3%) were managed 
endoscopically. Increasing size was associated with failure of endoscopic therapy 
and presence of cancer in the resection specimen. 
  
Conclusion 
ADR is a satisfactory indicator of colonoscopic performance. Measures of the total 
number of adenomas detected are likely to be more discriminatory indicators of 
performance. 
The optimal mean withdrawal time for adenoma detection was 10 minutes. Longer 
mean withdrawal times were not associated with increasing adenoma detection. 
12 month surveillance for high risk individuals is justified by the yield of advanced 
lesions. 
Larger or right sided LSCP were more likely to be managed surgically. Safe and 
effective management of LSCP can be delivered by a national screening programme. 
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General Introduction 
 
Colorectal cancer is the second most common cause of cancer related death in the 
United Kingdom causing around 16,000 deaths each year (Office for National 
Statistics, 2010). Despite advances in diagnosis and management leading to a 
twofold increase in five year survival over the last 30 years, the incidence of 
colorectal cancer has stayed much the same (Office for National Statistics, 2010).  
Colorectal neoplasia is an umbrella term including both colorectal cancer and 
colorectal adenomas. Colorectal adenomas are the slow-growing precursor lesion to 
cancer. This natural history, with a long premalignant phase, offers the opportunity 
for pre-symptomatic detection and removal of adenomas to radically alter the natural 
history of the disease. The seminal National Polypectomy Study (Winawer, 1993) 
provided proof of concept that adenoma detection and removal could reduce the 
incidence of colorectal cancer.  
Once an adenoma has progressed to cancer, the earlier the cancer is detected and 
treated, the better the outcome for the patient. There is a considerable survival 
advantage with earlier stage of disease at diagnosis (National Cancer Intelligence 
Network, 2009). Over the last 30 years there has been considerable interest in 
exploiting the natural history of colorectal cancer and the favourable outcome of 
earlier diagnosis to develop a screening strategy that could reduce the incidence and 
mortality of this common disease.  
Whilst colonoscopy is the gold standard test for detection of colorectal neoplasia, it 
is time-consuming, expensive, demanding on resources and potentially harmful to 
the individual, limiting the appropriateness of colonoscopy as a population-wide 
screening test.  
Three large randomised control trials (Mandel 1993, Hardcastle 1996, Kronborg 
1996) conducted in the United States, the United Kingdom and Denmark 
demonstrated the efficacy of faecal occult blood testing (FOBt) to reduce mortality 
from colorectal cancer. FOBt aims to detect microscopic amounts of blood which 
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may be present in the faeces of individuals with advanced colorectal adenomas or 
cancer. As a test, it is much safer, cheaper, more acceptable and less resource 
intensive than colonoscopy. This is offset by much reduced sensitivity and 
specificity. The use of FOBt as a mass screening tool however has been widely 
accepted. A large scale pilot study of FOBt for the general population in the United 
Kingdom (UK Colorectal Cancer Screening Group, 2004) demonstrated the 
feasibility for such a mass screening programme to be introduced. 
Two years later, the English National Health Service (NHS) Bowel Cancer 
Screening Programme (BCSP) was launched. This is only the third mass screening 
programme for cancer in England following the breast and cervical screening 
programmes and the first programme to include men. The screening strategy 
employed by the BCSP draws on the evidence available from the three large 
randomised control trials of FOBt and the national pilot by offering biennial guaiac-
based faecal occult blood testing to all adults in England aged 60 to 69 years of age. 
The upper age limit was extended to 74 years in 2010. Individuals with a positive 
FOBt are offered colonoscopy.  
The aim of the screening programme is to offer a test which identifies a subgroup of 
the target population at a higher risk of having colorectal neoplasia. The relatively 
scarce resources for colonoscopy can then be targeted towards this higher risk group. 
The main aim of colonoscopy within the screening programme is to detect cancer at 
an earlier stage, thus enabling the individual to receive earlier definitive treatment. A 
secondary aim of colonoscopy is to detect and remove adenomas, potentially 
reducing the risk of an individual subsequently getting colorectal cancer. 
This thesis concerns itself with the role of colonoscopy within the English Bowel 
Cancer Screening Programme. Its aims, outlined below, evolved in response to the 
needs of the screening programme to understand more about the detection and 
management of colorectal neoplasia. The gaps in knowledge of how best to assess 
the quality of colonoscopy within a screening programme, in particular whether 
adenoma detection rate is a satisfactory performance indicator and what factors 
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influence adenoma detection rate, gave rise to the first chapter of this thesis entitled 
‘Detection of neoplasia in the NHS Bowel Cancer Screening Programme’. 
The need to understand the outcome of surveillance colonoscopy in individuals 
found to have multiple or large colorectal adenomas during screening gave rise to 
the first part of the second chapter of this thesis, entitled ‘Management of colorectal 
neoplasia in the Bowel Cancer Screening Programme’.  The second part of this 
chapter examines how large colonic polyps are managed, necessitated by the 
absence of existing data on current clinical practice in England and the lack of clear 
evidence supporting either surgical or endoscopic management of such  lesions. 
The specific aims of each chapter are outlined below: 
 Chapter 3- Detection of colorectal neoplasia in the BCSP 
o Examine, using univariable and multivariable analysis, the 
relationship between adenoma detection rate (ADR) and other 
performance indicators (withdrawal time, intubation rate, rectal 
retroversion, buscopan use, sedation use, and adverse event rate). 
o The central hypothesis is that adenoma detection rate, if it is to be 
widely used as a performance indicator for colonoscopy in the 
screening programme, should correlate with other measures of 
colonoscopic performance. 
o Individual factors that may affect adenoma detection rate such as age, 
gender, body mass index, aspirin use and socioeconomic status will 
be considered. 
o This work will contribute towards the development of colonoscopy 
quality indicators for the Bowel Cancer Screening Programme. 
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 Chapter 4.1- Management of Colorectal Neoplasia in the BCSP 
o 12 month surveillance colonoscopy for high risk  individuals in 
the BCSP 
 The number and type of adenomas found at colonoscopy 
affect how often the patient should be followed up. A patient 
with  5 or more adenomas or 3 or more adenomas of which 
one is at least 10mm in size  is more likely to have a 
recurrence of polyps in the future and more likely to get 
bowel cancer. It is probably important therefore, to survey 
these patients more closely and perform surveillance 
colonoscopy at appropriate intervals. Current guidelines 
recommend surveillance colonoscopy at one year for patients 
who are at high risk of getting further adenomas. 
 In this section of the thesis the findings at colonoscopy of 
patients who have had both screening colonoscopy and one 
year surveillance colonoscopy will be compared. The work in 
this section will look at the factors that predict adenoma 
recurrence at one year. Univariable and multivariable analysis 
will be used to examine the factors which may predict 
adenoma recurrence at one year. 
 The hypothesis tested in this section is ’12 month surveillance 
colonoscopy in patients with ‘high-risk’ findings at index 
colonoscopy is not worthwhile’. 
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o Chapter 4.2- Management of large sessile or flat colonic polyps in 
the BCSP 
 Large colonic adenomas (≥20mm in size) comprise a 
subgroup of polyps for which the best approach to 
management is not clear. 
 A number of therapeutic options exist. These include:  
 Surgical resection- Which incurs the risks associated 
with abdominal surgery.  
 Endoscopic resection- Using relatively new techniques 
such as endoscopic mucosal resection. 
 Initial work will quantify the incidence of these polyps. The 
subsequent management of each polyp will be reviewed to 
give an insight into the use of current management strategies. 
 The main hypothesis for this section is ‘endoscopic treatment 
is as effective as surgical treatment for the management of 
large colonic polyps’. 
 
The thesis is presented as a series of papers, which collectively address the aims 
outlined above.  An initial methodology section will describe the Bowel Cancer 
Screening System (BCSS), the centralised database generated by collecting data 
from all individuals undergoing colonoscopy in the BCSP. Data quality and 
completeness in the BCSS will be reviewed and the process of defining and deriving 
colonoscopy quality indicators from the BCSS will be described. 
Subsequently, five papers will be presented, each with a brief introduction and 
discussion. A general discussion at the end of the thesis will summarise the findings 
as well as exploring other questions raised by this work. 
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General Methodology 
 
1.1.0- The NHS Bowel Cancer Screening System 
The NHS Bowel Cancer Screening Programme gathers data on all patients entering 
the programme. Further data on patients undergoing colonoscopy are 
contemporaneously uploaded by Specialist Screening Practitioners and 
administrative staff at screening centres around England as the patient passes 
through the screening pathway. The data are entered via a graphical user interface 
(known as the Bowel Cancer Screening System-BCSS) onto an Oracle database. 
Data can be exported to an SQL server to allow specific queries to be written.  
The benefits of the database are that the data are prospectively gathered and 
comprehensive. A wide range of parameters are recorded including demographics 
(age, sex, postcode of address at time of entry into screening programme, relevant 
medication history, weight and height), faecal occult blood test results, colonoscopy 
results, histology outcomes and subsequent management. 
Access to the national database is restricted. Dr M. Rutter is chair of the National 
BCSP Service Evaluation Group. The body of work contained within this thesis has 
been sanctioned by the evaluation group. As clinical supervisor for this MD he 
facilitated access to the National Database. Assistance in accessing the database was 
provided by the NHS BCSP National Office. Requests for specific datasets were 
made to the National Office who provided the data in a Microsoft Excel spreadsheet. 
The process of extracting the data for the purposes of this thesis from the main 
database was undertaken by myself in conjunction with Claire Nickerson (Data 
analyst, NHS Cancer Screening Programme). This involved defining the specific 
data that was required and writing the ‘query’ to the database to ensure the correct 
data was obtained. Additional assistance with this process was provided by data 
analysts from NHS Connecting for Health, based in Exeter.  
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The definitions and specifications of the colonoscopy quality indicators which were 
calculated are shown in Appendix A.  
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1.1.1- Data completeness and quality 
During the data collection phase of this thesis over 4 million people underwent 
screening and over 30000 colonoscopies were performed. The completeness of the 
data captured by the NHS Bowel Cancer Screening Programme Database was not 
previously known; initial experience suggested that the relevant data fields to this 
thesis were well populated. 
An initial exercise to assess the completeness of the dataset of adenomas detected at 
screening and 12 month surveillance colonoscopy showed that data fields completed 
at the time of the endoscopy (e.g. size and location of polyp) were well populated 
(97-100% complete). However, data requiring input onto the database after the 
procedure (such as pathology details) were not as complete (82-93.5% complete).  
The main potential gap in the data is in the `histological grade` field for each polyp. 
The data in this field are not central to the planned analyses but will be important 
when looking at factors which predict adenoma recurrence. 
Table 1 shows the data completeness for 2201 polyps which were found in 502 
patients who underwent screening colonoscopy between August 2007 and March 
2009. 
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Incomplete data (number 
of empty fields out of 
2201 fields) 
Proportion of incomplete 
data fields 
Polyp type (e.g. adenoma, 
metaplastic) 
68 3% 
Polyp size (endoscopic estimation) 92 4% 
38 polyps (2.4%) have neither 
pathological or endoscopically 
assessed size field completed 
Polyp size (pathologic estimation 262 12% 
Polyp Location  0 0% 
Histological grade (e.g. HGD, 
LGD) 
194 9% 
Table 1 - Data completeness for polyps detected at colonoscopy during the screening episode 
 
Table 2 shows the data completeness for 849 polyps found in 502 patients 
undergoing surveillance colonoscopy between August 2007 and March 2009 
 Incomplete data (number of 
empty fields out of 502 
fields) 
Proportion of 
incomplete data fields 
Polyp type (e.g. adenoma, 
metaplastic) 
55 6.5% 
Polyp size (endoscopic 
estimation) 
22 2.6% 
Polyp size (pathologic 
estimation 
175 20.6% 
12 polyps ((1.4%) have neither 
size field completed 
Polyp Location 0 0% 
Histological grade (e.g. HGD, 
LGD) 
150 18% 
Table 2- Data completeness for polyps detected at surveillance colonoscopy 
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The tables above suggest high levels of data completeness. However, these data 
were generated by requesting details of patients who had adenomas from the 
national database. If adenomas detected at colonoscopy are not recorded onto the 
database at a local level, they will not appear in the database and thus patients with 
adenomas may be missed from this analysis. 
A further exercise was therefore performed to assess the quality (accuracy) and 
completeness of the data in the BCSP database. This was undertaken in November 
2009 and involved comparing the data relating to 25 patients held in BCSP database 
with data obtained from their original pathology and endoscopy reports. A 
spreadsheet containing details of all colonoscopies performed in a certain period in 
the Tees BCSP area and all adenomas found in the same period was generated from 
the Bowel Cancer Screening System central database. 25 patients were randomly 
identified from this spreadsheet, which contained the details of patients who had 
undergone colonoscopy in the Tees BCSP centre between March 2007 and March 
2009. 
Details of polyps recorded on the spreadsheet (which were downloaded from the 
BCSS database) were compared with details of polyps obtained from the patients` 
paper records held in the Tees BCSP screening centre office. These paper records 
contain the colonoscopy and pathology reports. The specific fields which were 
compared were: 
 Number of adenomas 
 Site of adenoma 
 Size of adenoma 
 Morphology of adenoma 
 Histological type of adenoma 
 Dysplasia grade of adenoma 
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18 adenomas were recorded in 25 patients (according to the paper records) and 20 
adenomas in 24 patients according to the database. The adenoma detection rate 
(number of patients with one or more adenomas / total number of patients 
undergoing colonoscopy) was 48% according to the paper records and 56% 
according to the database. There is only data missing from one polyp record (size of 
polyp 12 from the database, see table 2). 
The adenoma count for each patient was the same in the database as in the paper 
records in 23 of 25 patients (92%). In the 2 patients in whom there was a disparity, 
no polyps were documented in the paper records whilst one polyp was recorded in 
the database. Both of the lesions recorded in the database but not in the paper 
records were small tubular or tubulovillous adenomas (<1cm) with low grade 
dysplasia. They were the only abnormality found in each patient and would not have 
altered clinical management. 
There were discrepancies in recording of site in 6 of 24 lesions (25%). The majority 
of these were minor (sigmoid colon vs. descending colon). One adenoma was 
recorded more than 1 segment apart in the database compared to the paper records 
(polyps 12 in table 2). There were discrepancies in recording of size between the 
database and paper records for 6 of 23 adenomas (26%). The mean difference was 
3.3mm. The discrepancies would not have altered the management of any of the 
patients. 
Morphological type of polyp (sessile vs. pedunculated), was consistently and equally 
reported in the database and paper records. Histological type differed in 2 of 24 
polyps. One polyp was recorded as a tubulovillous adenoma in the paper records and 
a tubular adenoma in the database. Another was recorded as a tubular adenoma in 
the database but as normal colonic mucosa in the paper records. Neither of these 
discrepancies would have altered the management of the patient. 
Dysplastic grade was recorded differently in none of the 23 adenomas 
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6 advanced colonic neoplasms (>1cm or high grade dysplasia) were recorded. Only 
1 of these would be incorrectly classified as a non-advanced colonic neoplasm by 
data from the database. 
In conclusion, in this sample there was good completeness of data in the BCSP 
database (99.5% complete). 
There are minor discrepancies in recording of polyp details between the two sources. 
However, none of these would have led to the misclassification of a patient into 
normal, low, intermediate or high risk groups based on the BSG guidelines for 
adenoma surveillance (Atkin  2002). This suggests good quality of data in the BCSP 
database.  
The disparity between adenoma detection rates was attributed to double counting of 
adenomas in the BCSS dataset due to duplicate entries for the same adenoma or 
counting of the same adenoma at more than one procedure. This problem was 
eliminated in further work by excluding duplicate lesions form calculations and by 
only analysing the first colonoscopic procedure in each screening round to avoid 
double counting of the same lesion. 
A weakness of the evaluation of data completeness and accuracy described above is 
the limited size of the study and restriction to one screening centre. Increasing the 
number of records validated and number of screening centres included may have 
increased the reliability of the data validation process. 
Limiting the exercise to one centre may have introduced bias to the assessment. The 
centre was known to be a well organised unit and an early-adopter of the BCSP. 
Data quality findings at this centre could potentially be at odds with a less well 
organised unit. These limitations and their implications are further discussed in 
section 5.9.1.  
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1.1.2- Ethical considerations 
The work involved in this thesis is evaluation of the NHS Bowel Cancer Screening 
Programme. As such it is termed ‘Service Evaluation’ and prospective ethical 
approval is not necessary. Written confirmation of this has been obtained from the 
Director of the Bowel Cancer Screening Programme. As such there is no allocation 
to intervention groups or randomisation planned. Similar work within the field of 
breast cancer screening over the past 20 years has not necessitated prospective 
ethical approval. The use of NHS BCSP data in this thesis has been sanctioned by 
the director of the NHS Screening Programmes. 
Confirmation of the situation regarding ethical approval of ‘service evaluation’ has 
been sought from the Chair of an NHS Research Ethics Committee who has 
approved this work as Service Evaluation. (Appendix B). The Bowel Cancer 
Screening Programme has PIAG (Patient Information Advisory Group) approval for 
use of data for service evaluation purposes. 
The use of sensitive data (such as patient postcode) contained in the Bowel Cancer 
Screening Programme database was sanctioned by the Caldicott Guardian for the 
Bowel Cancer Screening Programme National Office. Compliance with the PIAG 
approvals held by the Bowel Cancer Screening Programme was observed. 
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Literature Review 
 
2.1.0- Strategy for Literature Review 
The aim of this literature review is to: 
1. Provide an overview of the demographics and natural history of colorectal 
cancer based on evidence contained in relevant articles published in the 
medical literature. This overview will not be an exhaustive review of all 
aspects of colorectal cancer but will focus on aspects pertaining to the basis 
for screening for colorectal cancer and the evidence supporting population 
based screening programmes. 
2. Critically review the available literature regarding the following specific 
aspects of colorectal cancer screening: 
a. Adenoma detection rate and other performance indicators of 
colonoscopy. 
b. Surveillance colonoscopy within a screening programme. 
c. Management of large (>2cm) colonic polyps. 
This section of the literature review will be a comprehensive review of the available 
evidence. It will provide a perspective on the current opinions on the topics outlined 
above and identify areas in which ongoing research for this thesis will contribute. 
The literature review was performed using Pubmed for relevant publications 
between 1980 and 2009 (http://www.ncbi.nlm.nih.gov/pubmed). This time period 
was chosen in order to reflect modern clinical practice, articles from earlier than 
1980 were included if deemed to be relevant to the subject and not outdated. The 
following MeSH terms were used: Colonic polyps, colonoscopy, colorectal 
neoplasms, early detection of cancer. These terms were selected from the United 
States National Library of Medicine's controlled vocabulary used for indexing 
articles for MEDLINE/PubMed. MeSH terminology provides a consistent way to 
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retrieve information that may use different terminology for the same concepts. These 
concepts were selected to pertain to the aims of the literature review outlined above. 
Abstracts were reviewed and articles were excluded if they were in a language other 
than English or were not of sufficient relevance to the stated aims (see above) of the 
literature review. Full papers were then obtained. The reference lists of selected 
articles were scrutinised for additional papers (not restricted by year of publication).  
Due to the wide range of topics covered by this literature review, a single quality 
assessment method or data extraction process could not be applied to all papers. 
Where appropriate, the quality of individual studies was graded using the Centre for 
Evidence Based Medicine system below (Oxford Centre for Evidence Based 
Medicine, 2009): 
Ia: systematic review or meta-analysis of randomised controlled trials 
Ib: at least one randomised controlled trial 
IIa: at least one well-designed controlled study without randomisation 
IIb: at least one well-designed quasi-experimental study, such as a cohort study 
III: well-designed non-experimental descriptive studies, such as comparative studies, 
correlation studies, case–control studies and case series 
IV: expert committee reports, opinions and/or clinical experience of respected 
authorities. 
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2.1.1- Background 
 
Colorectal Cancer 
Colorectal cancer is the third most common cancer in the UK overall (Cancer 
Research UK 2009). In women it is the second most common cancer after breast 
cancer and is diagnosed in around 17,000 women each year. In men, it is the third 
most common cancer after prostate and lung cancer and is diagnosed in around 
20,400 men each year (Office for National Statistics 2009, Welsh Cancer 
Intelligence and Surveillance Unit 2009; Information Services Division Scotland 
2009; Northern Ireland Cancer Registry 2009).  
It is also an important disease internationally with over 1 million people diagnosed 
with bowel cancer worldwide annually (Ferlay et al 2010), however it is less 
common in Africa and Asia than in Europe, the Americas and Australasia, either due 
to lower prevalence or poorer detection. This variation in incidence globally is 
attributed to environmental factors rather than genetic factors. In particular a western 
diet (rich in saturated fat, refined carbohydrates and animal protein) associated with 
low physical activity, is thought to predispose to colorectal cancer. The incidence of 
colorectal cancer in migrant communities rapidly reaches the higher level of risk of 
the adopted country (World Health Organisation 2003). 
The colon and rectum, colloquially known as ‘the large bowel’, form the final stages 
of the gastrointestinal tract. The colon is around 1.5 meters long and the rectum 
constitutes the final 10-15cm of this. The chief roles of the colon and rectum are to: 
 Transport digested food and faeces form the small bowel to the anus  
 Store faeces prior to excretion  
 Remove water from the faeces. 
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Over 90% of colorectal cancers are adenocarcinomas (cancers arising from the 
mucosal lining of the bowel). These cancers arise from precancerous lesions called 
adenomas. The pathogenesis of adenomas and their progression to cancer is 
described in section 2.2. 
The detection of cancers at an early stage is the main aim of the NHS Bowel Cancer 
Screening Programme. The removal of adenomas before they become malignant is a 
secondary aim. This will be discussed in section 2.5. 
 
Colorectal Cancer Demographics 
Over 100 cases of colorectal cancer are diagnosed in the UK each day. The lifetime 
risk of colorectal cancer is 1 in 16 for men and 1 in 20 for women (Cancer Research 
UK 2009). The incidence of colorectal cancer increases with age. 83% of colorectal 
cancers are diagnosed in over-60 year olds. Colorectal cancer is more common in 
men with an overall male:female age standardized ratio of 1.6:1 (Cancer Research 
UK 2009). This male preponderance is most marked between the ages of 60 and 80 
years, however there are numerically more colorectal cancer in females than males 
over the age of 80 years. This is a result of females living longer than males and 
forming the numerical majority of the elderly population (see tables 3,4).  
The following definitions apply to the tables below: 
Age-specific rate- The number of cancer registrations or deaths for a particular sex 
and age group divided by the corresponding sex- and age-specific mid-year 
population; usually expressed per 100,000 persons per year. 
Age-standardised rate- An incidence or mortality rate which has been weighted 
using a standard population to control for differences in populations between 
geographical areas or over time, to allow unbiased comparison; usually expressed 
per 100,000 population years. The standard population used in figure 1 is a 
European standard population. 
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Crude rate- The crude rate is the total number of cases divided by the mid-year 
population, usually expressed per 100,000 population years. 
 
  Age (years) 
  30-49.9 50-79.9 ≥80 
Male 770 11899 3743 
Female 691 8528 4635 
Total 1461 20427 8378 
Table 3-Registrations of newly diagnosed colorectal cancer in the England in 2006 (Cancer 
Research UK 2009). 
 
    Age specific rate 
  
All ages 
(crude) 
60-64 
(years) 
65-69 70-74 75-80 80-84 >85 
Male 66.1 137.9 220.6 313.9 394.1 468.4 467.4 
Female 52.5 82.6 124.1 186 248.6 307 320.7 
Table 4- Age-specific rates of newly diagnosed colorectal cancer per 100,000 population in 
England in 2006 (Cancer Research UK 2009). 
 
The incidence of colorectal cancer is higher in areas of greater socioeconomic 
deprivation. Analysis of data on the incidence of colorectal cancer in males in 
England between 2000 and 2004 shows an 11% greater incidence in the most 
deprived areas compared to the most affluent areas (National Cancer Intelligence 
Network 2008). Factors underlying this are not entirely clear but relate to lifestyle 
factors (smoking, obesity, exercise). Differing health behaviour (delayed 
presentation) and lack of access to healthcare services may lead to later presentation 
and poorer prognosis in more deprived areas (Coleman et al 2004). 
Geographical variation of the incidence of colorectal cancer within the UK is 
relatively small however there is a higher than average incidence in Scotland and 
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Northern Ireland and in the north of England (See figure 1) (Quinn et al 2005). 
Again the reasons underlying this trend are not clear but probably relate to 
socioeconomic factors. 
 
 
 
Figure 1- Age standardized incidence rates by sex, colorectal cancer and region of England, UK 
and Ireland, 2006-8 showing 95% confidence intervals (Cancer Research UK ). 
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Natural history of colorectal cancer 
The term colorectal cancer comprises cancers arising in two relatively distinct 
locations. The colon is the large bowel proximal to the rectum. The rectum is 
defined as the 15cm of bowel proximal to the anal verge (UKCCR 1989). The 
location of a cancer with regards to the colon and rectum has important implications 
for diagnosis and management. 
The majority of colorectal cancers arise on the left side of the bowel (see figure 2). 
Right sided cancers are less common but emerging evidence may suggest an 
alternative pathological mechanism of their development (Nawa et al 2008). 
 
 
Figure 2- Percentage distribution of cases by site of colorectal cancer, England 1997-2000. 
(Cancer Research UK). 
It has been understood for some time that the majority of colorectal cancers arise 
from pre-existing adenomatous polyps. A polyp is a non specific term for a lesion 
developing on the lining of the bowel (Vogelstein et al 1988). There are many 
different types of polyp. Some are benign and have no potential to become 
cancerous (such as hyperplastic polyps or lipomas). Some polyps are adenomas. By 
definition adenomas are ‘neoplastic’. This term refers to the abnormal growth 
relative to normal tissue exhibited by adenomas. Adeneomas are also ‘dysplastic’, 
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this refers to the microscopic structural and organizational changes of cells that 
characterise dysplasia. Dysplasia is a spectrum from mild or low grade dysplasia to 
cancer, so the more dysplastic an adenomatous polyp is, the more likely it is to 
become malignant. 
The progression of normal colonic mucosa to adenoma and on to cancer was first 
described in the late 1980`s and is termed the ‘adenoma-carcinoma sequence’ 
(Vogelstein`s hypothesis) (Vogelstein et al 1988). 
The association between adenoma and carcinoma was originally contentious but the 
following arguments have reinforced the association: 
Anatomical distribution- The distribution of adenomas and cancers within the bowel 
is similar (Granqvist 1981). 
Synchronous carcinoma- 3-7% of patients will have colorectal cancer at more than 
one site in the bowel at the time of diagnosis. Around one third of patients with 
colorectal cancer will have adenomas elsewhere in the bowel at diagnosis (Chu et al 
1986; Eide 1986). 
Metachronous carcinoma- Patients with polyps in addition to colorectal cancer at 
diagnosis are twice as likely to develop a subsequent carcinoma after resection 
compared to patients with no other polyps at diagnosis (Bussey et al 1966). 
Age- The age related prevalence of adenomas relates well with that of carcinomas. 
The average age of patients with adenomas is around 5 years younger than patients 
with carcinomas (Muto et al 1975; Winawer et al 1975). This is consistent with the 
estimated duration of the adenoma-carcinoma sequence being around 10 years. 
In surgical resection specimens of colorectal cancer, adenomatous tissue is often 
present. Muto et al found that 278 of 1961 (14.2%) colorectal cancers contained 
adenomatous tissue; this figure rises to 50% in early cancers (Bussey et al 1966). 
Larger adenomas are more likely to display advanced neoplastic changes than 
smaller adenomas (Bussey et al 1966). 
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Familial adenomatous polyposis (FAP) is an autosomal dominant condition caused 
by a mutation in the tumour suppressor adenomatous polyposis coli (APC) gene on 
chromosome 5q. It is characterized by the presence of hundreds of colonic 
adenomas. The lifetime risk of colorectal cancer in these patients is virtually 100%. 
The adenomas in FAP are histologically identical to sporadic adenomas suggesting 
both have similar malignant potential (Phillips 2003). 
The incidence of colorectal cancer can be reduced by programmes involving long 
term screening for and removal of adenomas at colonoscopy (Winawer 2003).  Bond 
(2000) states that interruption of the adenoma carcinoma sequence by polypectomy 
and the resultant reduction in colorectal cancer and mortality is conclusive proof of 
the adenoma carcinoma sequence. 
A proposed genetic basis of the adenoma carcinoma sequence is demonstrated in 
figure 3. 
 
Figure 3-Accumulation of genetic mutations leading to adenomas and carcinoma 
 
Figure 3 represents a vastly simplified sequence of genetic mutations that can 
transform normal mucosa to adenoma and then to cancer. These mutations occur 
sporadically and not all adenomas will develop such mutations.  
It is estimated that the adenoma carcinoma sequence takes place over 10 years and 
that only a small proportion (1-10%) of adenomas complete the sequence during an 
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individuals lifetime (Muto et al 1975; Winawer et al 1987). More advanced 
adenomas (those with more dysplastic features such being greater than 1 cm in size 
or displaying high grade dysplasia) progress to cancer at a higher rate (up to 5% per 
year (Brenner et al 2007)). 
There is emerging evidence that some (the exact proportion is not currently known) 
colorectal cancers may develop via an alternative accelerated pathway which has 
become known as the serrated pathway. The premalignant lesions (sessile serrated 
adenomas) are characteristically morphologically flat and more likely than ‘typical’ 
adenomas to be found in the proximal colon (O’Brien et al 2000). These are more 
difficult to detect at colonoscopy (Nawa et al 2008; Kahi et al 2011). They are likely 
to develop via an alternative genetic pathway involving earlier activation of BRAF 
or KRAS1 resulting in activation of the MAP kinase pathway. Silencing of MLH1 
by methylation causing impaired mismatch repair gene function and microsatellite 
instability precedes the transition to cancer (Arain et al 2010; Leggett et al 2010). 
The recognition of this pathway has raised the profile of proximal metaplastic 
lesions which were previously felt not to have malignant potential but are now 
recognised as precursor lesions. 
 
Benefit of early diagnosis and treatment of colorectal cancer 
The prognosis of colorectal cancer depends on the disease stage. Disease stage 
depends on: 
1. Depth of invasion of the bowel wall 
2. Presence or absence of lymph node invasion 
3. Presence or absence of distant metastases. 
The original staging system is the Dukes classification which is still widely used 
(Dukes 1932). It was originally devised by the St Mark`s (London) pathologist 
Cuthbert Dukes (figure 4)  in the 1930s  for staging rectal cancer. The system 
however, also applies to colon cancer. The original Dukes classification was based 
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solely on pathological findings and did not take into account distant metastases. A 
modified Dukes classification to include stage D has therefore been widely adopted 
(table 5). 
 
 
Figure 4-Cuthbert Dukes (from www.polyposisregistry.org.uk/stmarks/about.htm) 
 
 Pathological findings 5 year survival 
(NCIN 2009) 
Percentage 
of cases 
(NCIN 2009)  
Dukes A Tumour confined to the bowel 
wall with no lymph node 
metastases 
93.2% 8.7% 
Dukes B Tumour penetrating through the 
bowel wall to serosa or 
perirectal fat with no lymph 
node metastases 
77.0% 24.2% 
Dukes C Lymph node metastases present 47.7% 23.6% 
Dukes D Distant metastases (e.g in the 
liver or lungs) present. 
6.6% 9.2% 
(Unknown 
35.4%) 
Table 5- Modified Dukes staging, pathological criteria, 5 year survival and distribution of cases. 
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The other commonly used staging classification is the TNM (Tumour, Node, 
Metastases- American Joint Committee on Cancer) classification. This provides 
greater definition in staging depth of invasion. 
Stage Criteria 
T1 Tumour beyond the muscularis mucosa into the submucosa 
T2 Tumour extending through the submucosa into the muscularis propria 
T3 Tumour invaded beyond muscularis propria into the subserosa 
T4 Tumour has breached the serosa 
N0 No lymph node involvement 
N1 1-3 lymph nodes close to the bowel involved 
N2 4 or more nodes involved that are more than 3cm from primary or 
lymphovascular invasion 
M0 No distant metastases 
M1 Distant metastases present 
Table 6- TNM classification of colorectal cancer 
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The TNM classification allows classification of colorectal cancer into 5 stages which 
can be converted to Dukes stages. 
Stage Features 
Equivalent 
Dukes Stage 
0 
Tumour confined to mucosa (equivalent of carcinoma in 
situ) 
- 
1 
Local invasion of tumour to muscle or serosa but no 
lymph node or distant spread. (T1 N0 M0 or T2 N0 M0) 
A 
2a 
Local spread beyond bowel wall but no lymph nodes 
involved (T3 NO MO) 
B 
2b 
Locoregional invasion to adjacent organs but no lymph 
node or distant spread (T4 NO MO) 
B 
3a 
Tumour confined to bowel wall but 1-3 local nodes 
involved (T1 N1 M0 or T2 N1 MO) 
C 
3b 
Locoregional invasion beyond bowel wall and 1-3 local 
lymph nodes involved (T3 N1 M0 or T4 N1 M0). 
C 
3c 
Any depth of invasion with 4 or more regional nodes 
involved and no other distant metastases (any T  N2 M0). 
C 
4 Distant metastases  (any T, any N, M1). D 
Table 7- TNM stages of colorectal cancer with equivalent Dukes stage 
 
5 year survival is the most commonly reported outcome measure of colorectal cancer 
management. This is because at least 90% of disease related events (cancer 
recurrence or death) will occur within 5 years of diagnosis. 
Treatment of colorectal cancer depends on the site and stage of the cancer, together 
with patient characteristics such as age and comorbidities. 
Non-malignant adenomas can usually be removed endoscopically without the need 
for surgery. Very large adenomas or those harbouring advanced neoplasia may 
require surgical resection (see section 4.2). 
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Cancer confined to a polyp (called ‘polyp cancer’) may also be managed 
endoscopically as the risk of local involvement of lymph nodes is relatively low. 
Dukes A and B colorectal cancer invariably necessitates surgery to provide a cure. 
The addition of post operative chemotherapy to surgery improves survival in Dukes 
C cancer (Dube et al 1997). 
Management options for metastatic (Dukes D) colorectal cancer include 
chemotherapy and palliative surgery but survival is poor in this group with a median 
survival of around 6-12 months (Cochrane colorectal cancer group 2000). 
It is clear that diagnosis and treatment of colorectal cancer at an early stage provides 
considerable survival advantages to the patient. If a patient is diagnosed with Dukes 
A cancer, they have around a 90% chance of surviving 5 years. If however, they are 
diagnosed at Dukes stage C, their five year survival drops to around 50% (Cancer 
Research UK 2009). The main aim of a screening programme for colorectal cancer 
is therefore to diagnose cancers earlier in order to confer these survival benefits. 
The evidence for the protective benefit of adenoma removal is largely based on 
historical studies and observational data. Prospective randomised control trials of 
polypectomy for adenomas with observation as control are not feasible for ethical 
reasons. Important data are available from randomized trials of different surveillance 
strategies following polypectomy. 
A study of serial barium enemas performed in the era before colonoscopy was 
available monitored polyps larger than 1cm left in situ over many years. It 
demonstrated a cumulative risk of malignancy at 5,10 and 20 years of 2.5%, 8% and 
24% (Stryker 1987). 
An important report from the US National Polyp Study provides direct evidence of 
the protective benefit of colonoscopy and polypectomy (Winawer 1993). This was a 
pooled study of all 1418 subjects who had undergone colonoscopy and had at least 
one adenoma removed. Patients were randomized to undergo surveillance 
colonoscopy at either 1 year, 3years and every 3 years subsequently or to miss the 1 
year examination and have 3 yearly surveillance. A lower incidence of colorectal 
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cancer in the surveillance period (average length was 5.9 years) compared to 
incidence in 3 different reference populations was observed. The incidence of 
subsequent colorectal cancer was reduced by 76-90% (p<0.001).  
Several studies have demonstrated the protective benefit of sigmoidoscopy and 
polypectomy resulting in reduction in distal colorectal cancer incidence and 
mortality from colorectal cancer. In Minnesota, 21,000 individuals underwent annual 
screening rigid sigmoidoscopy and polypectomy over a 20 year period. Incidence of 
rectal cancer in the study group was reduced by 85% compared with the known 
incidence in Minnesota (Gilbertsen et al 1992). Two U.S. case-control studies 
comparing rates of colorectal cancer in patients who had undergone screening 
sigmoidoscopy with matched controls suggest a reduction in mortality from distal 
colorectal cancer of 60 and 80% respectively (Selby et al 1992; Newcomb et al 
1992). In the first of these trials (Selby et al 1992) the protective benefit lasted for up 
to 10 years and proximal cancer rates were similar in both screening and control 
patients. A similarly designed case-control study, this time of flexible 
sigmoidoscopy, colonoscopy and polypectomy in 32,702 U.S. patients demonstrated 
a 50% reduction in risk of developing colorectal cancer with protection lasting 6 
years (Muller et al 1995). 
 
Screening for colorectal cancer 
Screening is defined by the UK National Screening Committee (2011) as:  
‘a process of identifying apparently healthy people who may be at increased risk of a 
disease or condition. They can then be offered information, further tests and 
appropriate treatment to reduce their risk and/or any complications arising from the 
disease or condition.’  
For a disease to be amenable to screening it should fulfil the criteria laid out by 
Wilson and Jungner for the World Health Organisation in 1968. These criteria are 
shown in table 8 with details relevant to colorectal cancer shown in the right hand 
column. 
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Wilson and Jungner Criteria 
(paraphrased) 
Evidence supporting screening for 
colorectal cancer 
The condition is an important health 
problem 
3
rd
 most common cancer in the UK 
(Cancer Research UK 2009) 
Its natural history is well understood Adenoma-carcinoma sequence 
(Vogelstein 1988) 
It is recognisable at an early stage Premalignant lesion is the adenoma 
An acceptable treatment exists Polypectomy or surgery are acceptable 
treatments. 
A suitable test exists Faecal occult blood (FOB) testing has 
sensitivity for colorectal cancer of 50-
70% (Steele 2005). 
An acceptable test exists FOB testing is accepted by 
approximately 50% of those invited. 
Adequate facilities exist to cope with 
abnormalities detected 
Colonoscopy and surgical services are 
adequately equipped to cope with 
demand (Dent et al 2009) 
Screening is carried out at repeated 
intervals when the onset is insidious 
Trials of FOB testing have used a 
biennial FOB test strategy. 
The chance of harm is less than the chance 
of benefit 
FOB testing is safe.   
The cost is balanced against benefit Similar cost effectiveness to breast 
cancer screening in the short term. 
Possibly superior in the long term 
(Whynes et al 1998) 
Table 8- Criteria for a disease to be suitable for screening (after Wilson and Jungner 1968) 
 
Colorectal cancer therefore, is a disease which should be suitable for screening. 
Wilson and Jungner`s criteria do not explicitly mention that early treatment of the 
disease in question should be favourable, however, this requirement is also a 
desirable characteristic of a condition amenable to screening. With respect to 
colorectal cancer, 5 year survival of Dukes A cancer (early stage) is 93%; 5 year 
survival of Dukes D cancer (more advanced) is 7% (NCIN 2009). 
In light of this theoretical evidence that colorectal cancer should be amenable to 
screening, numerous studies have examined various approaches to colorectal cancer 
screening. Colonoscopy is the current ‘gold-standard’ test for adenomas and 
                      Detection and Management of Colorectal Neoplasia in the NHS Bowel Cancer Screening Programme 
30 
 
colorectal cancer. Mass population screening in the UK using colonoscopy is not 
economically or logistically viable as manpower and financial resources could not 
currently permit every adult of a certain age to undergo colonoscopy, in addition the 
potential harms and risks of colonoscopy would need to be taken into account. The 
use of colonoscopy for mass population screening however, is employed in the USA 
where guidelines recommend average risk adults should undergo colonoscopy at 50 
years of age and subsequently every 10 years (Winawer et al 2003).  
In the UK an alternative approach is required which allows mass population 
screening, is economically viable and is safe and acceptable for patients. The most 
widely studied test that fulfils these criteria is faecal occult blood testing (FOBt).  
Faecal occult blood testing is based on the peroxidase-like activity of haematin in 
faeces on guaiac (a phenolic compound derived from wood resin extracted from 
trees in the genus Guaiacum). When hydrogen peroxide is added to guaiac, oxidation 
occurs resulting in a colour change to blue. This reaction is very slow but the 
pseudoperoxidase activity of haematin (if present in blood in stool) catalyses the 
reaction so that it takes place in seconds.  
Faecal occult blood testing relies on the fact that adenomas, particularly advanced 
adenomas and colorectal cancers tend to bleed. This bleeding is intermittent and at a 
slow rate and is due to a combination of their vascular structure and trauma from 
passing faeces. The peroxidase-like activity of haematin diminishes as it passes 
through the gastrointestinal tract reducing the chance that upper gastrointestinal 
bleeding will cause false positive results. Ingestion of animal haemoglobin or 
peroxidase containing vegetables however, may cause false positives, therefore 
dietary restriction can be recommended, particularly if the FOBt result is equivocal 
(Robinson et al 1993). 
The particular type of FOBt that has been most extensively studied is Haemoccult. 
There are two distinct methods of processing a guaiac-based FOB test: the stool 
sample can be rehydrated prior to analysis, this results in more positive test results 
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and higher false positive rate than the alternative, which is to not rehydrate the 
sample (Mandel et al 1999).  
FOB testing to screen for colorectal cancer is not a new concept. It’s use was first 
described by Greegor in 1971. In this study 900 asymptomatic adults underwent 
FOB testing over a 3 ½ year period. 5% were FOB test positive and underwent 
barium enema examination. 1% (12 cases) were found to have colon cancer. The 
author concludes, with some prescience, that ‘every adult should have this screening 
test annually’. 
Three large prospective randomised control trials of FOB testing have been 
conducted in Minnesota (USA) (Mandel et al 1993), Funen (Denmark) (Kronberg et 
al 1996) and Nottingham (UK) (Hardcastle et al 1996). The details of each trial are 
given in table 9.  
The Funen and Nottingham trials have similar outcomes when the groups of patients 
undergoing biennial screening with non rehydrated FOB testing are compared.  This 
method of screening reduces mortality from colorectal cancer by 15-18% (Kronberg 
et al 1996; Hardcastle et al 1996). In both trials the rate of positivity of the FOB test 
was between 0.9 – 3.8%. This resulted in the cumulative proportion of screening 
participants undergoing colonoscopy being around 5%. In the Minnesota trial a 
rehydrated FOB test (Haemoccult) was used. This is a less sensitive test. It resulted 
in 28% of participants requiring colonoscopy in the biennial screening group and 
40% requiring colonoscopy in the annual screening group but led to reductions in 
mortality from colorectal cancer of 21% and 33% respectively (Mandel et al 1993). 
It is possible that the benefits in this study were due to the high proportion of 
patients having colonoscopy rather than the FOB test itself. 
The Funen and Nottingham trials were the only truly randomised control trials in 
which a population based approach was taken. The Minnesota trial required 
participants to volunteer to participate, after which they were randomised. This may 
have contributed to higher compliance (uptake of FOB testing) in the US study (75-
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78% in Minnesota) compared to uptake in the European studies (53.4% in 
Nottingham, 56% in Funen). 
This relatively lower uptake of FOB testing in the English and Danish studies may 
have diluted the effect on mortality and contributed to the finding that neither of the 
European trials demonstrated a reduction in colorectal cancer incidence over the 
course of the trial (Scholefield et al 2002, Jorgensen et al 2002).  The Minnesota trial 
however, did demonstrate a statistically significant reduction in mortality of 33% in 
the annual group (RR 0.67 (0.51-0.83) and 21% (Risk ratio 0.79 (0.62-0.97) in the 
annual group (Mandel et al 2000). The Minnesota trial also demonstrated a 
statistically significant reduction in colorectal cancer incidence of 17% in the 
biennial group and 20 % in the annual group. This however, was at the expense of 
the high cumulative colonoscopy rates (28% and 40% respectively) described above. 
In all three trials a much higher proportion of early cancers were detected in the 
screening group than the control group. In the Funen study 36% of cancers were 
Dukes A in the screening group compared to 11% in the control group (Kronberg et 
al 1996).  
The outcomes described above suggest the screening programme trials were 
successful. The results should be interpreted with caution as these large trials of 
biennial FOB testing to screen for colorectal cancer have some limitations and are 
subject to the following inherent biases (Steele 2005):  
Selection Bias- This arises from the tendency of particularly healthy and health-
conscious people to take up the offer of screening, who may not be typical of the 
underlying population. This effect is said to account for the minimal reduction of 6% 
in colorectal cancer mortality seen in the first phase (1976-1982) in the biennial 
screening group of the Minnesota study (Mandel et al 1993). The effect diminished 
with extended follow up so that in phase 2 (1986-92) the reduction in mortality 
became 21%. 
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Length bias- This describes the tendency of screening programmes to detect more 
slow growing cancers during the asymptomatic phase of the cancer. Such cancers 
have a good prognosis anyway, leading to a favourable impact on survival of screen 
detected compared to non-screen detected cancers.  Non-screen detected cancers are 
more likely to be faster growing lesions, associated with poorer prognosis. 
 
Lead-time bias- This is based on the difference between the time at which a cancer 
is detected in a screening programme and when the cancer would have been 
diagnosed had the patient not been screened. Survival is measured from the date of 
diagnosis thus it can be lengthened by screening without necessarily impacting on 
the time to death. Equally, screening can pick up many of the prevalent cancers in a 
population which may have gone unnoticed had it not been for screening 
 
Overdiagnosis bias- Screening is capable of detecting very early lesions (such as 
small adenomas). These are unlikely to cause any health problems during a patient’s 
lifetime. Because these lesions are more likely to be found in a screening group than 
a non-screened group, comparisons may favour the screening group. Overdiagnosis 
bias and length bias may have similar effects on survival data however length bias 
refers specifically to the timing of the screening test with respect to the natural 
history of the disease whilst overdiagnosis bias refers to the clinical relevance of 
preclinical disease. 
 
The Nottingham and Funen trials were both randomised, controlled trials which 
demonstrated strong age and sex comparisons between the intervention and control 
groups (Hardcastle et al 1996; Kronberg et al 1996). In addition, colorectal cancer 
mortality was used as the primary outcome measure in both trials. These factors 
contribute to minimising the impact of the biases described above. The Minnesota 
trial randomised patients only after they had volunteered to take part.  This may have 
introduced selection bias and limit the external validity of the trial.
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Date 
 
Follow up 
period 
Inclusion 
Criteria 
Screening test 
 
Screening 
Programme 
Participation 
Uptake of the 
FOB test 
Size 
Colonoscopy 
Rate 
Minnesota 
Colon Cancer 
Control Study 
Mandel et al 
1993,1999, 
2000 
Phase 1 
1976-1982 
Phase 2 
1986-1992 
 
Mean 
follow up 
13 years 
Age 50-80 
years 
Volunteers from 
American 
Cancer Society 
and fraternal, 
veterans and 
employer 
groups. 
First 3 years- 
non rehydrated 
FOBt. 
From year 3  all 
Rehydrated  
Haemoccult 
(with dietary 
restrictions) 
 
2 groups: 
Annual 
screening 
Biennial 
screening 
In 2 phases 
over 11 years 
Annual group- 
90.2% completed 
round 1, 46.2% 
completed all 
rounds. 
Biennial group- 
89.9% completed 
round 1, 59.7% 
completed all 
rounds 
Annual group- 
75% 
compliance 
Biennial group- 
78%  
compliance 
46551 
participants 
Annual group- 
15570 
Biennial 
group- 15587 
Control group- 
15394 
Annual group- 
40% 
underwent 
colonoscopy 
Biennial 
group- 28% 
Nottingham 
Hardcastle et 
al 1996, 1999, 
2002 
Pilot 1981-
83 Main 
study 
1985-1991 
Follow up 
ceased 
1995 
 
Mean 
follow up 
7.8 years 
(range 4.5-
14.5) 
Age 45-74 
years 
From General 
Practice  
registers. 
Randomisation 
by household 
 
Non rehydrated 
Haemoccult (no 
dietary 
restrictions, 
except for 
retests after a 
positive  FOBt) 
Biennial 
screening. 
Participants 
offered tests 
between 3-6 
times over  
14 years. 
53% completed 
round 1. 
38.2% completed 
all rounds 
53.4% uptake 
overall 
152850 
participants 
 
Screening 
group- 75253 
Control group- 
74998 
Cumulative 
proportion of 
those 
undergoing at 
least one 
colonoscopy= 
4% 
Funen 
Kronborg et al 
1996, 2002, 
2004 
 
 
1985-1995 
5 rounds 
 
Mean 
follow up 
10 years   
 
 
Age 45-75 
years 
From the island 
of Funen 
population 
registers. 
Non Rehydrated 
Haemoccult  II 
(with dietary 
restrictions) 
Biennial 
screening in 
5 rounds over 
10 years 
67 % completed 
round 1. 
45.9% completed 
all 5 rounds 
56% uptake 
overall 
61933 
participants 
Biennial group 
– 30967 
Control group- 
30966 
Cumulative 
proportion of 
those 
undergoing 
colonoscopy- 
5.3% 
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Positivity 
rate of 
FOB test 
Sensitivity and 
Specificity of 
FOB test for 
colorectal 
cancer 
Reduction in 
colorectal 
cancer 
mortality 
Effect on 
colorectal 
cancer 
incidence 
Dukes stage of 
screening 
detected 
cancers 
Dukes stage of 
control group 
cancers 
Interval 
cancers 
Complication of 
colonoscopy 
Minnesota 
 
9.8% 
Rehydrated FOBT: 
Sensitivity- 92.2%  
Specificity- 90.4% 
 
Non rehydrated: 
Sensitivity- 80.4% 
Specificity- 97.7% 
At 18 years 
follow up: 
Annual group-
33% 
(RR 0.67 (0.51-
0.83)) 
Biennial group 
21%  
(Risk ratio 0.79 
(0.62-0.97))  
At 18 years: 
Annual 
group- 20% 
reduction in 
incidence 
 
Biennial 
group- 17% 
reduction in 
incidence 
Annual group- 
Dukes A- 30.2% 
 
Biennial group- 
Dukes A- 26.6% 
Annual group-    47 
% reduction in 
Dukes D, Biennial 
group – 32% 
reduction in Dukes 
D compared to 
control group. 
Control group-
Dukes A- 
22.3% 
Not reported 
Out of 12246 
colonoscopies 
 
4 perf, 11 serious 
bleeds 
(0.12% risk of 
serious 
complication) 
Nottingham 
2.1% +ve 
in first 
round. 
1.2% +ve 
in 
subsequent 
rounds 
Sensitivity- 
53.6% 
 
Specificity 
estimated at 96-
98% 
 
13% (95% CI 3-
22%) at median 
follow up of 11 
years (p=0.01)  
 
Risk ratio 0.87; 
CI 0.78-0.97 
p=0.01 
Not reported Dukes A- 20% Dukes A- 11%  
28% of cancers 
were interval 
cancers (26% 
screening, 46% 
in non 
uptakers) 
 
 
Cardiovascular 
complications- 
6.4/1000py 
 
7/1474 (0.5%) 
colonoscopy 
complication, (5 
perfs, 1 bleed, 1 
other, no deaths) 
Funen 
1st round-
1%+ve. 
0.9-3.8% in 
subsequent 
4 rounds. 
Cumulative 
risk of a 
+ve FOBt- 
5.7% 
 
 
 
 
Sensitivity- 82% 
 
Specificity 
estimated at 
98% 
At 17 yrs: 
16% reduction in 
colorectal cancer 
mortality* (RR 0.84 
(0.73-0.96))  
 
11% reduction if 
complications of 
treatment included ( 
not significant) 
Not reported 
Dukes A- 36% 
(72/199) 
Dukes A- 11% 
(162/889) 
Screening cancer- 
199 (26%) 
 
Interval cancers- 
239 (32%) 
 
Cancers in those 
refusing invitation- 
306 (41%) 
‘No deaths from 
colonoscopy 
itself’ 
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Table 9- Comparison of the three large controlled trials of FOB screening for colorectal cancer 
 
 
Lost to 
follow up 
Compliance 
with 
colonoscopy 
 
Completeness 
of colonoscopy 
Positive 
predictive 
value for 
adenoma 
>=10mm 
Positive 
predictive 
value of 
FOB test 
for 
colorectal 
cancer 
Number of 
colorectal 
cancer cases 
 
 
Number of 
colorectal 
cancer deaths 
Number of 
deaths from 
colorectal 
cancer and 
complications 
of treatment 
All cause 
Mortality 
Minnesota 
Follow up 
statistics 
complete at 17 
years for: 
91.3% of 
annual group, 
91.7% of 
biennial 
group, 91.2% 
of control 
group 
95% 
 
Annual group- 83%, 
Biennial group- 84% 
received complete 
colonoscopy or 
flexSig+BaEnema 
Annual group- 
5.99% (1 +ve 
slide), 7.87% (6 
+ve slides) 
 
Biennial Group- 
6.86% (1 +ve 
slide), 10.08% 
(6 +ve slides) 
Annual group- 
0.87% (1 +ve 
slide), 4.53% (6 
+ve slides) 
 
Biennial group- 
1.12% (1 +ve 
slide), 6.13% (6 
+ve slides) 
Annual group- 323 
(1.75/1000 py) 
 
Biennial group 323 
(1.76/1000 py) 
 
Control group- 356 
(1.96/1000 py) 
Annual group- 121 
(9.46/1000) 
 
Biennial group- 
148 (11.2/1000) 
 
Control group- 121 
(14.9/1000) 
Not reported 
Annual group- 
5236 (342/1000) 
 
Biennial group- 
5213 (340/1000) 
 
Control group- 
5186 (343/1000) 
Nottingham 
2599 
(1.7%) 
participants 
lost to 
follow up 
(Excluded 
from 
analysis. 
Not reported 
Adenoma 10-19mm 
screened 25%, 
control 35% 
 
Adenomas >19mm 
screened 27%, 
control 27% 
First screen 
9.9% 
 
Rescreen 
within 27 
months 
11.9% 
Screening group- 
1268 
(1.51/1000py) 
 
Control group-  
1283 
(1.53/1000py) 
py= patient years 
 
Screening 
group- 593 
(0.7/1000py) 
 
Control group- 
684 
(0.81/1000py) 
Not reported 
Screening group- 
20421 
(24.18/1000py) 
 
Control group- 
20336 
(24.11/1000py) 
Funen 6 persons 
93.2% 
 
 
89.9% 
1st screening 
31.6% 
 
9th screening 
22.1% 
1st 
screening- 
17.2% 
 
9th 
screening-
16.5% 
 
Screening group 
889 (2.06/1000py) 
 
 
Control group 874 
(2.02/1000py) 
 
Screening 
group 362 
(0.84/1000) 
 
 
Control group 
431 (1/1000) 
Screening 
group 427 
(0.99/1000) 
 
Control group 
479 (1.1/1000) 
Screening group 
12,205 
(28.3/1000) 
 
Control group 
12,248 
(28.4/1000) 
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A Cochrane Collaboration review and meta-analysis of screening for colorectal cancer 
using FOB testing has been performed (Hewitson 2007). This review excluded 10 trials 
of colorectal cancer screening as they were either non randomised or non controlled or 
only screened patients once. 4 trials were reviewed in greater detail, the 3 trials described 
above (Mandel et al 1993; Hardcastle et al 1996; Kronberg 1996) and a trial from 
Göteborg, Sweden (Kewenter et al 1994). This trial only included patients aged 60-64 
years and used sigmoidoscopy and double contrast barium enema to investigate a positive 
FOB test. The three trials considered in more detail have more relevance to the design of 
the English Bowel Cancer Screening Programme as they employed biennial screening 
with FOB testing followed by colonoscopy to investigate a positive result. 
The meta-analysis of the trials demonstrated a 15% reduction in the relative risk of 
colorectal cancer mortality (risk ratio 0.85, 95% confidence interval 0.78-0.92). Due to 
the high number of patients not complying with FOB testing in these trials (33-46% in the 
first screening round and 22-40% in at least one screening round) the reduction in 
colorectal cancer mortality adjusted for attendance was calculated as 25% (risk ratio 0.75, 
95% confidence interval 0.66-0.84) for those screened.  
The review concluded that colorectal cancer screening led to a ‘modest reduction in 
colorectal cancer mortality and a possible reduction in incidence through the detection 
and removal of adenomas, and potentially, less invasive surgery that earlier treatment of 
colorectal cancers may involve’. This suggests that FOB screening may avoid 
approximately 1 in 6 colorectal cancer deaths.  The review also warned of the harmful 
effects of screening which include: 
 Psychosocial consequences of a false positive result (unnecessary colonoscopy) 
 Complications of colonoscopy 
 False negative results (interval cancers) 
 Possibility of overdiagnosis (leading to unnecessary investigations or treatment) 
 Complications associated with treatment 
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A summary of the key findings from these three main trials are as follows: 
 15% reduction in colorectal cancer mortality by biennial non rehydrated FOB 
testing (Hewitson et al 2007).  
 25% reduction in colorectal cancer mortality amongst those attending for 
screening (Hewitson et al 2007).  
 No significant difference in all cause mortality between the control and screening 
groups in any of the trials. (RR 1.00, 95% confidence interval 0.99-1.03) 
(Hewitson et al 2007). 
 Modest attendance for FOB testing in the Nottingham trial (53% in the first 
round, 38.2% completed all three rounds) (Scholefield et al 2002).  
 The sensitivity of non-rehydrated FOB testing for colorectal cancer is 55-57%. 
(Defined as the proportion of all cancers detected by screening where ‘all cancers’ 
is the sum of screen-detected cancers (true positives) and interval cancers within 2 
years of screening (false negatives)) (Hewitson et al 2007).   
 The positive predictive value of non-rehydrated FOB testing is 5-18.7%, based on 
FOB positivity rates of 0.8-3.8% (Hewitson et al 2007). 
 The positive predictive value of rehydrated FOB testing is 0.9-6.1% based on 
FOB positivity rates of 1.5-15.4%. 
 Use of rehydrated FOB tests increases sensitivity to 82-92% but at the expense of 
much higher colonoscopy rates and lower positive predictive value of FOB 
testing. 
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Despite the apparent benefits of a population screening approach to colorectal cancer,  
arguments against such a programme exist. These are as follows: 
 FOB testing fails to identify 20-50% of colorectal cancers and up to 80% of 
adenomas. 
 The specificity of FOB testing is low and can depend on whether patients have 
eaten certain peroxidase containing food types beforehand. 
 Sensitivity may be increased by rehydrating the FOB test but this is at the expense 
of specificity which would result in many more people requiring colonoscopy. 
 Prior to introduction of the NHS BCSP there was concern that colonoscopy 
services within the UK were already stretched and would not be able to absorb the 
increased workload a screening programme would impose. Similar concerns 
existed for the pressures on radiology and pathology services (Bowles et al 2004). 
Investment in endoscopy infrastructure has meant that these concerns have not 
been borne out. 
 In the Nottingham trial, 28% of cancers were ‘interval cancers’- cancers 
diagnosed after a negative FOB test or negative colonoscopy and between 
screening rounds.  
 The proportion of advanced cancers (Dukes D) in the control and screening 
groups of the Nottingham and Funen trials were unchanged. The reduction in 
stage at diagnosis was due to a shift from Dukes C to Dukes A disease. 
 Population screening with flexible sigmoidoscopy is more sensitive and specific 
for distal cancers and polyps than FOB testing (Atkin et al 1996). However, it is a 
more invasive test than FOB entailing bowel preparation, potential discomfort and 
the risk of perforation or bleeding. 30-40% of cancers arise proximally to the 
reach of the sigmoidoscope and thus would be missed. However, distal adenomas 
may serve as a marker for such lesions (Atkin et al 1992) and would prompt 
colonoscopy in such patients. This may detect up to one third of proximal cancers 
(Atkin et al 1993). A randomised controlled trial of one-off sigmoidoscopy 
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between the ages of 55 and 60 demonstrated a 23% reduction in colorectal cancer 
incidence and a 31% reduction in colorectal cancer mortality but no effect on 
proximal cancer incidence or mortality was demonstrated (Atkin et al 2010). 
 Compliance with FOB testing is modest (around 55% in the Nottingham trial). 
More deprived socioeconomic groups have even lower uptake (Whynes et al 
2003).  Increasing uptake is a significant challenge. Uptake of the screening test in 
other screening programmes (breast and cervical), is much higher (75% in the 
NHS Breast Cancer Screening Programme) (NHS Breast Cancer Screening 
Programme 2006). 
 To prevent one colorectal cancer death in the Nottingham trial, 1250 people (95% 
confidence interval 690-9090) had to be offered screening over an 8 year period. 
This could be seen as a significant burden on society for limited benefit. There is 
also a risk that false positive FOB tests impose a significant physical and 
psychological burden on individuals (Marshall 2000). 
 
Cost–effectiveness analysis of colorectal cancer screening using biennial FoB testing has 
been conducted (Whynes et al 1998). This work showed that the cost per QALY gained 
using data from the Nottingham study was £5685 for men and £4951 for women. Cost-
effectiveness is greater in women than in men due to their increased life expectancy.  
This analysis is limited as it does not take into account the indirect costs of colorectal 
cancer screening such as psychological costs associated with anxiety and it does not 
include the costs of implementing a mass screening programme. A separate analysis of 
the cost effectiveness of faecal occult blood testing estimated the cost per life year saved 
as £5900 per life year saved (Steele et al 2004). This is less than the threshold at which 
healthcare interventions are considered to economically acceptable, the median 
intervention costs of 500 ‘life-saving interventions’ was estimated at £26,000 per life-
year saved by Tengs et al in 1995. 
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Colorectal cancer screening and surveillance in non ‘average risk’ populations. 
 
The approaches to screening described above are only suitable for mass population 
screening of ‘average risk’ individuals. Certain groups of individuals are at higher risk of 
colorectal cancer due to underlying medical conditions or genetic and or familial 
predisposition. Such individuals should have screening strategies in place appropriate to 
their individual risk and are not suitable for inclusion in population screening 
programmes.  Examples of high risk groups are: 
 Familial Adenomatous Polyposis 
o Dominantly inherited condition, constitutes 0.5% of all colorectal cancers. 
Due to mutation in the APC gene on chromosome 5q, almost 100% risk of 
colorectal cancer by middle age. It is associated with duodenal polyposis 
and other extraintestinal manifestations. Known family history in 80%, 
25%  are due to sporadic mutation (Bisgaard 1994). Genetic screening of 
at risk individuals is recommended. Prophylactic colectomy or 
proctocolectomy for affected individuals is usually necessary. 
 Peutz-Jeghers Syndrome (PJS) 
o Autosomal dominant syndrome defined by presence of hamartomatous 
polyps in the small and large intestine in association with mucocutaneous 
pigmentation. The risk of colorectal cancer is 10-20% (Giardiello 1987). 
Surveillance is required every 2-3 years. 
 Hereditary Non-Polyposis Colorectal Cancer (HNPCC) 
o Constitutes 2% of all colorectal cancers. It results from a mutation in one 
of five DNA mismatch repair genes. Average age at diagnosis of 
colorectal cancer is 45 (compared to 65 in background population. Cancers 
in this group tend to be proximal and synchronous in the bowel and have 
characteristic pathological features. HNPCC is associated with 
extracolonic cancers such as endometrial (in 40% of women) and stomach 
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cancer (in 15%) (Aarnio 1995). Colonoscopy is recommended every 2 
years from age 25 or 5 years younger than the youngest affected relative 
(Dunlop 2002; Cairns et al 2010) . Screening for extracolonic cancers may 
be necessary. 
 Family history 
o This may constitute up to 30% of colorectal cancers. Risk of colorectal 
cancer may be 2 to 6 times that of the general population in low and 
moderate risk groups. Requirement for colonoscopic surveillance depends 
on the family history (Cairns et al 2010). 
 Inflammatory Bowel Disease. 
o Patients with ulcerative colitis or Crohns colitis, are at increased risk of 
colorectal cancer (Devroede 1971, Cairns et al 2010). 
o Current guidelines recommend surveillance should commence 8-10 years 
following onset of symptoms and 1-3 yearly thereafter (Cairns et al 2010). 
o Using dye spraying techniques to target biopsies may be a more effective 
surveillance methodology that taking multiple non targeted biopsies 
(Rutter et al 2004, NICE 2011). 
 
Origins and structure of the NHS Bowel Cancer Screening Programme 
As a result of the findings of the three large trials of biennial FOB testing described 
above, the Department of Health commissioned a pilot screening programme to assess the 
feasibility of using biennial FOB testing to screen the UK population. Two areas in the 
UK (Coventry, Warwickshire in England and Tayside, Grampian and Fife in Scotland) 
introduced screening programmes from 2000 onwards, inviting men and women aged 50-
69 years for screening. The initial report of the UK Colorectal Cancer Screening Pilot 
(UK CRC Screening Pilot Evaluation Team
 
2003) concluded that similar outcomes in 
terms of test positivity, positive predictive value and shift in stage of screening detected 
cancers were observed in the pilot studies as in the Nottingham trial. Uptake of FOB 
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testing in the pilot project was around 60%. Lower uptake in certain sub-groups was 
noted. These sub-groups included men, younger people, those from more deprived areas 
and individuals from ethnic minorities, particularly Asian groups (Whynes et al 2003, UK 
CRC Screening Pilot Evaluation (Ethnicity) Team 2003).   
478,250 individuals were invited to take part in the screening pilot. As mentioned 
previously, the uptake of FOB testing was 56.8% (271,646 individuals). The rate of 
positivity of the FOB test was 1.9% and the rate for detecting cancer was 1.62 per 1000 
people screened. The positive predictive value of a positive FOBt result was 10.9% for 
cancer and 35.0% for adenomas (UK CRC Screening Group 2004). 552 cancers were 
detected by screening. 17% were polyp cancers. 48% were Dukes stage A. 
The report concluded by recommending a screening programme of biennial FOB testing 
for the UK to the Department of Health. 
A review of the second round of the pilot (Weller et al 2007) noted a lower uptake of 
FOB testing (52.1%). Second round positivity of FOB tests was 1.77% which was higher 
than expected based on findings in round one and in previous studies, the reasons for this 
are not clear. A lower cancer detection rate was observed in the second round of the pilot 
compared to the first round and the similar group of patients in the Nottingham trial. The 
findings of this report contributed to the ‘roll out’ of the national programme.  
One other conclusion of note in this report was that there is need for more evidence to 
achieve national consensus on the optimal colonoscopy intervals for adenoma/polyp 
surveillance. The section of this thesis examining surveillance of patients with ‘high risk’ 
adenomas will contribute to knowledge in this area. 
Subsequently the Department of Health ‘rolled out’ the NHS Bowel Cancer Screening 
Programme for England from July 2006 onwards. Coverage by the BCSP in England is 
shown in figure 5. Scotland, Northern Ireland and Wales have similar but separately 
organised programmes. 
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The screening programme in England consists of five programme hubs across the country 
operating a national call and recall system to send out FOB testing kits to eligible 
individuals (figure 6). Adults aged between 60 and 69 years are currently being screened. 
Patients over 70 years may opt in. Extension of the screening programme to include 70-
74 year old adults is being rolled-out across England (figure 5). FOB testing is performed 
according to a protocol designed to optimise sensitivity and specificity of the test 
No dietary restriction is recommended prior to completion of the test. Individuals receive 
the kit by mail and, after completion, return it by mail to the screening Hub in the World 
Health Organization (WHO) approved postage paid envelope provided within 14 days of 
the first sample. When repeat testing is required, this is performed within 13 weeks of 
previous test. All FOB kits are assessed on the day they are received by the hub by 
trained individuals. Quality assurance consists of continuous internal and external 
assessment for both FOB kits and kit readers to ensure that standards remain high. Table 
10 shows how FOBt are interpreted and when repeat testing is necessary.  
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Table 10- Classification of FOBt results (from Lee et al 2011). 
 
Screening centres (up to 20 per hub (figure 7)) then provide endoscopy services and 
specialist screening nurse clinics to individuals as necessary. For instance if a patient had 
a positive FOB analysed at the hub they would be invited to a screening centre for 
colonoscopy closer to their home. Patients found to have cancer are managed and 
followed up through the colorectal multi-disciplinary meeting at the patient’s local 
hospital. Adenoma management and surveillance are coordinated by the screening 
programme along current BSG guidelines (Atkin et al 2002, Cairns et al 2010).  
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Figure 5- National coverage of the BCSP in June 2011 including roll-out of the age extension (from 
http://www.cancerscreening.nhs.uk/bowel/publications/in-the-loop-summer-2011.pdf) 
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Figure 6- Division of England into Bowel Cancer Screening Programme Hubs (from 
http://www.cancerscreening.nhs.uk/bowel/). 
 
Figure 7- Structure of the NHS Bowel Cancer Screening Programme (from 
http://www.cancerscreening.nhs.uk/bowel/). 
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Based on data from the pilot studies around 98 in 100 people will receive a normal FOBt 
result and will be returned to routine screening. They will be invited for bowel cancer 
screening every two years if still within the eligible age range. 
Around 2 in 100 people will receive an abnormal result. They will be referred for further 
investigation and usually offered a colonoscopy. Around 40-50% of patients who go onto 
to have colonoscopy will be found to have one or more adenomas. Around 10% will be 
found to have bowel cancer. This is demonstrated in figure 8. 
 
 
Figure 8- Schematic illustration of predicted outcomes of Bowel Cancer Screening (from 
http://www.cancerscreening.nhs.uk/bowel/#screening-work) 
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Summary 
1. Colorectal cancer is a common disease which imposes a significant burden on 
society, both in health terms and economic terms.   
2. Great advances in understanding of the natural history of colorectal cancer have 
been made over the last 40 years. 
3. This has led to the acceptance of the ‘adenoma-carcinoma’ sequence being the 
origin for most colorectal cancers. 
4. Fortunately the transition of adenomas to cancer takes place over many years and 
this provides the ideal opportunity for a screening programme to detect and 
remove such lesions before they become malignant. 
5. Larger adenomas and colorectal cancers tend to bleed intermittently. This means 
that the detection of blood in the faeces (using a faecal occult blood test (FOBt)) 
may allow their detection. However FOBt testing only detects around 50% of 
such lesions due to the intermittent nature of the bleeding. 
6. Early diagnosis of colorectal cancer confers significant survival advantages. 
7. Three large randomised control trials of biennial FOB testing have demonstrated a 
reduction in mortality from colorectal cancer of  13-21%. One of these studies 
demonstrated a 17% reduction in colorectal cancer incidence after 18 years of 
follow up. 
8. On the basis of these large trials, the NHS Bowel Cancer Screening Programme 
(NHS BCSP) invites men and women aged 60-69 years to enter a biennial FOB 
testing programme with colonoscopy recommended if the FOB test is positive. 
9. The NHS BCSP aims to detect cancers at an earlier stage and detect and remove 
adenomas. 
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2.2.0- Detection of Neoplasia in the NHS Bowel Cancer Screening 
Programme 
  
2.2.1- Adenoma detection rate and other performance indicators in the NHS 
Bowel Cancer Screening Programme. 
The degree of success with which a colonoscopy detects adenomas and carcinomas is a 
marker of the quality of that colonoscopy and depends on a wide range of factors. High 
quality colonoscopy is important, particularly within a screening programme, to 
maximise diagnostic yield, minimise harm to the patient and optimise the benefit to the 
patient undergoing screening (Valori et al 2010).Being able to measure the quality of a 
colonoscopy (or colonoscopist) is important for monitoring standards and allowing 
continuous improvement of the screening programme (Faigel et al 2006). This section of 
the literature review will examine the evidence available on adenoma detection rate and 
in particular examine it’s role as an indicator of performance. The other factors which 
may or may not influence adenoma detection rate will also be examined. 
 
Adenoma detection rate 
Adenoma detection rate (ADR) is a measure of the frequency at which adenomas are 
detected at colonoscopy. Usually ADR is described as the proportion of patients in whom 
one or more histologically proven adenomas are found in a defined group of patients in a 
defined period of time (Church 2008). ADR is usually expressed as a percentage (e.g. 
47%) or as a proportion (0.47). For example if  colonoscopy is performed on 100 patients 
by a single colonoscopist in a one year period and one or more adenomas are found in 40 
of these patients, the adenoma detection rate for that colonoscopist in that one year period 
would be 40% (0.4). Occasionally it is expressed as the total number of adenomas per 
patient. This may be more relevant in populations with high polyp prevalence. In the 
example above, if a total of 60 polyps were found in those 40 patients who had one or 
more adenomas, the total number of adenomas per patient would be 0.6 . There is no 
evidence available to inform which of these two measures of adenoma detection rate 
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should be used to compare individual colonoscopists, however the first definition 
(number of patients in whom at least one or more adenomas is found) is far more widely 
used. ADR requires that the adenoma be histologically confirmed. Thus it relies not only 
on the adenoma being detected in the first place but also removed, retrieved and analysed 
in a laboratory by a pathologist. In this way ADR differs from polyp detection rate (PDR) 
which simply requires a polyp (of any nature) to be macroscopically identified at 
colonoscopy. 
A number of studies have demonstrated variable adenoma detection rates amongst 
colonoscopists (Atkin et al 2004; Barclay et al 2006; Millan et al 2008; Bretagne et al 
2010). In one of these studies, which looked at six experienced colorectal surgeons (each 
had performed more than 1000 procedures) at the Cleveland Clinic, Ohio; the adenoma 
detection rates amongst the surgeons varied from 14.2% to 27.4% (Millan et al 2008). 
This was independent of completion rate which was uniformly greater than 95%. 
Although this was a small study it demonstrates variability in ADR and raises questions 
as to why this should be the case. 
The following factors have been suggested as contributing to variation in adenoma 
detection, the magnitude of the potential effect of these factors is shown in table 11. 
 Endoscopist characteristics 
o A study of 9 colonoscopists at the Indiana University Hospital reviewed 
10,034 colonoscopies (Chen et al 2007). Multivariable analysis indicated 
that increasing age and male gender of the patient were associated with 
increased adenoma detection rate. When these factors were controlled for 
in a further multivariable analysis, there were significant differences in 
adenoma detection rate (p<0.0001) among the colonoscopists (range 14%-
46%). All endoscopists had a caecal intubation rate of 93% or higher but 
had a wide range of previous experience in clinical practice on entering 
the trial (mean number of years 8.8, range 0-25). The impact of previous 
experience and intubation rate was not examined in this study but the 
influence of the individual colonoscopist was demonstrated.  
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 Technical factors 
The techniques used to perform colonoscopy can have an important impact on 
adenoma detection rate.  These factors include: 
o Withdrawal time greater than 6 minutes (Barclay et al 2006) 
o Position change during colonoscopy (East 2007a; East 2011) 
o Use of an antispasmodic agent (East 2007b) 
 One study has suggested premedication with Buscopan (Hyoscine 
Butylbromide) can increase adenoma detection though the effect 
was small, non-significant and confined to individuals with marked 
colonic spasm (Lee 2010). A study from St Marks (Saunders 1996) 
suggested Buscopan could decrease colonoscope insertion time, a 
further study from the same institution showed that Buscopan 
could increase the amount of colonic mucosa that can be inspected 
(East 2009).  
o Re-examining folds and flexures (Rex 2000) 
o Rectal retroflexion (Hanson et al 2002) 
o Quality of bowel preparation (Harewood et al 2003) 
o Time of day (Sanaka et al 2009; Chan et al 2009) 
 A higher ADR is reported in the morning than the afternoon, 
possibly due to changes in the quality of bowel preparation or 
endoscopist fatigue. Two US studies have demonstrated that polyp 
detection decreases in afternoon compared with morning 
colonoscopies and with each subsequent hour of the day (Sanaka 
2009, Chan 2009). A recent single centre US study (Long 2011) of 
20 colonoscopists has observed a similar phenomenon of declining 
polyp detection toward the end of an endoscopist`s shift.   
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 Endoscopic equipment 
o Use of high definition (HD) colonoscopes and narrow band imaging to 
augment adenoma detection rate have not been shown to improve 
detection rates (Rex et al 2007; East 2008b). Both these studies were 
performed by operators with very high baseline adenoma detection rates 
which may have masked any advantage due to sample size due to high 
detection rates in the ‘control’ arm. Individual trials of variable stiffness 
colonoscopes have shown mixed outcomes in improving caecal intubation 
rate. However a meta-analysis has suggested an association with higher 
intubation rate (Othman et al 2009) and possibly increased patient 
comfort. There is no evidence at present that the manufacturer of the 
endoscopic equipment in use affects adenoma detection rate. 
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Factor 
 
Degree of effect Reference 
Withdrawal time greater 
than 6 minutes 
ADR 11.8% vs. 28.3%, 
p=0.001 
Barclay 2005 
Position change during 
colonoscopy 
ADR positively correlated 
with an improved distension 
score (correlation 
coefficient, 0.12; p< .001). 
East 2008a, 2011 
Use of an antispasmodic 
agent 
Mean number of polyps in 
patients with high colonic 
spasm score in hyoscine 
group 1.2  vs. 0.41 in the 
placebo group, p=0.060 
Lee JM 2010 
Rectal retroflexion 1% increase in ADR Hanson 2002 
Quality of bowel 
preparation 
Odds ratio for polyp 
detection 1.46 (1.11-1.93) 
for high quality vs. low 
quality preparation 
Froelich 2005 
Time of day 27% more polyps earlier in 
the day than later 
 
Morning ADR- 29.3% 
Afternoon ADR 25.3% 
(p=0.008) 
Chan 2009 
 
 
Sanaka 2009 
High definition 1.34 small (<6mm) 
adenomas vs. 0.83 in the 
control group (p=0.03) 
East  2008b 
Chromendoscopy 33% in dye spray group vs. 
25% in control group 
p<0.001 
Brooker 2002  
Narrow Band Imaging No different to white light 
in Rex 2007, Increase in 
total number of adenomas 
in Inoue 2008. 
Rex 2007 Inoue 2008 
Table 11- Technical colonoscopy factors affecting ADR and the potential magnitude of effect. 
 
Limitations of using ADR as the primary indicator of colonic performance exist. ADR 
depends on the underlying prevalence of adenomas in the population being colonoscoped. 
It also varies depending on the indication for the colonoscopy (Millan 2008) and the age 
and sex of the patient (Rex 1993). Care is required therefore, when comparing the ADRs 
of different colonoscopists as the populations they are investigating may differ.  
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As mentioned, many factors impact upon adenoma detection rate during colonoscopy. 
Each will be considered below. 
 
Colonoscopy withdrawal time 
Colonoscopy withdrawal time (CWT) is the length of time the colonoscopist spends 
withdrawing the colonoscope from the colon once the caecum has been reached. It is 
assumed that during this phase of the examination detailed mucosal inspection takes 
place and abnormalities, subtle or otherwise, are identified.  
CWT has been shown to positively correlate with an individual colonoscopist’s polyp and 
adenoma detection rate (especially for polyps smaller than 5 mm (Simmons et al 2006)). 
In a study by Barclay et al (2006) of 2053 screening colonoscopies, colonoscopists with a 
mean CWT of less than 6 minutes detected less neoplasia than those with mean CWT 
greater than 6 minutes (11.8% vs. 28.3%, p=0.001). Similarly, advanced neoplasia was 
detected less frequently (2.6% vs. 6.4%, p=0.005). In this trial CWT was measured in 
both procedures in which no polyps were discovered and procedures in which ‘a polyp or 
mass was manipulated’. Encountering pathology and possible removal of the pathology 
(polypectomy) during colonoscopy will inevitably prolong withdrawal time. A more 
accurate reflection of the duration of mucosal inspection should therefore be drawn from 
analysing CWT during ‘normal’ colonoscopies. The figures quoted from this study refer 
to CWT in procedures in which no pathology was encountered. 
The same authors then went on to impose a minimum withdrawal time of 8 minutes in 
their unit. They used the data presented in their original study as baseline (Barclay et al 
2008). During the subsequent 13 months in which 2325 screening colonoscopies were 
performed, a minimum withdrawal time of 8 minutes and optimal withdrawal technique 
were employed. An increase in ADR from 23.5% to 34.7% (p<0.0001) was seen. The 
increase in advanced adenoma detection rate was not significant (5.5% in the baseline 
group vs. 6.3% in the post-intervention group (p=0.18)). There were however, positive 
correlations between CWT in procedures without polyp removal and adenoma, and 
advanced adenoma detection rates (rs=0.64, p=0.03 and rs=0.53, p=0.07). This study is 
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limited by being an observational study in which the colonoscopists were aware of the 
intervention. It suggests a modest benefit from imposing a minimum withdrawal time. 
Sawhney et al (2008) did not find an increase in polyp detection rate (PDR) when they 
studied the effect of a policy of a minimum CWT of 7 minutes in their institution. In this 
study 42 colonoscopists performed 23,910 colonoscopies. At the start of the study period 
there was 65% compliance with a 7 minute CWT. At the end of the study period, 
compliance had risen to nearly 100%, however no significant increase in polyp detection 
rate was observed. The absence of an increase in PDR in this study may have been 
because of the high baseline PDR (48%) amongst the colonoscopists. The authors suggest 
that CWT does not in itself affect lesion detection rate but rather, it is a marker of 
meticulousness of the colonoscopist and the quality of their technique.  
In the NHS Bowel Cancer Screening Programme, which also has a high baseline ADR, a 
small study presented as an abstract compared mean CWT for 5 colonoscopists with their 
respective adenoma detection rates. A significant positive correlation was found 
(Spearman r=0.97, p=0.02) (Nylander et al 2008). 
CWT has not been shown to correlate with longer term clinical outcomes such as interval 
cancer rate (Gellad et al 2010). However, baseline withdrawal time was calculated from 
only 304 procedures where no polyps were detected. The mean withdrawal time at 
baseline (calculated per medical centre) may have been too high (12 minutes) to 
demonstrate variation which is associated with lower withdrawal times.  
In summary, the evidence suggests that a minimum CWT of 6 to 8 minutes is associated 
with an increased ADR, especially for colonoscopists with low baseline adenoma 
detection rates and for the detection of small lesions.  
The concept of having an arbitrary cut off for minimum CWT may help with setting 
minimum standards. It is likely however, that a linear relationship between CWT and 
ADR exists (Rex 2002). No plateau effect has been observed, however there must be a 
point at which ADR ceases to increase with increased CWT as there is a finite number of 
adenomas in each colon.  Thus the optimal CWT is one which allows complete inspection 
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of the colonic mucosa and maximizes ADR without prolonging the examination such that 
it is uncomfortable for the patient or uneconomic in terms of allocation of resources. 
 
Caecal intubation rate 
Caecal intubation rate (CIR) was, for many years, the most frequently used marker of 
colonoscopic performance. Opinion recently has favoured outcome related quality 
indicators (such as ADR) because CIR is felt to be a measure solely of the colonoscopists 
ability to reach the caecum rather than their ability to perform a quality examination in 
terms of mucosal inspection. CIR has been shown to be independent of ADR as an 
indicator of quality (Millan et al 2008).  
Caecal intubation is defined as reaching the caecal pole during colonoscopy. 
Identification of the caecal landmarks (ileocaecal valve, appendiceal orifice and the tri-
radiate fold) are essential. For quality monitoring purposes this should be documented by 
taking a photograph of the caecal pole. Caecal intubation rates in the major trials of 
colorectal cancer screening have consistently been above 95%. Therefore, the use of CIR 
as a discriminator of quality of colonoscopy within a screening programme may be 
limited. 
A large retrospective study (of contemporaneously gathered data) reviewed the details of 
17,100 colonoscopies performed by 45 colonoscopists (Harewood et al 2005). The mean 
CIR was 93.9% (SD 2.9%). Table 12 shows the factors tested for correlation with CIR. 
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Variable 
Correlation 
 
Statistical significance 
Extubation time (CWT) 
(average withdrawal time 
6.5 minutes (SD2.8min)) 
No correlation between 
increasing CWT and 
increasing CIR 
r=0.12  p=0.41 
Gender of endoscopists 
(female 12.8%, male 
87.2%) 
No difference in CIR 
between males (94.2%) and 
females (92.8%) 
p=0.40 
Experience of the 
colonoscopist 
(mean experience=10.1 
years (SD 7.4)) 
Weak correlation between 
increasing volume and 
increasing CIR 
 
r=0.11 p=0.46 
 
 
Annual volume of 
colonoscopy per 
endoscopist 
(mean volume=363.8 
procedures (SD 176.0)) 
Increasing experience 
correlates with improving 
CIR 
 
>9 years experience is a 
predictor of CIR 
r=0.35, p=0.017 
 
 
OR 3.43 95% CI 1.03-12.29 
p=0.04 
For junior faculty members 
(≤5 years experience)- 
higher volume predicts CIR 
Within this group- 
CIR if volume >200/year= 
92.5% 
CIR if volume<200/year= 
88.5% 
 
OR 12.0 (95% CI 1.03-
33.3) 
 
P=0.04 
 
 
Insertion time 
(average insertion time= 
9.5 minutes (SD 2.8) 
Correlation between 
declining insertion time and 
increasing CIR 
 
Correlation between 
increasing endoscopist 
experience and declining 
insertion time 
r=0.36  p=0.013 
 
 
r=0.47  p=0.0008 
Age of endoscopists 
(mean age= 44 years (SD 
7.0) 
Correlation between 
increasing age and 
increasing CIR 
 
Strong correlation between 
age and experience 
r=0.37  p=0.011 
 
 
r=0.92  p<0.0001 
Table 12- Factors associated with (green) and not associated with (red) caecal intubation rate: 
findings from an analysis of 45 colonoscopists (Harewood et al 2005). 
                      Detection and Management of Colorectal Neoplasia in the NHS Bowel Cancer Screening Programme 
59 
 
The main conclusions of this study were a direct correlation between endoscopists 
experience and caecal intubation. The author recommends that inexperienced 
colonoscopists need to perform at least 200 procedures per year to maintain adequate 
CIR. The study is limited by being retrospective in nature, however the data were 
gathered in ‘real-time’. Another limitation was that confirmation of caecal intubation 
relied on the judgement of the endoscopist. It is known that there is high intraobserver 
variability amongst endoscopists in recognising the anatomical landmarks in the caecum 
(Marshall et al 1996). 
Patient specific factors may also impact upon caecal intubation (Waye 1991). These 
include: 
 Age 
 Gender (Saunders et al 1996) 
 Adequacy of bowel preparation 
 History of pelvic surgery 
 
The frequency of patients with these characteristics may vary within different study 
populations, these variables should be controlled for in trials examining caecal intubation 
rate. 
Complete examination of the colon to the caecum is important as a proportion of 
colorectal neoplasms may be found in the proximal colon. More careful inspection of the 
right side is increasingly important in the light of studies demonstrating that screening 
colonoscopy does not reduce mortality from right sided cancer.  A Canadian community 
based study examined the protective benefit against colorectal cancer of having had a 
colonoscopy (Baxter et al 2009). Patients who were diagnosed with colorectal cancer 
were 31% less likely to have had a colonoscopy in the preceding 6 months than people 
who were not diagnosed with colon cancer. Complete colonoscopy was strongly 
associated with fewer deaths from left sided colorectal (adjusted conditional OR 0.33 
(95% CI 0.28-0.39)) but not from right sided colorectal cancer (OR 0.99 (95 % CI 0.86-
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1.14)). The quality of the colonoscopists in this trial, however, is not known (69% were 
generalists or surgeons) and the quality of the procedures (including extent) cannot be 
verified. More recently, data from the German studies (Brenner 2011) have suggested 
that colonoscopy is protective against right and left sided colorectal cancer with adjusted 
odds ratio for left sided cancer of 0.44 (CI, 0.35 to 0.55), and right sided cancer 0.16 (CI, 
0.12 to 0.20) if colonoscopy had been performed in the preceding 10 years. Overall, 
colonoscopy in the preceding 10 years was associated with a 77% reduction in the risk of 
colorectal cancer (95% CI 73-81%) 
Another contributing factor to the lack of protection from right sided colorectal cancer by 
colonoscopy may be the different natural history of right sided cancers. There is 
increasing awareness of the heightened malignant potential of serrated polyps/adenomas 
(SSP(A)s) which tend to be found proximally and are difficult to detect at colonoscopy. 
Such large (>1cm), proximal polyps may be as common as or more common than large 
adenomas. (East et al 2008c; Spring et al 2006; East et al 2008d) 
 
Bowel preparation 
Prior to performing colonoscopy it is necessary to purge the bowel to remove faecal 
matter using laxatives and other purgative agents. This allows inspection of the mucosa. 
Residual faecal matter not cleared by the bowel preparation may be removed during 
colonoscopy by washing or suction; however, if it is unable to be removed it may obscure 
the endoscopist’s view of the mucosa and contribute to the risk of missing lesions. 
Poor preparation increases intubation time and reduces detection of small and large 
adenomas (Harewood et al 2003; Froelich et al 2005).  In addition, the quality of bowel 
preparation is an indicator of quality of the endoscopy unit itself as the logistics of getting 
the correct bowel preparation to the patient with adequate instructions requires 
infrastructure and organization.  
US guidelines state that the quality of bowel preparation should be recorded for each 
procedure (Rex et al 2006). At present there is no standard system for measuring 
adequacy of bowel preparation. Most scales in use are based on the amount of 
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intraluminal contents remaining and use terms such as “excellent, good, poor or 
inadequate”. These terms lack standard definitions.  
The U.S. Multi-Society Taskforce on Colorectal Cancer has defined an adequate bowel 
preparation as allowing the detection of polyps 5mm or larger in size (Rec et al 2002). 
Two recently described and validated scales for measuring quality of bowel preparation 
have been described. Both score the quality of preparation in each colonic segment. The 
Boston Bowel Preparation Scale (BBPS) has been shown to have good intra-observer 
reliability (weighted kappa= 0.77 (95% CI, 0.66-0.87)) amongst 22 colonoscopists. It has 
also been shown to be associated with endoscopic findings such as ADR and other 
variables such as CWT. It is applied after the endoscopist has performed any additional 
cleansing manoeuvres, which makes it more clinically relevant (Lai et al 2009). The 
Ottawa Bowel Preparation Scale also demonstrates intraobserver consistency (kappa ICC 
of 0.94 (95% CI, 0.91-0.96) but has not been demonstrated to be positively correlated 
with colonoscopy findings (Rostom et al 2004).  
 
Patient comfort and use of sedation 
Multiple factors may be associated with increased patient discomfort during colonoscopy 
(Park et al 2007). 
 Procedure 
o Longer Duration 
o Technically difficult procedure 
o Use of air instead of CO2 insufflation (Sumanac et al 2002) 
o Non-use of variable stiffness colonoscopes (Brooker et al 2001) 
o Use of transparent caps (Sata et al 2008) 
 Patient 
o Younger age 
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o Female sex 
o Previous pelvic surgery 
o Diagnosis of IBD 
o Low BMI 
 Colonoscopist 
o Lesser experience 
 Sedation 
o Type 
o Amount 
 
As with quality of bowel preparation, no validated scoring system for patient comfort is 
widely in use. Patient comfort during colonoscopy is important for a number of reasons. 
First, in order to ensure a satisfactory experience for the patient colonoscopy should not 
be a painful procedure. Second, to ensure the patient is not deterred from having another 
colonoscopy as repeated procedures may be necessary within a screening or surveillance 
programme. Third, recent studies have suggested that deeper sedation may improve 
adenoma detection rate (Radaelli et al 2008; Hoda et al 2009). It may be concluded that a 
calm, unrushed environment in which the patient is deeply sedated and the colonoscopist 
is able to concentrate fully on the procedure itself allows more careful mucosal 
examination. An awake, comfortable patient should provide a similar environment with 
the added benefit of enabling position changes and continuous feedback from the patient. 
Patient comfort and sedation practice are intimately linked. Conscious sedation is the 
recommended approach to sedation in the UK (Guidelines on Safety and Sedation During 
Endoscopic Procedures, BSG 1991). This acknowledges the trade-off between 
minimising patient discomfort and the increased risk of complications associated with 
deeper sedation (especially cardiorespiratory complications) (Scoping Our Practice, 
NCEPOD, 2004). Use of sedation however, may affect adenoma detection rate. An 
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Italian prospective review of 12835 patients undergoing colonoscopy found that use of 
sedation was significantly associated with finding one or more polyps (use of sedation vs 
no sedation odds ratio 1.17 95% CI 1.07-1.23) (Radaellii et al 2008). Two US studies 
have demonstrated higher ADR in more deeply sedated patients (Hoda et al 2009; Wang 
et al 2010). 
Increasingly, sedation free colonoscopy is being performed, with or without the use of 
nitrous oxide and air. A US review of 578 patients choosing to undergo colonoscopy 
without sedation found that 85% of men and 67% of women were able to tolerate the 
procedure without requesting analgesia or sedation. Caecal intubation rates were 
maintained regardless of the need for sedation. 97.4% of patients undergoing sedation 
free colonoscopy were satisfied with their comfort level and would undergo the 
procedure again without sedation (Petrini et al 2009).  This may be seen as a marker of 
colonoscopic expertise, requiring technical excellence to negotiate the colon without 
causing discomfort. However, minimising sedation use should not compromise the 
quality of the colonoscopy in terms of mucosal inspection, CWT and lesion detection.  
 
Rectal retroflexion 
Rectal retroflexion is the technique of inspecting the distal rectum and anus from above 
by placing the colonoscope in a “J” position. It overcomes the difficulty inspecting the 
distal rectum with a forward viewing endoscope. A study of rectoflexion during flexible 
sigmoidoscopy estimated an absolute 1% increase in ADR when retroflexion is routinely 
performed, without any increase in patient discomfort (Hanson et al 2002).  
A more recent US study has suggested a much lower yield for neoplasia with retroversion 
(Saad et al 2008). 1502 patients underwent colonoscopy with retroflexion successfully 
performed in 1411 (93.1%). Only 7 of 40 polyps were seen at retroflexion that were not 
seen with careful forward viewing examination of the rectum. 6 of these 7 polyps were 
metaplastic and 1 was a sessile tubular adenoma. Retroflexion in the rectum can be 
associated with discomfort and perforation and is therefore not routinely recommended 
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by US Guidelines. In the NHS BCSP however, retroflexion is recommended. Further 
studies of the need for rectal retroversion are required. 
 
Incidence of interval lesions 
The aim of the NHS BCSP is to detect colorectal cancers at an earlier stage or to prevent 
colorectal cancer by removing adenomas. If a cancer or an adenoma is present but is not 
detected by colonoscopy it constitutes a missed lesion. Missed lesions only become 
apparent if the patient becomes symptomatic and requires repeat investigation or if a 
lesion is found during a surveillance colonoscopy within a timeframe such that it was 
likely to have been present during the previous investigation. These cancers are 
collectively termed ‘post colonoscopy colorectal cancers’ (Rabeneck 2010). Interval 
cancers are lesions detected between screening rounds or following a screening test in a 
previous round. 
Early studies of colorectal cancer screening in the 1990`s indicated that colonoscopy and 
polypectomy prevented 76% to 90% of interval cancers (cancers that are found between 
scheduled screening episodes) (Winawer et al 1993; Citarda et al 2001; Thiis-Evenson et 
al 1999), these trials involved close colonoscopic surveillance. More recent trials have 
suggested a higher rate of interval cancers than found in the earlier studies (Schatzkin et 
al 2000; Alberts et al 2000; Robertson et al 2005). This suggests that colonoscopy and 
polypectomy is not as protective against colorectal cancer as previously thought. An 
analysis of individual cases in one of the aforementioned trials (Pabby et al 2005) 
suggests that over half of interval cancers were either missed or occurred at sites of 
previous adenomas. A retrospective study of interval cancers (defined as cancers being 
found within 5 years of a complete colonoscopy) in an American screening programme 
found that 27% of the interval cancers developed in segments of bowel in which 
polypectomy had previously been performed (Farrar et al 2006), suggesting incomplete 
resection of the adenoma at index colonoscopy, the remaining 73% of lesions may have 
been missed all together.  
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A number of recent Canadian studies have suggested that colonoscopy is poor at 
detecting right sided lesions and subsequently confers less protection against right sided 
cancer (Singh et al 2006; Baxter et al 2009). 
Baxter (2009) performed a community based study in Canada which showed that 
colonoscopy was associated with a reduction in risk of dying from left sided colon cancer 
(adjusted conditional OR, 0.33 (CI, 0.28 to 0.39)) but not right sided cancer (adjusted 
conditional OR, 0.99 (CI, 0.86 to 1.14)). This study has been criticised as the competency 
of the colonoscopists was not known, many were community practitioners for whom no 
data on colonoscopic quality were available. However, a follow on study from the same 
group has shown an inverse relationship between increasing colonoscopic quality in 
terms of caecal intubation and decreasing interval cancer rates (Baxter et al 2011).   
Similar findings were made in a German study showing reduced rates of left sided 
advanced adenomas for 10 years following colonoscopy but no reduction in right sided 
advanced lesions (Brenner et al 2010). 
It is possible that some interval lesions are fast-growing cancers, this is supported by the 
discovery that interval cancers were almost 4 times as likely to display microsatellite 
instability (a result of loss of function of mismatch repair genes, associated with fast 
growing tumours) than non-interval cancers (Sawhney et al 2006). 
It is known that colonoscopy is not a perfect test and has an inherent “miss-rate” due to a 
wide range of factors (see 2.2.1). Studies of back to back colonoscopy demonstrate miss 
rates during colonoscopy of adenomas ≥1cm of 0-6%, 6-9mm of 12-13% and ≤5mm of 
15-27% (Hickson et al 1990; Rex et al 1997). A pooled analysis (van Rijn et al 2006) 
demonstrated a pooled miss rate for polyps of any size of 22% (95% CI: 19-26%; 
370/1,650 polyps). Adenoma miss rate by size was, respectively, 2.1% (95% CI: 0.3-
7.3%; 2/96 adenomas > or =10 mm), 13% (95% CI: 8.0-18%; 16/124 adenomas 5-10 
mm), and 26% (95% CI: 27-35%; 151/587 adenomas 1-5 mm). Subsequent studies using 
CT colonography have measured the miss rate of adenomas ≥1cm in size by conventional 
colonoscopy as 12-17% (Pickhardt et al 2004; van Geder et al 2004).  
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Minimising the interval cancer or miss rate is crucially important to the success of the 
NHS BCSP as it will contribute significantly to the ability of the screening programme to 
reduce mortality from colorectal cancer, an outcome by which the success of the 
programme is likely to be judged. Monitoring the interval cancer rate, therefore, will be 
an important outcome related quality indicator. Detection of interval cancers will be 
difficult as few patients will undergo repeat colonoscopy within the programme unless 
they require surveillance based on findings at index colonoscopy or have a further 
positive FoBt in a subsequent round. Thus the use of interval cancer rate as a potential 
marker of quality of colonoscopy in the BCSP will take many years to measure. 
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Summary 
1. Adenoma detection rate is an increasingly important marker of colonoscopic 
performance and quality. 
2. Monitoring colonoscopic performance is important, particularly within the 
framework of a screening programme, in order to optimize the benefit of the 
procedure to patients and minimize harm. 
3. There is variability in the adenoma detection rates of individual colonoscopists; 
this can be attributed to a wide range of factors. The functional impact of this may 
be an association with miss rates of adenomas and cancers. 
4. British Society of Gastroenterology and US guidelines recommend that 
colonoscopists measure their adenoma detection rate. 
5. Adenoma detection rate is dependant on a wide range of factors. These factors 
may relate to the endoscopists, to the patient or to technical aspects of the 
procedure. 
6. Improving adenoma detection rate may reduce interval lesion rate, further 
research in this area is necessary. 
7. Increasing colonoscope withdrawal time (CWT) is probably correlated with 
increasing adenoma detection rate however this effect may be attenuated if there 
is a high baseline ADR. CWT may be used as a marker of the quality of an 
individual colonoscopist’s technique. 
8. Caecal intubation rate (CIR) is of limited use as a marker of quality as it lacks 
variation. It may however be used to identify poor performance. 
9. Quality of bowel preparation and sedation practices are useful surrogate markers 
of quality of colonoscopy. 
10. A single, universal marker of quality of colonoscopy has not been identified. It is 
likely that a combination of the markers of quality described above is necessary to 
cover all aspects of procedure (patient-related markers, operator-related markers 
and outcome-related markers).  
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2.3.0- Management of Neoplasia in the NHS Bowel Cancer Screening 
Programme 
 
2.3.1- 12 month surveillance colonoscopy in patients at high risk of future 
neoplasia 
 
Evidence supporting the BSG guidelines 
Patients who have undergone colonoscopy and polypectomy are at a greater risk than the 
background population of having further adenomas or colorectal cancer in the future 
(Winawer et al 2003; Atkin et al 1992; van Stolk et al 1998).  The risk of having further 
adenomas or developing colorectal cancer depends on a number of factors including the 
number, size and degree of dysplasia of the original adenomas (see below).  
For this reason patients who have had polypectomy are often recommended surveillance 
colonoscopy. The interval between index colonoscopy, first surveillance colonoscopy and 
subsequent surveillance intervals should depend on the magnitude of the individual 
patient’s risk of having further adenomas or cancer at any particular time interval. 
Other considerations such as the age, comorbidity, family history, quality of the index 
colonoscopy and risk of having missed lesions at the index colonoscopy should also be 
taken into account. 
The reasons for finding further adenomas or colorectal cancer at colonoscopy after a 
patient has already had colonoscopy and polypectomy (of all detected lesions) are 
threefold. 
 New adenomas or cancers 
o Adenomas develop slowly over many years. If the interval between 
colonoscopies is short it is less likely that new lesions will have 
developed. Fast growing flat or depressed lesions, particularly in the right 
colon may have more of a propensity to grow quickly. 
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 Missed lesions 
o The miss rate by colonoscopy of adenomas greater than 1cm is up to 6% 
(van Rijn et al 2006). This may account for lesions found at surveillance 
colonoscopy. 
 Recurrence 
o Incompletely resected adenomas may recur. 
The purpose of surveillance colonoscopy therefore is to detect new, missed or recurrent 
lesions. 
Certain subgroups of adenomas have a higher risk of becoming malignant over time. The 
following features are associated with an increased risk of progression to malignancy 
(Eide 1986):  
 1cm or greater in size 
 Higher grade of dysplasia 
 Villous architecture 
 Increasing number of adenomas 
Adenomas which are 1cm or larger in size and those displaying high grade dysplasia are 
collectively termed advanced adenomas. Because these polyps have a greater malignant 
potential, there is an emphasis on detecting and removing advanced lesions during 
colonoscopic surveillance. The presence of advanced adenomas is also a marker for the 
presence of other lesions which may have been missed. Incidence of advanced adenomas 
(or advanced adenomas and colorectal cancer, collectively termed ‘advanced neoplasia’) 
is an important outcome measure in trials of colonoscopic surveillance. 
Advanced adenomas are often defined differently in the US and English literature. In the 
US literature adenomas with villous histology are included. This is not practice in 
England due to the perceived inconsistencies of biopsying adenomas leading to 
unrepresentative sampling and significant intra-observer variability of histological 
subtyping (Atkin et al 2002; Constantini et al 2003).  
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A meta-analysis of advanced adenoma incidence during surveillance colonoscopy in 
patients with a history of adenomas (Saini et al 2006) showed that patients with 3 or more 
adenomas at index colonoscopy had a higher risk of having recurrent advanced adenomas 
at follow up than patients with 1 or 2 adenomas at index (Risk Ratio 2.52, 95% CI 1.07-
5.97). Patients with high grade dysplasia at index were also at increased risk (Risk Ratio 
1.84, 95% CI 1.06-3.19), as were patients with increasing size of adenoma at index.  
These results contain data from patients undergoing surveillance at heterogeneous 
intervals (range 10-48 months) and both definitions of advanced adenoma were included. 
Only surveillance intervals of 2 years or more were included in the analysis suggesting 
that the lesions found at follow up may have been new or missed lesions. 
In the US National Polyp Study (Winawer et al 1993) (a randomised comparison of 
different surveillance intervals in 1418 patients with adenomas removed at colonoscopy), 
the cumulative detection rate of advanced neoplasia (US definition) was 3% in the groups 
having either 1 or 2 colonoscopies in the 3 years following the index procedure.  
In the Danish Funen Adenoma follow-up Study the incidence of advanced adenomas was 
5.2% at 2 years and 8.6% at 4 years (Jorgensen et al 1995). 
Patients with only 1 or 2 small (<1cm) adenomas are at a much lower risk of developing 
further adenomas or having adenomas missed at index colonoscopy (Zauber et al 1999; 
van Stolk et al 1998; Noshirwani et al 2000; Martinez 2001). The risk of these patients 
subsequently developing colorectal cancer is also low. A study of 751 patients who had 
had small adenomas removed did not show any increased risk of cancer over 10,000 
person-years of follow up (Spencer et al 1984). A study of 1618 patients who underwent 
rigid sigmoidoscopy and polypectomy of rectosigmoid lesions included a group of 776 
patients with small (<1cm) tubular adenomas in which no increase in colorectal cancer 
was observed compared to the general population (Atkin et al 1992).  
Patients with a few, small adenomas do not, therefore, warrant colonoscopic surveillance. 
If, however, a patient has a high adenoma burden, their risk of having had a lesion missed 
at index colonoscopy or of developing further adenomas is much higher. 
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Figure 13 demonstrates the increased risk associated with baseline colonoscopic findings. 
Findings at index colonoscopy 
Risk of advanced adenoma at 
follow up 
Reference 
≥3 adenomas 
 
 
≥1 adenoma displaying HGD 
RR 2.52 (95% CI 1.07-5.97) 
compared to having 1-2 
adenomas 
 
RR 1.84 (95% CI 1.06-3.19) 
 
 
Saini et al 1996 
(Meta-analysis) 
≥5 adenomas 
 
≥1 villous adenoma 
 
≥1 proximal adenoma 
24.1% (SE 2.2) 
 
OR 1.28 (95% CI 1.07-1.52) 
 
OR 1.68 (95% CI 1.43-1.98) 
Martinez et al 2001) 
(Pooled analysis) 
1 adenoma (any size) 1% at first follow up 
National Polyp Study (Winawer 
et al 1993) 
Four or more adenomas (any size) 
5-fold increase compared to 1 or 
2 small adenomas at index 
 
Cleveland Clinic  
Foundation Adenoma Registry 
(Noshirwani et al 2000) 
Multiple adenomas, at least one 
of which is ≥1cm 
10 –fold increase compared to 1 
or 2 small adenomas at index 
Cleveland Clinic Foundation 
Adenoma Registry (Noshirwani 
et al 2000)  
Adenoma larger than 1cm 
2.7- fold increase risk of 
colorectal cancer compared to 
general population 
Lofti AM et al 1986 
Multiple adenomas and at least 
one large (>1cm) adenoma 
5-fold increase risk of colorectal 
cancer compared to general 
population 
Lofti AM et al 1986 
Table 13- Findings at baseline colonoscopy associated with advanced neoplasia during surveillance 
 
A recent pooled analysis (Martinez et al 2009) from 8 prospective studies comprising 
9167 patients who had undergone colonoscopy and polypectomy showed that 12% of the 
patients were found to have advanced neoplasia during a median follow up period of 47.2 
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months. The irsk of developing advanced neoplasia was higher in patients with 5 or more 
baseline adenomas (24.1%, SE 2.2) and adenoma greater than 2cm at baseline (19.3%, 
SE 1.5). The presence of an adenoma with villous architecture and proximal location 
were also significantly associated with metachronous advanced adenomas (OR 1.28, 
(95% CI 1.07-1.52) and OR1.68, (95% CI 1.43-1.98) respectively).  
Older age (p<0.0001 for trend) and male sex (OR 1.4, (95% CI1.19-1.65)) were also 
significantly associated with metachronous advanced neoplasia. High grade dysplasia in 
baseline adenoma was not associated with further advanced neoplasia when other polyp 
characteristics were adjusted for. In the group of patients with multiple or large polyps at 
baseline colonoscopy, closer colonoscopic surveillance may be indicated. The evidence 
outlined above forms the basis of the British Society of Gastroenterology guidelines on 
adenoma surveillance (Atkin et al 2002; Cairns et al 2010). The summary of these 
guidelines are shown in figure 9. 
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Figure 9- Adenoma surveillance guidelines. BSG (Atkin et al 2002). 
 
These guidelines are widely used in the UK and form the basis of adenoma surveillance 
in the NHS Bowel Cancer Screening Programme (BCSP). The only variation is that 
patients with ‘low risk’ polyps in the BCSP return to the biennial FOB testing screening 
strategy rather than following the guidelines above which would suggest either no further 
surveillance or a 5 year interval. There are no published data yet on the outcomes of 
surveillance in the BCSP.  
A more recent pooled analysis (de Jonge 2011) of factors predicting the presence of 
adenomas at surveillance has reinforced the importance of age greater than 60 (pooled 
relative risk (RR) 1.81, 95% CI ), three or more adenomas (RR 1.64), advanced adenoma 
at index colonoscopy (RR 1.81, 1.13-2.89) and size ≥ 10mm (RR 1.66, 1.32-2.10). Less 
strong associations were seen for villous adenoma at index (1.21, 0.97-1.45), high grade 
dysplasia (1.66 (1.26-2.19), proximal location of adenoma at baseline (1.43, 1.30-1.57) 
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and male gender (RR1.22, 1.12-1.32). Marked variation in study design and substantial 
heterogeneity between studies included in the pooled analyses were noted. 
The European guidelines for quality assurance in colorectal cancer screening and 
diagnosis make slightly different recommendations for high risk individuals to the BSG 
guidelines (Segnan et al 2011). The European guidelines recommend an additional 
clearing colonoscopy at 12 months for individuals with 5 or more adenomas or an 
adenoma of 2cm or larger due to the substantial risk of missing adenomas with high 
malignant potential. 
Recent studies have examined the effect of dietary and pharmacological interventions on 
subsequent adenoma development following polypectomy. A US study (Schatzkin et al 
2000) of 2079 men and women who had one or more histologically confirmed adenomas 
removed were randomized to receive either a low-fat, high-fibre diet or to continue on 
their normal diet. They then underwent colonoscopy at 1 and 4 years. 1905 subjects 
completed the study. 39.7% and 39.5% had at least one recurrent adenoma during follow 
up in each group respectively (unadjusted risk ratio 1.00 (95% CI 0.9-1.12)). No 
protective benefit from this dietary intervention was seen. A trial of high fibre cereal 
supplements (Alberts et al 2000) did not demonstrate protection against adenoma 
recurrence in 1303 subjects (47% adenoma recurrence in the high fibre group, 51.2% in 
the low fibre group (odds ratio 0.88, 95% CI 0.7-1.11, p=0.28)). 
The enzyme cyclo-oxygenase 2 (COX-2) is overexpressed in colorectal adenomatous 
polyps. The PreSAP trial (Arber et al 2006) of Celecoxib (a COX-2 inhibitor) 
randomized patients who had had one or more adenomas removed to receive either 
400mg of Celecoxib daily or placebo. All patients underwent colonoscopy at 1 year and 3 
years. The cumulative rate of adenomas detected by year 3 was 33.6% in the celecoxib 
group and 49.3% in the placebo group (relative risk, 0.64; 95% CI 0.56-0.75; P<0.001). 
The cumulative rate of advanced adenomas detected through by year 3 was 5.3%  in the 
celecoxib group and 10.4% in the placebo group (relative risk, 0.49; 95% CI 0.33-0.73; 
P<0.001). Adjudicated serious cardiovascular events occurred in 2.5% of subjects in the 
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celecoxib group and 1.9% of those in the placebo group (relative risk, 1.30; 95% 
confidence interval, 0.65 to 2.62).  
In a similar trial of Rofecoxib (Baron et al 2006), adenoma recurrence was less frequent 
for rofecoxib subjects than for those randomized to placebo (41% vs. 55%; p< 0.001; 
relative risk 0.76; 95% confidence interval 0.69-0.83). Rofecoxib also conferred a 
reduction in risk against advanced adenoma recurrence (p < 0.001). In this trial excess 
serious cardiovascular events and upper gastrointestinal bleeding was observed in the 
treatment arm. The concerns over cardiovascular and gastrointestinal toxicity have 
limited the clinical usefulness of COX-2 inhibitors in chemoprevention of recurrent 
adenomas. 
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Summary 
1. An important aim of colonoscopy is to detect and remove adenoma. 
2. Colonoscopy may miss adenomas allowing them to continue to develop. 
3. Adenomas may recur following colonoscopy and polypectomy. 
4. Despite colonoscopy and polypectomy a patient may go on to develop adenoma 
and/or colorectal cancer. 
5. Certain characteristics of the patient (increasing age, male sex) and of the baseline 
adenomas (increasing number and size, possibly advancing histological grade and 
villous architecture) predict adenoma recurrence and likelihood of colorectal cancer 
following polypectomy. 
6. Patients with multiple or large polyps are more likely to benefit from colonoscopic 
surveillance. 
7. The BSG guidelines for adenoma surveillance are incorporated into the NHS 
Bowel Cancer Screening Programme. Outcomes of 1 year surveillance within the 
screening programme are not yet known will be reported in this thesis. 
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2.3.2- Management of large colonic polyps. 
 
When a polyp is detected at colonoscopy, a decision must be made whether to remove the 
polyp endoscopically, surgically or to not remove it at all. 
The following factors will influence the decision: 
 Site of the lesion 
 Size of the lesion 
 Histological nature of the lesion (may require representative biopsies to be taken 
to assess) 
 Age and comorbidities of the patient 
 The patients wishes 
 Operator experience of endoscopic or surgical management 
 Risk of surgical management  
 Risk of endoscopic therapy 
 Feasibility of endoscopic resection 
Endoscopic techniques have progressed to allow the removal of larger and sessile polyps 
which previously would have necessitated surgical management. New endoscopic 
techniques such as endoscopic mucosal resection (EMR) and endoscopic submucosal 
dissection (ESD) have facilitated this progress. 
Equally, the advent of laparoscopic colorectal surgery has made surgical management of 
large polyps less invasive and potentially safer than open surgery. The management of 
large or complex rectal lesions has been advanced by the development of Trans-anal 
endoscopic Micro-surgery (TEMS) which allows the removal of rectal lesions without a 
skin incision. 
The management of polyps which are shown to have a malignant component on biopsy 
will not be considered in this literature review as the management of such polyps is 
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subject to other variables such as depth of invasion and risk of loco-regional spread. The 
management of presumed large benign polyps will be focused on. Some of these polyps 
may turn out to have a malignant component once removed. 
There is no specific definition for ‘large colonic polyp’.  Generally, it refers to polyps 
larger than 2-3cm in size. Polyps larger than 3 cm are sometimes referred to as ‘giant 
polyps’. 
Pedunculated polyps (polyps with a definite stalk) are easier and safer to remove than 
sessile of flat polyps. Therefore the management of sessile lesions will be focused on in 
this review. 
There is no consensus in the literature on the best approach to the management of large 
colorectal polyps. In experienced hands both approaches seem to be acceptable (Church 
2003). Endoscopic management by non experts may be associated with worse outcomes 
(Brooker et al 2002). 
Both surgical and endoscopic approaches to management of large colonic polyps have 
advantages and disadvantages as shown in table 14. 
 
 
 
                      Detection and Management of Colorectal Neoplasia in the NHS Bowel Cancer Screening Programme 
79 
 
 Advantages Disadvantages 
Endoscopic 
management of 
large adenomas 
Avoids the need for general 
anaesthesia 
No skin incision 
Usually performed as a daycase 
Potentially lower costs incurred 
En-bloc* resection may be possible 
 
Risk of perforation or bleeding 
during therapy 
May require repeated sessions 
of therapy or site checking 
Lesion may turn out to be 
malignant and subsequently 
require surgery 
Piecemeal removal may 
compromise histological 
analysis 
Risk of incomplete resection 
Surgical 
management of 
large adenomas 
Complete excision is technically 
easier 
Less likely to require repeated 
episodes of therapy 
Complete resection specimen is 
better for pathological analysis 
Risk of surgical complications 
Need for skin incision and 
subsequent scar 
Need for general anaesthesia 
Longer hospital stay 
Potentially more costly 
Table 14-Advantages and disadvantages of endoscopic and surgical management of large polyps. 
*En bloc refers to removal of the polyp in one piece, allowing pathological determination of extent of 
resection. Piecemeal removal of the polyp does not allow the completeness of resection to be 
determined.There is little evidence available to evaluate the factors outlined in table 14.  
No head to head randomized controlled trials of endoscopic versus laparoscopic surgical 
management of large colonic polyps have been undertaken. Current practice is variable 
and depends on the local expertise available. 
A study from St Mark`s Hospital, UK emphasized the importance of a specialist 
endoscopist (with experience of managing large polyps) rather than a non-specialist 
endoscopist assessing such lesions (Brooker et al 2002). In this study two specialist 
endoscopists attempted endoscopic resection of 80/86 large polyps (≥2cm). Resection was 
successful in 61/86 (71%) of patients thus avoiding the need for surgery. Non-specialist 
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endoscopists however, attempted resection of 15 large polyps, 9 of which subsequently required 
surgical intervention, thus surgery was only avoided in 40%. 
A review of 71 patients referred for surgical management of large colonic polyps 
(average size 24mm, range 10-63mm) demonstrated the importance of colonoscopic 
reassessment of the polyp by an expert prior to surgery (Lipof et al 2005). In 23/71 (32%) 
of patients the polyp was removed colonoscopically, obviating the need for surgery.  
 
Endoscopic Management of large colonic polyps 
Table 15 displays the available published series of endoscopic management of large 
colonic polyps. The studies are mostly retrospective in design. The management 
protocols and inclusion criteria are broadly heterogeneous. However, the same underlying 
principles of management of large polyps are applied in all studies and the range of data 
gives a clear overview of the potential benefits and complications associated with 
endoscopic management of such lesions. 
In summary: 
 The definition of a large colonic polyp is not consistent. The majority of studies 
refer to polyps larger than 2 cm in diameter. 
 The rate of residual adenoma detected during surveillance varies between 5-54%. 
The more recent series suggest a rate of residual adenoma or recurrence of around 
10%. Comparison of this outcome is limited by variation of definition between 
studies.  
 Bleeding is the most common complication. Delayed bleeding occurs in 0-11% of 
cases. The most recent, larger series suggest a delayed bleeding rate of 1.5-7%. 
 The majority of cases of bleeding can be managed endoscopically without the 
need for surgery. 
 Perforation is a rare complication. It occurs in 0-3% of cases and is almost always 
associated with attempted resection of a malignant lesion. 
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 EUS has not been widely used in the assessment of large lesions prior to 
resection. It’s use may improve selection of benign lesions for resection 
(Hurlstone et al 2005).  
 Invasive malignancy is detected in 0-68% of resected polyps. This depends on the 
assessment process prior to resection. Recent studies in which polyps are assessed 
endoscopically prior to resection and non lifting lesions excluded suggest 3-5% of 
large polyps (≥2cm) will contain invasive malignancy and may require surgery. 
 Argon plasma coagulation following piecemeal EMR of large sessile polyps 
reduces recurrence (Zlatanic et al 1999; Brooker et al 2002). 
 The rate of surgery following endoscopic management of large colonic polyps is 
between 0-37%. The indication is usually either presence of invasive malignancy 
or incomplete resection. Surgery mandated by a complication such as bleeding or 
perforation is less common. The most recent series suggest a need for surgery due 
to recurrence, incomplete resection or malignancy in 4-16% of cases. 
 Death associated with endoscopic resection of large colonic polyps has not been 
reported in any of these series. 
 
US (Winawer et al 2006) and UK guidelines (Cairns et al 2010) recommend surveillance 
of the polypectomy site following resection of large colonic polyps is undertaken at 3 
months. Khashab et al (2009) followed up 136 large polyps (≥2cm). 24 (17.6%) had 
macroscopic evidence of recurrence at follow up. 18 displayed recurrence at first follow 
up whilst 6 (4.4%) demonstrated ‘late recurrence’ – the presence of recurrence despite 
initially normal surveillance. Negative biopsy of the polypectomy scar was associated 
with lower recurrence rates in long term follow up. 92 of 94 (97.9%) of normal appearing 
scars with negative scar biopsies remained free from recurrence at one year. Only 36 of 
42 (85.7%, p=0.005) polyps with macroscopic or microscopic evidence of recurrence 
were successfully eradicated at long term follow up. The role of chromendoscopy and 
endomicroscopy in post polypectomy surveillance is yet to be established. 
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Endoscopic submucosal dissection (ESD) allows en-bloc resection of large polyps which 
may lead to lower recurrence rates but is associated with higher complication rates and 
requires an added level of technical expertise. Zhou et al (2009) reviewed their series of 
73 patients undergoing ESD. The mean size of lesions removed was 32.6mm (range 20-
85mm). Minor bleeding occurred in all cases. One patient (1/74, 1.4%) had massive 
bleeding requiring endoscopic therapy. 6/73 patients (8.1%) experienced perforations. All 
but one settled with conservative management. One patient (1.4%) required surgery due 
to perforation. En-bloc resection was possible in 69/74 procedures. The overall residue or 
recurrence rate at one year was 0%. 
 
Surgical Management of large colonic polyps 
A retrospective review comparing 2500 endoscopic polypectomies with 58 patients 
requiring laparoscopic resection for non-endoscopically removable polyps in a single 
German unit (Hauenschild et al 2009), showed that laparoscopic surgery was a safe and 
effective approach for managing such polyps. 4 of 58 patients (6.9%) required conversion 
to open surgery. 5 patients (9.5%) experienced peri-operative complications. Details of 
endoscopic complications were not presented. 
Two US studies including a series of 51 patients referred for laparoscopic colectomy for 
endoscopically unremovable polyps to the Cleveland clinic in Ohio (Pokala et al 2007; 
Brozovich et al 2008) warned against the endoscopic management of such lesions. 
Adenocarcinoma not previously detected at colonoscopy was found in 11 polyps (20%). 5 
patients (9.8%) required conversion to open surgery. Mean hospital stay was 3.1 (+/- 1.9) 
days. 6 surgical complications occurred (17.7%) (1 anastamotic leak, 1 small bowel 
obstruction, 1 abcess, 2 exacerbations of existing medical conditions). 
A comparison between open and laparoscopic resection of colonic polyps from the 
Cleveland Clinic, Florida (Joo et al 1998) showed definite advantages of laparoscopic 
over open surgery in terms of post-operative pain, earlier return of bowel function and 
earlier return to normal function. The limitations of the laparoscopic approach were 
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longer operation times (although this study is now 11 years old) and shorter resection 
specimens (long term follow up data was not presented). 
Laparoscopic-assisted colonoscopic polypectomy, in which the polyp in located and 
removed endoscopically but with concurrent laparoscopy allowing mobilization of the 
colon and close inspection of the serosal surface, has been suggested to minimize the risk 
of complications (Hensma et al 2009). The use of this approach has not become 
widespread. 
Transanal endoscopic microsurgery (TEMS) is a surgical approach to remove large rectal 
lesions. A number of retrospective and prospective case series have demonstrated 
recurrence rates of 0-19% and complication rates of 2-21%. These figures are comparable 
to endoscopic management (Neary et al 2003; Middleton et al 2005). TEMS has never 
been compared to endoscopic mucosal resection of large rectal adenomas in a large 
multicenter randomized controlled trial, however, such a trial is currently underway 
(TREND-study) (van der Broek et al 2009). 
The cost implications of endoscopic versus laparoscopic management of large colonic 
polyps have been estimated in a number of studies. Swan et al (2009) reviewed 174 
patients referred to a tertiary unit for management of 193 polyps. 173 lesions were 
excised by EMR. 11 patients went straight to surgery due to suspicion of malignancy and 
a further 7 required surgery due to incomplete resection or malignancy in the resected 
specimen. They assumed that the 157 of 168 patients with benign lesions successfully 
treated endoscopically had avoided the need for surgery and on this basis they calculated 
a cost saving of $6990 (US) per patient.  
Brooker et al (2002) estimated the mean cost per patient of endoscopic management by a 
specialist endoscopist as £1500. Using available data on 16 patients in their study who 
required surgery they estimated the mean cost of surgical management of benign large 
colorectal polyps as £5260. 
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Year Lead 
Author 
Country Size Number of 
Polyps  
Morphology 
(Sessile or 
Pedunculated) 
Rate of 
residual 
adenoma at 
initial 
surveillance 
Bleeding Perforation Presence of 
malignancy  
in resected 
polyps 
EUS 
used  
Need for 
surgery 
Deaths 
1986 Bedogni  Italy ≥3cm 66 (36 sessile) Mixed 6/36 (16.7%) 2/66 (3%) 0 N/R No 0 0 
1992 Walsh  USA ≥2cm 132 Sessile 28% 2% 1% 17% No 27% 
(malignancy) 
0 
1996 Binmoeller  Germany ≥3cm 129 Sessile 16% 9% 0 12% No 1 residual 
tumour, 1 
malignancy 
0 
1996 Kanamori  Japan ≥3cm 25 Sessile 0 3/33 (9%) 0 16% No 0 0 
1999 Zlatanic  USA ≥2cm 77 Sessile 50% 5% 1/77 0 No 0 0 
2000 Iishi  Japan ≥2cm 56 Sessile 54% 0 0 68% No 4 residual 
tumour 
1 bleeding 
0 
2001 Dell’Abate  Italy ≥3cm 104 (35 sessile) Mixed 3/63 (5%) 1/104 (1%) 0 27/104 (26%) No 2 synch Ca, 1 
recurrence HGD 
0 
2002 Brooker  UK ≥2cm 130 Sessile 9/80 (11%) 
(benign polyps) 
4% 0 14% No 21(malignancy) 
24 (benign 
polyps) 
0 
2002 Morton  USA ≥2cm 131 (116 
sessile) 
Mixed 41/82 (50%) 14/131 
(11%) 
0 4/131 (3%) No 1 (malignancy) 0 
2002 Stergiou  Germany ≥3cm 68 (41 sessile) Mixed 12/68 (28%) 3/68 (4%) 0 7/68 (10%) yes 1 (malignancy) 0 
2003 Higaki  Japan ≥2cm 24 Sessile 4/23 (22%) N/R N/R 1/24 (4%) No 0 0 
2003 Regula Poland ≥18mm 82 Sessile 14% 2% 0 7/82 (9%) No 2 malignancy  
2 recurrence 
0 
2003 Doniec  Germany ≥3cm 186 (141 
sessile) 
Mixed 7/186 (4%) 3/104 (2%) 1 (cancer) 27/104 (26%) No 1 (bleeding) 
1 (perforation) 
9 (cancer) 
0 
2003 Church  USA ≥2cm 311 (263 managed 
endoscopically, 48 
surgically) 
 
Mixed (238 
flat/sessile) 
44/201 (22%) 17/311 0 19/311 (6.1%) No 18 (recurrence or 
malignancy) 
0 
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Year Author Country Size Number of 
Polyps  
Morphology 
(Sessile or 
Pedunculated) 
Rate of 
residual 
adenoma at 
initial 
surveillance 
Bleeding Perforation Presence of 
malignancy  
in resected 
polyps 
EUS 
used  
Need for 
surgery 
Deaths 
2004 Conio  It/Fr ≥2cm 139 Sessile 21/96 (22%) 0 0 17/136  (13%) No 10 (malignancy) 0 
2005 Hurlstone  UK ≥18mm 83 Sessile 5/62 (8%) 0 0 0 Yes 1 (non lifting) 0 
2006 Boix  Spain ≥4cm 74 Sessile 5/54 (9%) 10/74 
?timing 
0 12/74 (16.2%) No 12 (16%) 
malignancy 
0 
2007 Arebi  UK ≥2cm 161 Sessile 60/146 (40%) 7 (5.7%) 0 5.5% No 3 (recurrence) 
1 (Incomplete 
resection) 
3 (malignancy) 
0 
2008 Al-Kawas   
(Abstract) 
USA ≥2cm 96 (76 sessile) Mixed 10/96 (10.4%) 7/96 (7%) 3/96 (3%) 18/96 (18.8%) No 2 (perforation) 
8 (malignancy) 
3 (incomplete 
resection) 
0 
2009 Khashab  USA ≥2cm 136 Sessile 24/136 (17.6%) 6/136 (4.5%) 0 1 (0.7%) No 0 0 
2009 Caputi 
Iambreghi  
Italy ≥2cm 151 (72 sessile) Mixed 9/151 (6.9%) 2/151 (1.5%) 3/151 (2.3%) 
all malignant 
5/147 (3.4%) No 3 (bleeding) 
2 (Perforation) 
5 (malignancy) 
0 
2009 Swann  Australia ≥1cm 193 (186 
sessile) 
Mixed 10.5% 7/193 (3.7%) 0 9/193 (3%) No 5 (malignancy) 
2 (incomplete 
resection) 
11(lesion not 
amenable to 
EMR) 
0 
2010 Ferrara Italy ≥2cm 182 Sessile 12/172 (6.9%) 22 (12.4% 2 (1.1%) 13 (7.3%) No 13/157 (8.3%) 0 
2011 Moss  Australia ≥2cm 479  Sessile 20.4% 14/476  
(2.9%) 
admitted, 6 
required 
endo, 1 
surgery 
6/476 (1.3%) 33/476 (6.9%) No 78/476 (16.3%) 0 
Table 15- Published series of endoscopic management of large colonic polyps 
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Summary  
1. Historically, large colonic polyps were managed by open surgical resection. 
2. Modern endoscopic techniques such as EMR and ESD make removal of large colonic 
polyps possible. Endoscopic management has a number of advantages over surgical 
management. 
3. Advances in laparoscopic surgery mean that surgery for large polyps is less invasive 
and still has a role in the management of such lesions. 
4. Current management of large colonic polyps depends on available local expertise. 
5. Ideally, large polyps should be assessed by an expert endoscopist and resection only 
attempted if malignancy is not suspected. 
6. Endoscopic resection of large polyps is reasonably safe and effective in expert hands. 
Bleeding is the most common complication but rarely requires surgical intervention. 
The risk of perforation can be minimized by avoiding attempted resection of malignant 
lesions 
7. APC following piecemeal resection can reduce recurrence rate. 
8. Surveillance following resection of large polyps should take place at 3, 6 and 12 
months. Biopsies of the scar should be taken. Late recurrence is a possibility. Negative 
scar biopsies and normal macroscopic appearance at surveillance is a good predictor of 
success but does not obviate the need for ongoing surveillance. 
9. Endoscopic management of large polyps is unsuccessful and surgery necessary in 4-
16% of cases due to recurrence, incomplete resection or presence of malignancy in the 
resected specimen. 
10. Endoscopic management is associated with a complication rate of bleeding in 1.5-11% 
and perforation in 0-3%. The majority of complications are managed conservatively. 
Death directly related to EMR is very rare. 
11. Laparoscopic surgical management is associated with complications such as infection 
or bleeding in 9.5-20.8%. Mortality form laparoscopic colorectal surgery is very rare. 
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Chapter 3- Detection of Neoplasia in the NHS Bowel Cancer 
Screening Programme 
 
Chapter 3.1- Colonoscopy quality measures in the NHS Bowel Cancer 
Screening Programme 
 
3.1.1 Introduction 
Screening for colorectal cancer (CRC) is undertaken in many countries worldwide. One 
widely used strategy is biennial faecal occult blood testing (FOBt) followed by colonoscopy 
for those with a positive FOB test (Benson et al 2008).The main aim of CRC screening is to 
reduce mortality by early detection and treatment of cancer. A secondary aim is to detect and 
remove adenomas in order to prevent progression to cancer. Adenoma detection is known to 
vary widely both between and within screening programmes (Bretagne et al 2010; Atkin et al 
2004; Mandel et al 2000; Kronberg et al 1996; UK Colorectal Cancer Screening Group 
2004). Much of this variation may be explained by factors relating to quality of the 
colonoscopy. The importance of ensuring high quality colonoscopy within screening 
programmes has been emphasised in a number of recent studies and guidelines (Kaminski et 
al 2010; Rex et al 2002; Segnan et al 2011).
 
Adenoma detection rate (ADR) is a widely used indicator of colonoscopy quality (Millan et 
al 2008; it is a marker both of the technical quality of the procedure and of the efficacy of the 
screening strategy. Other domains of quality assessment including safety and patient 
experience are also crucial. A UK audit of colonoscopy published by Bowles et al 2004 
raised concerns regarding the quality of colonoscopy in the United Kingdom, showing caecal 
intubation in only 76·9% of 9223 procedures and an overall perforation rate of 1:769. 
Measures have been introduced in the UK over the last decade to improve the quality of 
colonoscopy. These include a national endoscopy training programme, defined parameters for 
endoscopy training coordinated by the Joint Advisory Group on Gastrointestinal Endoscopy 
(JAG) and national endoscopy standards (defined by the Global Rating Score (GRS). Clear 
standards and accreditation of colonoscopists for bowel cancer screening were developed. 
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In this study, quality indicators are used to examine the quality of colonoscopy delivered 
within the NHS Bowel Cancer Screening programme.  
 
3.1.2 Methods 
Screening Programme 
The NHS Bowel Cancer Screening Programme (BCSP) commenced in England in August 
2006. During the study period, adults aged between 60 and 69 years were offered faecal 
occult blood testing (FOBt) on a biennial basis using a non-rehydrated guaiac-based test. 
Adults over 70 years were able to opt-in to the programme on a voluntary basis. The upper 
age limit for invited screening was extended to 74 years in January 2010. Individuals with 
positive FOB testing were offered colonoscopy. 
Prior to commencing practice in the BCSP, all colonoscopists are required to have performed 
at least 1 000 colonoscopies in their career with a caecal intubation rate (CIR) above 90% and 
an ADR above 20% in the preceding twelve months. In addition, sedation levels have to be in 
keeping with National Patient Safety Agency (NPSA) recommendations and British Society 
of Gastroenterology (BSG) guidelines and complication rate has to be reported and deemed 
acceptable (National Patient Safety Agency 2004; Bell et al 1991). Completion of an 
accreditation examination at an independent unit is undertaken; this consists of a multiple 
choice question exam and performance of two colonoscopies observed by two independent 
and trained examiners using objective directly observed colonoscopic procedural skills 
(DOPs) assessment criteria (available at: 
http://www.thejag.org.uk/TrainingforEndoscopists/DOPSForms.aspx).
 
Accredited 
colonoscopists are subject to ongoing audit of colonoscopic performance. 
For the purposes of quality assurance within the screening programme, extent of 
colonoscopy, quality of bowel preparation, patient comfort, colonoscope withdrawal time and 
rectal retroversion are recorded at the time of colonoscopy by a dedicated screening nurse 
present in the endoscopy room for the entire procedure. All polyps removed in the study 
period were sent for histopathological examination by an accredited BCSP pathologist and 
laboratory. 
All demographic, colonoscopic and histopathological data were recorded by the screening 
centre on a national database (Bowel Cancer Screening System (BCSS)). Adverse events 
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were recorded on the BCSS, reported to the national office of the BCSP and verified by direct 
contact with each screening centre. 
 
Study Procedures 
Specific searches of the national database (BCSS) were designed to provide data to calculate 
each quality indicator (see appendix A). Missing data, where possible, were recovered from 
screening centres and included in the calculation of quality indicators. Data quality in the 
database was generally good for the data required for this study with over 98% completeness 
in the majority of fields (see section on data quality in General Methods). Audits comparing 
BCSS data with locally held records were performed demonstrating satisfactory accuracy. 
Entries in the database which appeared clinically implausible, as adjudicated by panel 
decision, were excluded from further analysis (table 16).  
 
Variable Plausible range Number of implausible 
values n, (% of complete 
dataset) 
Colonoscopy withdrawal 
time (negative and 
complete to caecum) 
1–60 minutes 147 (2.7%) 
Midazolam dose 0·5–10 mg 132 (0.36%) 
Fentanyl dose 12·5–200 mcg 26 (0.07%) 
Pethidine dose 12·5–200 mg 113 (0.31%) 
Table 16- Limits for considering data implausible 
 
The prevalent round of screening was defined as the first two years following commencement 
of screening at each centre. Any screening colonoscopies performed after two years of 
commencement of screening were considered to be in the first incident round (consisting of 
colonoscopies not performed in the prevalent round).  Approval of this work as service 
evaluation was obtained from a regional ethics committee.  
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Quality Indicators 
Ten quality indicators were identified and defined for the purpose of evaluation of 
colonoscopy in the NHS BCSP. These indicators, their definitions and level of accountability 
are shown in table 17. 
Quality indicator Abbreviation Accountability Definition 
1. Adenoma 
detection rate 
ADR Colonoscopist 
Number of colonoscopies at which one or more 
histologically confirmed adenomas were found 
divided by the total number of colonoscopies 
performed in the same time period  
2. Polyp detection 
rate 
PDR Colonoscopist 
Number of colonoscopies at which one or more 
polyps were found (regardless of histological 
type) divided by the total number of 
colonoscopies performed (in the same time 
period). 
3. Colonoscopy 
withdrawal time 
CWT Colonoscopist 
Average time taken to withdraw the colonoscope 
from the caecal pole to the anus in complete, 
negative procedures 
4. Unadjusted caecal 
intubation rate 
uCIR Colonoscopist 
Proportion of all colonoscopic procedures in 
which the caecum, terminal ileum or anastamosis 
was reached (no adjustment made for poor bowel 
preparation or impassable strictures) 
5. Rectal 
retroversion rate 
RRR Colonoscopist 
Proportion of procedures in which the 
colonoscope was retroverted in the rectum 
6. Polyp retrieval 
rate 
PRR Colonoscopist 
Proportion of resected polyps which were 
retrieved and sent for histological analysis 
7. Sedation practices - Colonoscopist 
Mean doses of pethidine, fentanyl and midazolam 
when used. 
Patient comfort assessed during colonoscopy 
using the modified Gloucester score to grade 
patient discomfort as none, mild, moderate or 
severe (Chilton et al 2011) 
8. Buscopan use - Colonoscopist 
Proportion of procedures in which hyoscine n-
butyl bromide (Buscopan) was administered. 
9. Bowel preparation 
scores 
- Screening centre 
Quality of bowel preparation assessed by 
colonoscopist at the time of colonoscopy using a 
4 point modified Likert scale. Descriptors for 
quality of bowel preparation were: incomplete 
examination due to inadequate preparation; 
complete examination despite inadequate 
preparation; adequate or excellent preparation 
(Chilton et al 2011). 
10. Adverse events AE 
Colonoscopist/ 
Screening 
centre/unit. 
Data from BCSS, AE log and screening centres 
Table 17- Colonoscopy quality indicators 
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Where quality indicators were calculated as an average per colonoscopist or screening centre, 
only those having performed over 50 procedures were included in analysis. A cut-off of 50 
procedures was chosen as below this number the confidence intervals around a point estimate 
of ADR are too wide and there is insufficient statistical power. In part, the basis for this cut-
off was to allow reliable comparison of a colonoscopist`s ADR with the minimum standard 
ADR recommended by the NHS BCSP Quality Assurance Guidelines (Chilton et al 2011). 
This document recommends the use of 80% confidence intervals for proactive quality 
assurance. A colonoscopist would need to have performed a minimum of 50 procedures to 
allow an ADR of 25% to be statistically significantly below the 35% standard. At less than 50 
procedures the confidence intervals are too wide for use in quality assurance. Table 18 
illustrates the ADR and associated 80% confidence intervals depending on number of 
procedures performed. Values are in bold in the right-hand column if the upper confidence 
limit excludes 35%. 
 
No of procedures No with ≥1 
adenoma 
Point estimate 
ADR 
80% confidence 
limits* 
200 50 25% 21.0% - 29.4% 
100 25 25% 19.4% - 31.4% 
  60 15 25% 17.7% - 33.6% 
  48 12 25% 16.9% - 34.7% 
  40 10 25% 16.2% - 35.9% 
  20   5 25% 12.7% - 41.5% 
    8   2 25%   6.9% - 53.8%  
    4   1 25%   2.6% - 68.0% 
Table 18- with associated 80% confidence intervals (from Chilton et al 2011) 
  
In general screening terms the ADR can be referred to as the positive predictive value (PPV) 
for adenoma(s), that is the proportion (%) of individuals undergoing colonoscopy with one or 
more adenomas. To avoid double-counting of adenomas only first screening colonoscopies 
were included in the analysis. Measures of neoplasia detection, other than ADR, may provide 
additional information for quality assessment of colonoscopy. Other measure include polyp 
detection rate (PDR, number of colonoscopies at which one or more polyps (regardless of 
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removal or histological subtype) were found divided by the total number of colonoscopies), 
mean adenomas per procedure (MAP, total number of adenomas detected divided by the 
number of procedures) and mean adenomas per positive procedure (MAP+, total number of 
adenomas detected divided by the number of procedures in which one or more adenoma were 
detected). The role of PDR, MAP and MAP+ in assessing the quality of colonoscopy is less 
clear than that of ADR, I therefore calculated PDR, MAP and MAP+ for each colonoscopist 
and compared the measures with ADR using tests of correlation. 
Colonoscopy withdrawal time (CWT) was recorded (to the nearest whole minute) by a nurse 
at the time of colonoscopy. Only complete, negative procedures were included in analysis to 
remove the impact of therapeutic manoeuvres on the procedure duration. Mean negative 
complete withdrawal time (nc-CWT) was calculated per colonoscopist. 
Caecal intubation was recorded at the time of colonoscopy and based on the colonoscopist’s 
assessment of extent of intubation using anatomical landmarks. Unadjusted caecal intubation 
rate (uCIR) was calculated on an intention to reach the caecum basis: no adjustment for 
pathology, strictures or bowel preparation quality was made. Obtaining photographic 
evidence of caecal intubation is stipulated in the BCSP but was not reviewed for the purposes 
of this study.  In order to be considered satisfactory indicators of colonoscopy quality, 
technical factors such as uCIR, CWT, RRR and PRR should correlate with ADR. The 
relationships between ADR and these factors were assessed. 
Adverse events were defined as those which prevented completion of the planned procedure 
(excluding technical failure or poor preparation) or resulted in admission to hospital, 
prolongation of existing hospital stay, another interventional procedure or subsequent 
medical consultation (Chilton et al 2011).
 
Adverse events were classified in terms of severity 
according to a stratification tool defined by the BCSP Quality Assurance Guidelines for 
Colonoscopy (figure 10) (Chilton et al 2011).
  
 This tool is based on a report from the ASGE 
workshop on colonoscopy related adverse events (Cotton et al 2010). In order to capture all 
adverse events, patients were encouraged to contact their local screening centre if any 
problems arose following discharge. In addition, a questionnaire, which specifically 
requested information on any adverse events experienced, was sent to all patients 30 days 
following their procedure. Records of colonoscopy related adverse events were obtained from 
two sources (interrogation of the BCSS database and analysis of the log of adverse events 
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reported to the national office). These were validated against locally held records of adverse 
events at each screening centre which were examined in a national survey of adverse events. 
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Figure 10- Stratification of complications arising from colonoscopy in the NHS Bowel Cancer Screening Programme
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Statistical analysis 
Normally distributed continuous variables were presented as mean (range). Categorical 
variables were presented as a proportion (%). Where categorical variables are summarized for 
the whole sample, a mean proportion (%) as well as a range of individual proportions are 
presented (e.g. mean adenoma detection rate (ADR) for all colonoscopists (%), lowest ADR 
per colonoscopist– highest ADR per colonoscopist). Univariable analysis was undertaken 
using a two sample T-test to compare continuous variables and the χ2 test for categorical 
variables. Correlation of normally distributed continuous variables was assessed using 
Pearson’s correlation coefficient (r). Correlation of non-parametric variables was assessed 
with the Spearman Rank correlation coefficient (ρ). A p value of less than 0·05 was 
considered to be statistically significant. All reported p values are two sided. All analyses 
were performed with Stata (version 10, Statacorp, Texas, USA). 
A summary flowchart of the study methodology is shown in figure 11. A flowchart of the 
numbers of patients included in the study at each stage of the data collection process is shown 
in figure 12. 
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Figure 11- Flowchart of methodology for chapter 2.1.1 
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Bowel Cancer Screening System (BCSS) Database
August 2006-August 2009
n=36460 colonoscopies
Flowchart of the data collection process
Query 1 Query 2 Query 3 Query 4 Query 5
Include: 
Screening tests 
only, first 
diagnostic test 
per episode.
Exclude:
Surveillance 
tests, Flexi sig.
Include: 
Screening tests 
only, first 
diagnostic test 
per episode.
Exclude:
Surveillance 
tests, Flexi sig.
Include: Screening 
or surveillance tests, 
only one test per 
episode.
Exclude:flexi sig.
Include: 
Screening or 
surveillance 
tests, ≥1 tests 
per episode. 
Where ≥1 polyp 
removed.
Include: 
Screening or 
surveillance 
tests, ≥1 tests 
per episode.
Exclude:none.
n1= 32213
176 colonoscopists
n1= 32213
176 colonoscopists
n1= 34831
177 colonoscopists 
n1= 36460
178 colonoscopists 
n2= 31633
175 colonoscopists
n2= 22385
177 colonoscopists
n2= 31630
175 colonoscopists
n3= 31088
148 colonoscopists
n3= 31091
148 colonoscopists
n3= 21616
141 colonoscopists
ADR PDR PRR
Prep quality
359  excluded 
preparation quality 
not recorded
n2= 36101 (50 
screening centres)
n3=36079  (48 
screening  centres
Comfort
Exclude 663 as 
colonoscopists ID 
null. Exclude 272 
as patient comfort 
not recorded
n2= 35525 (177 
colonoscopists) 
n3=34995  (148 
colonoscopists)
Sedation
Exclude 663 as 
colonoscopist ID null
Midazolam 132, 
Fentanyl  282, 
Pethidine 113  
excluded due to 
implausible doses.
n2= 35515-35684 
(148 colonoscopists)
n3(<70 years)30437-
30623.  (142 col.)
n3(>70 years)1027-
1079 (13 col.)
Buscopan
Exclude 663 as 
colonoscopists ID 
null. Exclude 2 
implausible 
doses.
n2= 35795 (178 
colonoscopists)
n3=35261  (149 
colonoscopists)
CIR+RRR
629 excluded as no 
consultant ID
n2= 34202 (177 
colonoscopists)
n3=33635  (148 
colonoscopists)
Exclude 579  
procedures as 
colonoscopist ID 
null.
Exclude 1 
procedure by 1 
consultant as only 
procedure by that 
consultant.
Exclude 582 
procedures as 
colonoscopist ID 
null.
Exclude 1 
procedure by 1 
consultant as only 
procedure by that 
consultant.
CWT
Exclude 26537 
procedures as not 
normal or complete.
Exclude 153  
clonoscopist ID null, 
5 implausible data, 
183 no CWT 
recorded, 1 duplicate 
test ID.
n2= 7952 (173 
colonoscopists)
n3=5443 (61 
colonoscopists).
13881procedures 
not included as no 
polyps resected or 
number of polyps 
resected not 
recorded.
Exclude 194 as 
colonoscopist ID 
null.
n1= 22579
178 colonoscopists 
Key
n1= Number of colonoscopies
n2= Number of colonoscopies 
following exclusions.
n3= Number of colonoscopies 
where colonoscopist had 
performed ≥50 procedures.
ADR=Adenoma detection rate,PDR=Polyp detection rate,CWT=Colonoscopy withdrawal time,CIR=Caecal intubation rate,RRR=Rectal ret roversion rate,PRR=Polyp retrieval rate  
Figure 12- Flowchart of the data collection process 
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3.1.3 Results 
 
Colonoscopy Quality Indicators 
Between August 2006 and August 2009, 2 269 983 individuals completed FOB testing. 
Uptake of FOB testing was 52·9%. 2·02% of FOB tests positive. 36 460 colonoscopies and 
1708 sigmoidoscopies were performed by 177 different colonoscopists at 50 screening 
centres. The mean age of patients undergoing colonoscopy was 66·0 years (range 60–92 
years). 61·6% were male. 3848 cancers were detected at colonoscopy with a positive 
predictive value of colonoscopy (following positive FOB testing) for cancer of 10·6%. 
Summary data for each of the quality indicators attributable to the colonoscopist are shown in 
table 19. The denominator is different for each indicator due to differing definitions of 
eligible procedures and differences in missing or implausible data between each variable. 
 
 Mean per 
colonoscopist 
Range Denominator 
(number of 
procedures 
counted) 
Adenoma detection 
rate 
46·5% 21·9–59·8 % 31 088 by 148 
colonoscopists 
Polyp detection rate 59·7% 39·8–76·3 % 31 091 by 148 
colonoscopists 
Mean colonoscopy 
withdrawal time 
9·4 minutes 5·6–12·3 minutes 5 443 by 61 
colonoscopists 
Unadjusted caecal 
intubation rate 
95·2% 76·2–100 % 33 635 by 148 
colonoscopists 
Rectal retroversion 
rate 
89·5% 27·0–100 % 33 635 by 148 
colonoscopists 
Polyp retrieval rate 92·7% 68·9–100 % 21 616 by 141 
colonoscopists 
Table 19- Summary data for colonoscopist attributable quality indicators 
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Adenoma detection rate  
ADR per colonoscopist ranged from 21.9% to 59.8% with a mean of 46.5% (median 47.2%). 
ADR is a key metric for measuring quality of colonoscopy and may be used to compare two 
or more colonoscopists, it is therefore important to consider major confounding factors such 
as gender, age and screening round. It is known that adenomas are more common in males 
and incidence increases with age (Rex et al 1995, Johnson et al 1990). In our study, the mean 
ADR per colonoscopist in males was 52.9% and the mean ADR in females 36.5% (p<0.001).  
ADR was therefore standardised by gender (GS-ADR) to allow for variation in the proportion 
of males and females in the case-mix of a particular colonoscopist.  For the majority of 
colonoscopists these two measures (ADR and GS-ADR) were closely matched (mean 
difference between ADR and GS-ADR was -0.02, sd 0.93). Older patients in the screening 
population undergoing colonoscopy were more likely to have one or more adenomas. The 
ADR in patients less than 65 years of age was 44.0% compared to 48.2% in those age 65 or 
older (p<0.001). However, there was little variation in the average age of patients undergoing 
colonoscopy between colonoscopists (mean age 65.8 years, SD= 0.6, range 64.2-67.9).  The 
mean difference between the ADR and the age-standardised (AS-ADR) for all colonoscopists 
was 0.13 (sd 1.73). In addition, ADR and GS-ADR correlate strongly (r=0.99, p<0.001), as 
do ADR and AS-ADR (r=0.96, p<0.001), the crude ADR was therefore an adequate measure 
for the data presented here. 
Analysis of ADR in colonoscopies occurring in the prevalent round (P-ADR) and in the first 
incident round (I1-ADR) was performed. The prevalent round was defined as the first two 
years following commencement of screening at an individual centre, during this period all 
individuals in the target age range would be offered FOB screening once. The first incident 
round was defined as the next 2 year period; the majority of individuals would be receiving 
their second invitation to FOB screening, a minority would be receiving their first if they had 
entered the target age range  The P-ADR in 28 607 prevalent round colonoscopies was 46.2% 
compared to 46·3% in 2 882 incident round colonoscopies (p=0·90). Therefore, no 
standardization of ADR by screening round was required. 
ADR per colonoscopist correlates positively with caecal intubation rate (ρ=0.203, p=0.013), 
mean nc-CWT (ρ=0.236, p=0.004) (figure 13), rectal retroversion rate (ρ=0.193, p=0.019) 
and polyp retrieval rate (ρ=0.241, p=0.003). No correlation between ADR and bowel 
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preparation quality (per colonoscopist, ρ=0.086, p=0.300) or comfort score (ρ= -0.004, 
p=0.958) is seen; both these measures were subjectively assessed.  
 
 
Figure 13- Scatterplots of colonoscopy withdrawal time and caecal intubation rate against 
adenoma detection rate per colonoscopistMAP (mean adenomas per procedure) and ADR 
were shown to be positively correlated (table 20), this is largely because 53.0% of individuals 
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with one or more adenomas have only one adenoma. MAP+ correlates less well with ADR as 
it is possible for a colonoscopist to have a MAP+ near or above the mean with a low ADR. 
The relationship between ADR, MAP and MAP+ are demonstrated in figure 14. 
Correlating MAP with caecal intubation rate (ρ=0.21, p=0.009), mean nc-CWT (ρ=0.30, 
p<0.001), rectal retroversion rate (ρ=0.17, p=0.03) and polyp retrieval rate (ρ=0.25, p=0.002) 
produces very similar relationships as ADR with these measures. This is because ADR and 
MAP are so closely correlated. MAP+ is not amenable to correlation with these measures in 
view of the unreliability of MAP+ when it is low. 
 
 
 Mean Range Standard 
deviation 
Correlation 
with ADR 
(r) 
ADR 46.5% 21.9-59.8% 7% n/a 
MAP 0.91 0.31-1.86 0.25 0.85 
(p<0.001) 
MAP+ 1.94 1.3-3.1 0.35 0.54 
(p<0.001) 
Table 20- Others measures of neoplasia detection at colonoscopy and their relationship with ADR 
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Figure 14-Scatterplots of MAP and MAP+ against ADR per colonoscopist. Blue lines in the chart 
represent the respective means of the measures for the population. 
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Sedation Practice, antispasmodic use, patient comfort and bowel preparation quality 
Mean doses of the most frequently used benzodiazepine and opiate medications are shown in 
table 21 sub-grouped into under 70 years and 70 and over age groups. The mean percentage 
per colonoscopist of patients receiving no sedation was 14.1% (range 0–63·0%).  
 
 Mean dose (range of means per colonoscopist) 
Mean midazolam dose 
 
<70 years 
 
2·23mg  (1·0–4·4)   
≥70 years 
 
2·13mg  (1·0–4·5)  
Mean fentanyl dose  <70 years   
 
59·3mcg  (25–100)  
≥70 years 
 
60·1mcg  (29·5–100)  
Mean pethidine dose <70 years 
 
33·5mg  (22·6–50) 
 
≥70 years 
 
30·7mg  (19·0–53·2) 
 
Table 21- Mean sedative doses 
 
Among colonoscopists who performed unsedated colonoscopy less frequently than the mean, 
89.0% of procedures were associated with no, minimal or mild discomfort. This figure was 
89.6% for colonoscopists who performed unsedated colonoscopy more frequently (p=0.62). 
Mean adenoma detection rates were the same in both groups (46.5%, p=0.97). 
 Entonox (nitrous oxide and air, BOC, UK) was used at least once, either alone or in 
combination with other medications, by 32 of 149 (21.5%) colonoscopists who had 
performed 50 or more procedures. Among these colonoscopists, 10.0% of procedures were 
performed with Entonox but no intravenous sedation (range 0.1-47.5%). Propofol was used at 
least once by 14/149 colonoscopists accounting for 0.75% of procedures (range 0.1-2%). The 
use of reversal agent was infrequent with flumazenil or naloxone used in 0.15% and 0.66% of 
procedures respectively. 
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Hyoscine n-butyl bromide (Buscopan), used as an intravenous antispasmodic to aid 
visualization of the colonic mucosa, was used in more than 80% of procedures by 31 of 149 
colonoscopists (20·8%). The mean proportion of procedures per colonoscopist in which 
buscopan was used was 32·7% (range 0–98·1%). 
Nurse assessed patient comfort scores during colonoscopy were as follows: 64·3% (range 
23.9-100%) of patients had no or minimal discomfort during colonoscopy; 24·9% (0–59.5%) 
reported mild discomfort; 9·6% (0–31·1%) reported moderate discomfort and 1·3% (0–
10·4%) reported severe discomfort. The mean proportion of procedures in which the bowel 
preparation was excellent or adequate was 94·2% (range 81·5–100%). 
 
Adverse events 
All centres completed a detailed record of all adverse events. Table 22 shows the incidence of 
complications in the NHS BCSP. Adverse events were stratified according to their severity. 
49 major or intermediate severity bleeds occurred (0·13%), this excludes minor bleeds not 
requiring transfusion, intervention or prolonged admission (less than 3 nights). 35 
perforations occurred (0·09%). Ten other adverse events requiring admission for three or 
more nights or surgical intervention occurred (0·03%). These included two episodes of 
obstruction secondary to cancer, two splenic injuries requiring surgery, one stroke, two 
adverse reactions to bowel preparation and three prolonged admissions due to pain. No deaths 
occurred as a result of screening colonoscopy. 
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  Number Incidence  
(%, n=38 168) 
Bleeding Minor 106 0·28 
Intermediate 45 0·12 
Major 4 0·01 
Fatal 0 0 
 
Perforation Major 35 0·09 
Fatal 0 0 
 
Other unplanned 
event 
Minor 75 0·20 
Intermediate 6 0·02 
Major 4 0·01 
Fatal 0 0 
Table 22- Incidence of adverse events, classified according the BCSP QA guidelines stratification tool 
 
3.1.4 Discussion 
This study demonstrates high quality colonoscopy in the NHS Bowel Cancer Screening 
Programme. These data show that colonoscopy in a national screening programme can be 
delivered to a high standard whilst ensuring patient comfort and safety. These standards are 
achieved despite the BCSP being one of the largest colorectal cancer screening programmes 
in the world (Benson et al 2008). 
The most widely used metric for assessing colonoscopy quality is the adenoma detection rate. 
Our study demonstrated a mean ADR of 46·5%. This figure reflects the above average risk of 
detecting adenomas in FOBt positive individuals in the target age group. The ADR reported 
here is higher than in the pilot study of bowel cancer screening in the UK (37.1%, p<0.001) 
(Weller et al 2007). This difference may be explained by a number of factors including the 
age range of the screened population and progress in technical aspects of colonoscopy such as 
bowel preparation quality, improved equipment and advances in colonoscopic technique. The 
mean CWT for normal procedures and unadjusted CIR in our study are further evidence of 
the high technical quality of BCSP colonoscopy and compare favourably to other reports 
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from large screening programmes (Regula et al 2006). These data demonstrate an 
improvement in the quality of UK colonoscopy when compared to the 2004 national audit in 
which the unadjusted CIR was 76·9% (Bowles et al 2004). This improvement in colonoscopy 
quality in England supports the measures employed by the Joint Advisory Group on 
gastrointestinal endoscopy (JAG) and the BCSP in promoting and enhancing colonoscopy 
quality. A national audit of colonoscopy practice in England (http://www.endoaudit.com/) 
including non-screening colonoscopy is currently being undertaken, it will provide an up-to-
date opportunity to compare performance indicators for screening and non-screening 
colonoscopy. 
Despite the overall high quality of colonoscopy demonstrated by this study, there is still 
considerable variation in adenoma detection rate between colonoscopists. ADR per 
colonoscopist ranged from 21.9 to 59.8%, an almost threefold difference between the highest 
and lowest detecting colonoscopists. This variation persists when ADR is standardised for 
age and gender and is not due to sample size variation as colonoscopists with less than 50 
procedures were excluded. It is of interest that this variation exists in spite of the quality 
standards colonoscopists must reach prior to commencing screening colonoscopy. Variation 
is also seen in other technical quality indicators (nc-CWT, uCIR, RRR, PRR). Significant 
correlations between these measures and ADR were demonstrated. Further work is being 
undertaken to examine the relationship between markers of colonoscopic practice and 
adenoma detection in individual patients. Ongoing quality assurance work within the 
screening programme is needed to minimise variations in colonoscopic performance. 
It is not known at present which processes will be most effective in minimising these 
variations, or indeed if it is possible for all colonoscopists to reach optimal standards. 
This study demonstrates that routine reporting of age, gender or screening round standardised 
ADR is not necessary, however these methods remain useful for quality assurance purposes 
to investigate the effect of these variables if an individual colonoscopist is noted to have 
particularly low or high ADR. For instance, a colonoscopist who has colonoscoped a larger 
proportion of females than the mean may have a lower non-standardised ADR. 
The role of MAP and MAP+ in addition to ADR for assessing technical aspects of 
colonoscopy quality have been explored. ADR has an inherent limitation in that it does not 
measure the total number of adenomas detected. MAP and MAP+ are more aligned with the 
ethos of colonoscopy in the BCSP which, in addition to detecting cancer, is to detect and 
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remove all adenomas. MAP and MAP+ may provide additional information about the 
performance of colonoscopists.  The mean MAP for the population suggests the majority of 
colonoscopies result in zero, one or two adenomas being found. The scatterplot of MAP 
against ADR in Figure 14 identifies a group of colonoscopists who have an ADR around the 
mean but with a broad range of MAP. This demonstrates that some colonoscopists are able to 
find more adenomas per patient than others; due either to underlying variation in adenoma 
prevalence or due to operator based technical (or non-technical) skills of the colonoscopists 
themselves. MAP+ is not useful if the ADR is low, however it provides extra information 
where ADR is high. The group of colonoscopists with a MAP+ over 2.5 and an ADR over 
50.0% appear to be capable not only of detecting adenomas in high numbers of patients but 
also of detecting multiple adenomas in these patients. I recommend that the BCSP routinely 
reports MAP and MAP+ in addition to ADR to give screening colonoscopists additional 
insight into their performance. 
The adverse event rates in this study compare favourably with other published series which 
report post colonoscopy bleeding in 0·03–0·22% of procedures and perforation in 0·01%–
0·8% of procedures (Weller et al 2007; Panteris et al 2009; Crisp et al 2009).The 2004 audit 
demonstrated low complication levels which have been maintained in this study. Given that 
46.5 % of procedures require at least one polypectomy and many involve removal of large 
and multiple polyps the low levels of adverse events are notable. 
No difference in adenoma detection rate was seen between the prevalent and first incident 
screening rounds. This pattern was also seen in the pilot study of the screening programme 
(Weller et al 2007). This is an important finding as it helps predict future colonoscopic 
workload for the screening programme and also allows ADR to be used as a comparative 
quality indicator for colonoscopists who perform different proportions of prevalent and 
incident round procedures.  
Cancer detection rate, however, is known to be lower in subsequent incident rounds 
compared to the prevalent round (Weller et al 2007). The fact that relatively small numbers of 
cancers are detected means that whilst cancer detection rate is crucially important, it is not a 
sensitive measure of colonoscopy quality and tends to be dependent more on the underlying 
prevalence of colorectal cancer than technical skills attributable to the colonoscopist. For this 
reason I have not reported cancer detection rate per colonoscopist in this study. 
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No correlation between ADR and bowel preparation quality (per colonoscopist) was 
observed. Although this appears counter-intuitive, the analysis is at a per colonoscopist 
summary level, not at an individual procedure level. This reflects therefore, that poor bowel 
preparation occurred at a similar rate for all colonoscopists and, to some extent, obviates the 
possibitly that low adenoma rate  per colonoscopist could be explained by a higher proportion 
of poor bowel preparations.The guaiac-based FOBt screening protocol used by the BCSP is 
designed to achieve a yield for adenomas and advanced adenomas above that of the general 
population. This limits comparison of colonoscopy performance indicators reported in this 
study with other screening programmes employing alternative screening modalities such as 
faecal immunochemical testing (FIT) or flexible sigmoidoscopy, which may have differing 
sensitivity and specificity for neoplasia detection. 
Any single quality indicator reported in this study would be insufficient in isolation to 
appraise the quality of colonoscopy. It is necessary to analyse a number of measures of 
quality as summarised in the model in figure 15. The data presented in this study provide 
evidence to support the use of this model to assess quality of colonoscopy. 
 
 
Figure 15- Three domains of colonoscopy quality assessment 
An important strength of this study is its size, both in terms of the number of colonoscopies 
analysed and the nation-wide coverage of the programme. Many colonoscopy quality studies 
are either single centre or restricted to a small number of colonoscopists. These data 
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demonstrate that a high level of colonoscopy quality can be achieved in a large programme. 
Nevertheless our study has several limitations. Firstly, data for all colonoscopies were not 
complete, however, complete datasets accounted for 98% of all data and missing data did not 
cluster geographically or around individual colonoscopists. This level of missing data should 
have only a minor effect on the measured quality indicators. The quality of collected data is 
in itself a marker of quality of a screening programme and feedback on data quality issues 
raised by this study will improve the future quality of the data collection process (Ellis et al 
2006).
 
Secondly, a number of the indicators relied on subjective assessments (patient comfort, bowel 
preparation quality) using non-validated scoring systems. This was necessitated by the 
absence of widely used, validated scoring systems for these measures. Common guidance on 
use of the scoring systems used for bowel preparation and patient comfort was given to all 
screening practitioners to standardise data collection. Incorporation of validated scoring 
systems for these measures into the BCSP colonoscopy quality assurance process is 
necessary. 
Thirdly, clinical outcome measures, such as interval cancers, were not measured. This study 
concentrated on measures of colonoscopy quality which can be recorded at or close to the 
time of colonoscopy. Further work is being undertaken to assess the incidence of interval 
lesions in the NHS BCSP. 
To ensure ongoing high quality colonoscopy in the BCSP, quality assurance guidelines have 
defined a number of auditable outcomes and quality standards.
15
 Auditable outcomes are 
defined as important indicators but as yet no clear standard exists (for example, the standard 
for perforation rate per colonoscopist is less than one per thousand colonoscopies). Quality 
standards are defined as an auditable outcome for which there is an evidence base that can 
support a minimum standard (table 23). These are designed to drive quality to higher 
standards whilst setting limits to identify suboptimal performance. The results presented here 
demonstrate that colonoscopic quality in the BCSP has exceeded these standards.  
The incorporation of measures of total adenoma detection as targets in the quality assurance 
guidelines would emphasise the importance of these measures of quality. Based on the 90
th
 
percentile of each measure, a MAP of 1.20 and a MAP+ of 2.27 (providing the ADR is 
satisfactory) as targets are suggested.  
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In summary, this large national study demonstrates high quality colonoscopy in the NHS 
Bowel Cancer Screening Programme. The adverse event rate is low despite the need for 
therapy associated with high adenoma detection rates. Assessment of a range of quality 
indicators including measures of total adenoma detection is necessary to evaluate 
colonoscopy quality. Potential screening programme participants should be reassured that 
screening colonoscopy within the NHS Bowel Cancer Screening Programme is high quality, 
safe and well-tolerated. 
 
Measure Minimum standard Target 
Adenoma detection rate ≥35% ≥40% 
Unadjusted caecal intubation rate ≥90% ≥97% 
Mean colonoscopy withdrawal time 
(negative-complete) 
≥6 minutes ≥10 minutes 
Bowel prep quality (described as 
excellent or adequate) 
≥90% ≥95% 
Polyp retrieval rate ≥90% ≥95% 
Perforation rate <1 per 1000  - 
Post polypectomy bleeding rate <1 per 100 - 
Comfort scores 100% recorded - 
Table 23- Minimum standards and targets for colonoscopy in the BCSP (Chilton et al 2011) 
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Chapter 3.2- Colonoscopy withdrawal time and adenoma detection rate in the 
NHS Bowel Cancer Screening Programme 
3.2.1- Introduction 
Increasing CWT has been shown to correlate with increasing adenoma detection rate (Rex 
2000). In a study by Barclay et al (2006) of 2053 screening colonoscopies by 12 
colonoscopists, those with a mean CWT of more than 6 minutes detected more than twice as 
many adenomas as those with mean CWT less than 6 minutes. Current US guidelines (Rex et 
al 2002) recommend an average CWT in normal colonoscopies of at least 6-10 minutes. 
Guidelines for colonoscopists in the NHS BCSP recommend a mean CWT of at least 6 
minutes (Chilton et al 2011). The aim of this study was to identify the optimal mean CWT 
within the context of the NHS Bowel Cancer Screening Programme.  
Recent studies have suggested a possible lack of protection by colonoscopy against right 
sided CRC (Baxter et al 2009, Brenner et al 2010). It known that increased adenoma 
detection is associated with reduced interval cancer risk (Kaminski et al 2010). A further aim 
of this study, therefore, was to examine the effect of duration of withdrawal time on right 
sided adenoma detection. 
 
3.2.2- Methods 
Study Population 
The study population consisted of all colonoscopies performed in the NHS BCSP between 
August 2006 and August 2009.  The indication for all colonoscopies was a positive faecal 
occult blood test result. Surveillance procedures (where the indication was a history 
adenomas) and repeat procedures were not included. The process for establishing the study 
population (n=31088 colonoscopies) is the result of query 1 to the National Bowel Cancer 
Screening Programme database as shown in figure 12 and appendix A. 
Colonoscopy withdrawal time was defined as the time taken to withdraw the colonoscope 
from the caecal pole to the anus. CWT was measured at the time of endoscopy by a screening 
nurse present in the endoscopy room whose role was to record procedural data independently 
from the colonoscopist and endoscopy nurse.  Only complete procedures in which no 
pathology requiring excision or biopsy was encountered were included in the calculation of 
                      Detection and Management of Colorectal Neoplasia in the NHS Bowel Cancer Screening Programme 
112 
 
the mean negative complete colonoscopy withdrawal time (nc-CWT) in order to remove the 
potential bias of therapeutic manoeuvres on the duration of withdrawal. The number of 
adenomas detected was based on histologically confirmed adenomas only. The size of 
adenomas was obtained from both the colonoscopist’s assessment and the pathology report 
with the larger measurement being used in the analyses. The site of adenomas was recorded 
by the colonoscopist at the time of polypectomy. Lesions at or proximal to the splenic flexure 
were termed right sided lesions, those distal to the splenic flexure left sided. Advanced 
adenomas were defined as 1cm or larger in size or displaying high grade dysplasia. Bowel 
preparation quality was recorded by the colonoscopist at the time of colonoscopy on a 4 point 
modified Likert scale (Chilton et al 2011). Descriptors were: Incomplete examination due to 
inadequate preparation; complete examination despite inadequate preparation; adequate or 
excellent. These data are recorded prospectively on the NHS BCSP national database for the 
purpose of quality assurance. Prospectively recorded data required for this study were 
retrieved from this database for analysis. 
 
Statistical analysis 
The mean negative complete colonoscopy withdrawal time (nc-CWT) and adenoma detection 
rates were calculated for each colonoscopist who had performed 50 or more procedures.  
Colonoscopists were grouped according to their mean nc-CWT into four groups (A- <7 
minutes, B- 7 to 8.9 minutes, C- 9 to10.9 minutes, and D- ≥11 minutes). The four groups 
were chosen to have 2 minute intervals in the centre groups, to represent the distribution of 
mean withdrawal time among the colonoscopists and reflect existing clinical guidelines for 
withdrawal time (Rex et al 2002; Chilton et al 2011). The lowest group was <7 minutes 
(rather than <6 minutes which could have been used) to give adequate numbers of procedures 
in the lowest group for statistical analysis. The percentage of all procedures where one or 
more adenomas were detected (ADR, %) and the total number of adenomas detected per 
procedure were calculated. These are presented as proportions with relative risk compared to 
the lowest withdrawal time group. A two sample test of proportions and a test of trend were 
used to compare adenoma detection in each of the groups. 
Multivariable analysis using logistic regression was performed to account for potential 
confounding factors including age, gender, smoking status, alcohol use, and bowel 
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preparation quality. Odds ratios with 95% confidence intervals (CI) were calculated. Analysis 
of advanced adenoma detection, right sided adenoma detection, and adenoma size in relation 
to nc-CWT was also performed.  All p values are two sided, a p value of less than 0.05 was 
considered significant.  All analyses were performed using Stata (version 10, Statacorp, 
Texas USA).  
 
3.2.3- Results 
31088 colonoscopies by 147 colonoscopists were analysed (mean number of procedures per 
colonoscopist- 211, range 51-730). The mean withdrawal time per colonoscopist in negative 
complete procedures (nc-CWT) varied from 5.4 to 20.1 minutes (mean 9.6 minutes). Table 
24 shows the number of colonoscopists and procedures in each of the four nc-CWT groups 
and the characteristics of the patients in each group. 
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 Colonoscopy withdrawal time groups 
 A B C D 
 <7 minutes 
 
7-8·9 minutes 9-10·9 minutes >11 minutes 
Number of 
colonoscopists 
15 43 51 38 
Mean nc-CWT 6.3 8.1 9.8 12.6 
Median nc-CWT 6.3 8.4 9.7 11.8 
Number of 
patients 
3297 8731 12180 6880 
Mean age  65.7 65·7 65.7 65.6 
Male (%) 59.4 61.0 60.4 59.8 
Current or ex-
smokers (%)* 
43.3 46.3 44.2 45.0 
Alcohol use (%)* 63.6 63.8 68.3 66.5 
Proportion of 
procedures with 
adequate or 
excellent bowel 
preparation 
quality (%)* 
95.1 95.5 95.0 93.3 
Table 24- Characteristics of patients in the 4 groups of colonoscopists by mean negative complete 
colonoscopy withdrawal time 
* Smoking status not recorded for 188 patients (0.6%), alcohol use not recorded for 304 patients (1.0%), 
bowel preparation quality not recorded for 248 patients (0.8%) 
 
Table 25 shows the adenoma detection rate and total adenoma detection rates in each group 
of colonoscopists. 28386 adenomas were detected in 31088 procedures (0.91 per 
colonoscopy). One or more adenomas were detected in 14394 procedures (46.3%). A test of 
trend for ADR by withdrawal group was highly significant (p<0.001). There was an 11% 
increase in the number of procedures yielding one or more adenomas (p<0.001) and a 25% 
increase in the total number of adenomas detected in favour of those colonoscopists with 
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longer withdrawal times (p<0.001).  Figure 16 shows the ADR in each of the withdrawal time 
groups. 
 
Group Number of 
procedures 
by 
colonoscopists 
in each group 
Procedures 
where 
adenoma(s) 
found (ADR %) 
[RR]
#
 
Total no. 
of 
adenomas 
detected 
Total 
adenomas 
detected per 
procedure 
[RR] 
Mean number 
of adenomas 
detected in 
procedures 
where 
adenoma found 
A   3297  1403    (42.5)  
[1.00] 
 
  2523 0.77  [1.00] 1.80 
B   8731  3966    (45.4)  
[1.07] 
 
  7597 0.87  [1.14] 1.92 
C 12180  5774    (47.4)  
[1.11] 
 
11776 0.96  [1.26] 2.04 
D   6880  3252    (47.3)*  
[1.11] 
 
  6490 0.94  [1.23] 2.00 
Total 31088 14394  (46.3) 28386 0.91 1.97 
Table 25- Adenoma detection rate and total adenomas detection rates for each withdrawal time group 
(univariable analysis) 
#
 Relative risk 
* Test of trend for ADR by group p<0.001 
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Figure 16- Graph of ADR (%) per colonoscopist against mean nc-CWT (minutes) by group (univariable 
analysis) 
  
Site and size of adenoma and advanced adenomas 
Colonoscopists with longer withdrawal times detected around 50% more right sided 
adenomas per procedure than those with shorter withdrawal times (Group D- 0.35 right sided 
adenomas per procedure, Group A- 0.23 right sided adenomas per procedure, p<0.001). 
Longer withdrawal times were also associated with an increase in left sided adenoma 
detection but with only a 10% difference between the longest and shortest withdrawal time 
groups (Group D- 0.59 left sided adenomas per procedure, Group A- 0.54 left sided 
adenomas per procedure, p<0.001).     
Group D colonoscopists detected 50% more small adenomas than Group A colonoscopists. 
No increase in detection of larger adenomas (≥1cm) was seen with longer withdrawal times. 
Similarly, no increase in advanced adenoma detection was seen in the longer withdrawal time 
groups (Table 26).
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Group Total 
number of 
adenomas 
detected* 
Percentage 
of 
adenomas 
on right 
side (%) 
Number of  
left side 
adenomas 
detected per 
procedure 
(RR) 
Number of 
right sided 
adenomas 
detected  per 
procedure  
(RR) 
Percentage 
of adenomas 
less 1cm (%) 
Number of  
adenomas    ≥ 
1cm in size 
detected per 
procedure 
(RR) 
Number of 
adenomas    
< 1cm in size 
detected per 
procedure 
(RR) 
Number of 
procedures 
where ≥1 
advanced 
adenoma(s) 
detected (%)  
Relative 
risk of 
detecting 
≥1 
advanced 
adenoma 
A   2523   30.1 0.54  (1.00)    0.23  (1.00)   54.1  0.351 (1.00) 0.414 (1.00)   950 (28.8)   1.00 
B   7597   33.2 0.58  (1.09)    0.29  (1.26)   58.5   0.361 (1.03) 0.509 (1.23)   2576 (29.5)   1.02   
C 11776   36.5 0.61  (1.14) 0.35  (1.53)   62.9 0.358 (1.02) 0.606 (1.46)   3508 (28.8)   1.00 
D   6490   37.3
#
 0.59  (1.10) 0.35  (1.53)   65.0
†
 0.329 (0.94) 0.611 (1.48)   1954 (28.4)
∞
   0.99 
Total 28386                                           
Table 26- Withdrawal time related to site and size of adenoma detection and advanced adenoma detection 
* includes all adenomas detected – some procedures detecting more than one adenoma  
#
 Test of trend for percentage of right sided adenomas by group p<0·001 
†  
Test of trend for percentage of adenomas less than 1cm by group p<0·001 
∞  Test of trend for proportion of procedures with ≥1 advanced adenoma p>0·05 
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Potential confounding factors  
Age, gender, smoking, and alcohol use are factors that may affect the probability of finding 
an adenoma in an individual (Lieberman et al 2000; Anderson et al 2003; Martinez et al 
1995). These potential confounding factors are similar between groups (table 24) and 
therefore not likely to have any major influence on the conclusions of the univariable 
analysis. Logistic regression models with and without these potential confounding factors are 
shown in table 27 showing that adjusting for these factors has minimal impact on the 
relationship between withdrawal time and adenoma detection rate. Figure 17 shows the 
adjusted odds ratio for detecting adenomas with increasing withdrawal time. 
 
Group No allowance Allowing for age, sex, 
drinking and smoking 
Allowing for age, sex, drinking,  
smoking and bowel 
preparation* 
A 1.00 
 
1.00 1.00 
B 1.12 (1.04-1.22) 
 
1.11 (1.02-1.20) 1.10 (1.01-1.19) 
C 1.21 (1.12-1.31) 
 
1.19 (1.10-1.29) 1.19 (1.10-1.29) 
D 1.20 (1.11-1.31) 1.18 (1.09-1.29) 1.21 (1.11-1.32) 
Table 27- Odds ratio (95% CI) for detection of adenoma before and after allowing for confounding 
factors using logistic regression 
* Bowel preparation quality (percentage described as excellent or adequate) 
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Figure 17- Graph of odds ratio (with 95% CI) for detecting adenoma versus nc-CWT, after allowing for 
confounding factors (age, sex, drinking, smoking and bowel preparation) 
 
3.2.4- Discussion 
This is the largest study to demonstrate an association between CWT and ADR, and the first 
study in a screening population that had undergone FOB testing. This study demonstrates 
that, even within a high quality screening programme, adenoma detection rate increases with 
longer mean negative colonoscopy withdrawal time. Previous studies have suggested a 
minimum CWT of 6 to 8 minutes (Rex et al 2002; Barclay et al 2008; Simmons et al 2006); 
our study demonstrates an optimum mean nc-CWT of 10 minutes. Above an nc-CWT of 10 
minutes, further increase in mean withdrawal time does not significantly increase ADR. This 
is evidence of the ‘ceiling effect’ (Tabar et al 2010; Vicari et al 2010), which may be 
explained by the presence of a finite number of detectable adenomas within a colon.  
An important strength of this study is it’s size. This is in comparison to previous studies of 
withdrawal time which are often single centre studies or restricted to a handful of 
colonoscopists. The number of colonoscopists covered by this study allows variation in 
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colonoscopic performance to be demonstrated despite the requirement that all colonoscopists 
have previously demonstrated high levels of colonoscopic competence prior to commencing 
screening colonoscopy. 
Our study reinforces the findings of Simmons et al (2006) that increasing ADR with 
increasing withdrawal time is due to detection of more small adenomas.
 
Contrary to the 
findings of Barclay et al (2006), no increase in advanced adenoma detection with increasing 
withdrawal time was seen in our study. This may be because the withdrawal time ceiling for 
detecting advanced adenomas is lower and is already achieved by the baseline mean 
withdrawal time in our population of colonoscopists (no colonoscopist had a mean 
withdrawal time lower than 5.4 minutes). The ethos of colonoscopy in the Bowel Cancer 
Screening Programme however, is to detect and remove all adenomas. This strategy has 
underpinned the success of randomised controlled trials and pilot studies of FOB screening 
for colorectal cancer (Scholefield et al 2002; Kronborg et al 2004; UK Colorectal Cancer 
Screening Group 2004). In addition, the detection rate of all adenomas rather than advanced 
adenomas, is recommended as a better quality indicator of screening colonoscopy (Rex et al 
2002). The increase in detection of smaller lesions is important therefore, both clinically and 
as a performance indicator.  
A recent Canadian community based study concluded that screening colonoscopy did not 
confer any protection from right sided CRC (Baxter et al 2009). In our study, longer 
withdrawal times resulted in detection of more right sided adenomas. A recent German study 
(Brenner et al 2011) has suggested that high quality screening colonoscopy may be more 
protective against right sided cancer than the Canadian study suggested. The authors attribute 
this, in part, to major efforts in terms of training and quality assurance. Proximal colorectal 
neoplasia may be harder to detect or have a different natural history to distal lesions with 
earlier malignant transformation (Singh et al 2006; Nawa et al 2008; Arain et al 2010). Our 
study demonstrates the importance of withdrawal time in detecting right sided lesions. 
Longer withdrawal time, as a marker of colonoscopic quality, may have contributed to the 
reduction in risk for both right and left sided CRC seen in the German study.  
Our study has a number of limitations. Firstly, we have not examined the relationship 
between CWT and a longer term clinical outcome measure such as interval cancer rate. A 
recent study has shown no detectable association between withdrawal time and risk of future 
neoplasia following screening colonoscopy (Gellad et al 2010). However, baseline 
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withdrawal time was calculated from only 304 procedures where no polyps were detected. 
The mean withdrawal time at baseline (calculated per medical centre) was 12 minutes. This 
may be indirect evidence of the ‘ceiling effect’ we describe here and suggests that CWT is a 
more relevant measure of colonoscopic performance below 10 minutes. A Polish study has 
shown a negative correlation between increasing ADR and risk of interval cancer (Kaminski 
et al 2010). This study did not include data on withdrawal times. Prospective analysis of 
colonoscopy quality indicators with interval neoplasia rate in the NHS BCSP is being 
undertaken. 
Secondly, although this study lacks the advantages of a prospective randomised controlled 
trial, the data were collected prospectively by an independent screening practitioner for the 
purpose of quality assurance. Due to the availability of data regarding a range of potential 
confounding factors, we have been able to control for these in the analysis. A number of 
known risk factors for colorectal adenomas, such as family history or nonsteroidal anti-
inflammatory drug (NSAID) use were not available for inclusion in the multivariable 
analysis. Individuals with known familial risk factors for colorectal cancer under surveillance 
were not included in the screening programme.  NSAID use was unlikely to differ between 
the groups or change the conclusions of this study. 
Thirdly, the choice of groupings could be criticised on the basis that there were fewer 
colonoscopists in the shortest withdrawal time group. The data were re-analysed with five 
groups with more equal numbers of colonoscopists in each group (results not shown), the 
results were similar.  The conclusions that the optimal mean withdrawal time was around 10 
minutes, lower withdrawal times were too short to optimise adenoma detection and mean 
withdrawal times of 11 minutes or more did not improve ADR, were confirmed. 
Fourthly, the study population was restricted to FOB positive screening programme 
participants in the screening programme target age range. Therefore, the external validity of 
these findings outside the context of screening colonoscopy is not clear. It is known that 
increasing CWT is associated with increasing ADR in non-screening populations (Barclay et 
al 2006; Simmons et al 2006, however, the clinical objective of non-screening colonoscopy 
may not be to detect and remove all neoplasia. The trade off between increasing procedure 
duration and detection of more adenomas is not clear-cut outside screening colonoscopy. The 
common indication for all the colonoscopies in our study however, minimises any bias that 
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could be introduced by variation in indication for colonoscopy between colonoscopists had 
the study been conducted in a non screening setting. 
Finally, we have assumed that screening colonoscopists utilise the withdrawal phase of 
colonoscopy to perform detailed mucosal inspection for neoplasia. Some lesions may be 
detected during the insertion phase and some colonoscopists may perform a longer, more 
detailed examination on insertion requiring less time on withdrawal. The use of mean nc-
CWT should account for this variation in practice across the population of colonoscopists. 
Studies of the effect on ADR of the introduction of a minimum CWT have had mixed results. 
Barclay et al (2008) set a minimum CWT of 8 minutes in conjunction with advice on optimal 
withdrawal technique leading to an increase in ADR from 23·5% to 34·7%. Sawhney et al 
(2008) however, did not find an increase in polyp detection rate (PDR) when they studied the 
effect of the introduction of a policy of a minimum CWT of seven minutes in one institution.  
We cannot make any firm conclusions from this study about whether it is the duration of 
withdrawal that is accounting for the change in ADR or simply that longer nc-CWT is a 
marker of good colonoscopic technique. It may be that manoeuvres to improve mucosal 
inspection (which incidentally increases CWT) such as re-positioning the patient, adequate 
insufflation and suction, meticulous mucosal re-inspection, retro-fold examination, and rectal 
retroversion are performed more frequently by ‘good’ colonoscopists leading to higher ADR 
and longer mean nc-CWT.  We recommend that screening colonoscopists ‘actively’ inspect 
the colonic mucosa using these manoeuvres rather than passively withdrawing the 
colonoscope. A study of an intervention to increase the nc-CWT in BCSP screening 
colonoscopists with an nc-CWT below 10 minutes, with ADR as the outcome variable, would 
be of value. 
In summary, the findings of this study demonstrate an optimal mean nc-CWT per 
colonoscopist for screening colonoscopy of 10 minutes. Increasing adenoma detection 
associated with longer withdrawal times is dependent on increasing detection of right sided 
and sub-centimetre adenomas. These findings reinforce the value of CWT as a metric of 
colonoscopy quality. 
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Chapter 3.3- Patient and colonoscopy factors affecting adenoma detection in 
patients undergoing colonoscopy in the NHS Bowel Cancer Screening 
Programme  
 
3.3.1- Introduction 
Screening for CRC with biennial faecal occult blood testing (FOBt) and colonoscopy for 
those with a positive FOBt has been demonstrated to reduce mortality from CRC by 15 to 
18% (Hewitson et al 2007). Reduction in mortality is mainly achieved through detection of 
cancer at an earlier stage.  
A secondary, objective of colonoscopy in an FOBt screening programme is detection and 
removal of all adenomas. Removal of adenomas, particularly large (10mm or greater in size) 
or histologically advanced (displaying high grade dysplasia) adenomas may prevent 
progression to cancer. In the National Polyp Study, removal of adenomas at colonoscopy was 
associated with a 76 to 90% risk reduction of CRC in people with colorectal polyps 
(Winawer et al 1993).
 
Adenoma detection is also important from a quality assurance perspective. Adenoma 
detection rate (ADR) is widely regarded as the key performance indicator of colonoscopy 
(Rex 2005). Increasing ADR has been shown to correlate with decreased interval cancer rate 
(Kaminski et al 2010).
 
Multiple factors may affect whether an adenoma is detected during colonoscopy. These 
include patient factors which influence whether or not the patient has an adenoma. These may 
be non-modifiable (male gender, family history and increasing age are all associated with 
increased adenoma incidence) (Lynch et al 2003; Lieberman et al 2003) or modifiable 
(cigarette smoking and alcohol use are associated with increased adenoma incidence) 
(Anderson et al 2003; Reid et al 2003; Anderson et al 2005; Martinez et al 1995). 
Additionally, there are colonoscopy related factors which determine whether an adenoma is 
detected. These factors, such as caecal intubation, colonoscopy withdrawal time or bowel 
preparation quality, relate to the completeness of pan colonic mucosal inspection for 
adenomas and are important as they are potentially modifiable, offering the opportunity to 
optimise adenoma detection (Harewood et al 2003; Barclay et al 2006; Chen et al 2007).
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Few previous studies have included the full range of currently known, measurable technical 
variables of colonoscopy in addition to modifiable and non-modifiable patient factors to 
examine the risk of an adenoma being detected. This approach is necessary to allow for 
confounding between potential risk factors and enables known risk factors for neoplasia to be 
controlled for whilst examining the role of potentially modifiable aspects of colonoscopy 
practice which are associated with an increased risk of adenoma detection. 
The aim of this study was to identify patient factors and colonoscopy technical factors 
associated with increased or decreased risk of adenoma detection in patients in the NHS 
BCSP.  
 
3.3.2- Methods 
Study Population 
All colonoscopies in the NHS Bowel Cancer Screening Programme (BCSP) between August 
2006 (when the screening programme commenced) and August 2009 were analysed. The 
indication for all procedures was a positive FOB test. Surveillance colonoscopies were not 
included and where an individual had more than one procedure in a screening episode, only 
the first procedure was included in order to avoid double-counting of adenomas. 
Demographic and lifestyle data (date of birth, gender, smoking status, alcohol consumption, 
height (metres), weight (kg), postal code) were collected from individuals prior to 
colonoscopy during a pre-colonoscopy assessment with a trained screening practitioner. 
These data are recorded on the BCSS database to which colonoscopy data are added at the 
time of the procedure. Histological data for any lesions detected at colonoscopy are also 
recorded on the database.  
Data were obtained from the BCSS database in April 2010. During the study period 36,460 
lower gastrointestinal endoscopic procedures were performed. 32,213 of these were index 
colonoscopies in a screening episode. 583 procedures were excluded where the colonoscopist 
was not recorded. Only procedures performed by colonoscopists who had performed 50 or 
more procedures were included in subsequent analysis because with fewer procedures, 
statistical analysis per colonoscopist is underpowered. 31,088 procedures were therefore 
eligible for inclusion in further analysis. The process for establishing the study population 
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(n=31,088 colonoscopies) is the result of query 1 to the National Bowel Cancer Screening 
Programme database as shown in figure 12 and appendix A. 
   
Study Procedures 
Data downloaded from the BCSS database were cleaned and checked. Where possible, 
missing data were retrieved from the Screening Centre. Completeness of data was validated 
by cross checking with local data sources. Data entries for continuous variables (height, 
weight, drug doses and withdrawal time) which were considered implausible, as adjudicated 
by panel decision, were excluded from further analysis.  
Age was recorded on the date of colonoscopy rather than at entry to the screening 
programme. Age was analysed both as a continuous variable and as a categorical variable 
(<62.5, 62.5-64.9, 65.0-67.49, ≥67.5 years).Univariable analysis showed the effect of age was 
more easily interpreted as a categorical variable. Smoking status was categorised as current 
smoker, ex-smoker or never smoked. Alcohol use was categorised as either current use or 
not. Patient body mass index (BMI, kg/m
2
) was calculated from self-reported height and 
weight measurements and grouped into two categories (<25.0 and ≥25.0 kg/m2). Deprivation 
scores were assigned using an individual’s postcode at the time of entry to the screening 
programme. Postal codes were linked to Index of Multiple Deprivation scores (IMD) at the 
Lower Super Output Area level (Department of Communities and Local Government. Indices 
of Deprivation 2007). In subsequent analysis the IMD scores of the study population were 
ranked in quintiles from highest to lowest deprivation scores where group 1 was the most 
deprived and group 5 the least deprived. 
The BCSP is coordinated by 5 Hubs which cover England. Hubs are responsible for inviting 
individuals to join the screening programme and conducting FOB testing. The Hub in which 
the individual lived at the time of invitation to the screening programme was included in the 
study as a geographical variable. 
Colonoscopy data recorded at the time of the procedure included caecal intubation (as 
evidenced by anatomical landmarks), withdrawal time (defined as the time taken to withdraw 
the colonoscope from the caecal pole to the anus), rectal retroversion, sedative medication or 
intravenous antispasmodic (hyoscine n-butyl bromide) use and quality of bowel preparation. 
Bowel preparation quality was recorded on a four point Likert scale. Descriptors for bowel 
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preparation quality were: incomplete examination due to inadequate preparation; complete 
examination despite inadequate preparation; adequate or excellent preparation (Chilton et l 
2011).  
Mean colonoscopy withdrawal times were calculated for each colonoscopist for negative 
complete procedures only (nc-CWT). Use of actual withdrawal times for individual 
procedures is not appropriate as it is influenced by the duration of therapeutic procedures 
rather than time spent examining the colonic mucosa during withdrawal.
 
Mean nc-CWT per 
colonoscopist were further categorised into two groups (<10 minutes, ≥10 minutes) based on 
exploratory analyses suggesting that colonoscopists with mean nc-CWT ≥10 minutes tended 
to have higher ADR than those with shorter mean withdrawal times. Each colonoscopy was 
therefore categorized based on the mean nc-CWT of the colonoscopist performing the 
procedure.  
Univariable analysis suggested a relationship between procedure start time and adenoma 
detection. The association appeared to depend on how early in the morning or afternoon 
session the procedure was commenced. Procedure start time was divided into two groups. In 
group one, the procedure commenced towards the start of either a morning or afternoon 
session (8am-11am or 2-4pm); group two consisted of procedures starting later in a session 
(11am-2pm or 4-6pm).  
All colonoscopists in the BCSP must have completed at least 1000 procedures during their 
career prior to obtaining accreditation to commence screening colonoscopy. To account for 
colonoscopist experience of screening colonoscopy, procedures were grouped into those 
among the first 300 procedures performed by an individual colonoscopist and subsequent 
procedures. The cut off at 300 procedures was determined by univariable analysis which 
showed no significant relationship when groups of 100 or 200 procedures were used. Finally, 
procedures were assigned to a group depending on whether intravenous sedative or analgesic 
medication was used. Entonox (nitrous oxide and air) may have been used in the group that 
didn’t receive intravenous medications. 
The results of each colonoscopy were categorised into one of  five different outcomes: 
negative (no adenomas detected), one or more adenomas detected, one or more advanced 
adenomas detected (defined as adenomas 1cm or greater in size or displaying high grade 
dysplasia or polyp cancer), one or more right-sided adenomas (lesions at or proximal to the 
splenic flexure) and one or more rectal adenomas detected. Only lesions which were 
                      Detection and Management of Colorectal Neoplasia in the NHS Bowel Cancer Screening Programme 
127 
 
histologically confirmed as adenomas were counted.The total number of adenomas counted at 
each colonoscopy was also recorded. 
 
Statistical Analysis 
Normally distributed continuous variables are presented as mean (standard deviation- sd). 
Categorical variables are presented as total proportions and percentages (n,%). Univariable 
analysis was performed using the χ2 test for comparing categorical variables and the unpaired 
t-test for continuous variables. This exploratory testing identified variables which were 
associated with the presence of one or more adenomas. The procedure was repeated to 
identify variables associated with the presence of one or more advanced adenomas, right 
sided adenomas and rectal adenomas. In order to allow for confounding between variables, 
multivariable analysis using binary logistic regression to calculate odds ratios (OR) with 95% 
confidence intervals (CI) was performed. Four separate models (with ≥1 adenomas, ≥1 
advanced adenomas, ≥1 right sided adenomas and ≥1 rectal adenomas as the dependent 
variables) were analysed using the forward logistic regression approach. The following 
patient variables were tested: gender, age, smoking status, alcohol use, BMI category, 
deprivation quintile, hub area. The following colonoscopy variables were tested: caecal 
intubation, rectal retroversion, colonoscopist’s mean nc-CWT group, bowel preparation 
quality, hyoscine use, procedure start time group, colonoscopist`s prior experience group and 
intravenous sedation group. Variables were included in the multivariable models if they 
reached a significance level of ≤0.1 in univariable testing. An ordinal logistic regression 
approach was used to analyse the effect of patient and colonoscopy factors on the total 
number of adenomas detected. The Pearson χ2 test was used toassess goodness of fit of 
models.  A p value of less than 0.05 was considered significant. All reported p values are two 
sided. Analyses were undertaken using SPSS version 17.0
®
 (SPSS Inc., Chicago, Illinois, 
USA). 
 
3.3.3- Results 
Patient and procedure characteristics 
31,088 colonoscopies were analyzed. These were performed by 148 colonoscopists. 
18,761(60.3%) procedures were on male patients. The mean age of patients at colonoscopy in 
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males was 65.8 years (sd 3.75 years) and in females 65.7 years (sd 3.73 years, p=0.051). One 
or more adenomas were detected in 9918 of 18761 procedures in males (52.9%) and in 4505 
of 12327 procedures in females (36.5%, p< 0.001). One or more advanced adenomas were 
detected in 6248 (33.3%) males and in 2737 (22.2%) females (p< 0.001). One or more right 
sided adenomas were detected in 4385 (23.4%) males and 1614 (13.1%) females (p< 0.001).  
 
Patient Factors 
Demographic and lifestyle characteristics of the study population are shown in table 28 with 
univariable analyses for each of the outcome variables. BMI was not significantly associated 
with any of the adenoma outcomes so was not included in subsequent multivariable analysis. 
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* Smoking status of patient not known for 188 procedures (0.60%) 
**Alcohol usage of patient not known for 302 procedures (0.97%) 
#
BMI of patient not known for 5807 procedures (18.7%) 
##
Postcode (and deprivation index) of patient not known for 16 procedures (0.05%) 
 
 
 
Patients 
(n=31088) 
number (%) 
≥1 adenoma 
(n=14423) 
number (%) 
p 
≥1 
advanced 
adenoma 
(n=5999) 
number (%) 
p 
≥1 right 
sided 
adenoma 
(n=8985) 
number (%) 
p 
Gender        
Female 12327 (39.7) 4505 (36.5) 
<0.001 
2737 (22.2) 
<0.001 
1614 (13.1) 
<0.001 
Male 18761 (60.3) 9918 (52.9) 6248 (33.3) 4385 (23.4) 
Age (years)        
<62.5 8415 (27.1) 3644 (43.3) 
<0.001 
2273 (27.0) 
<0.001 
1418 (16.9) 
<0.001 
62.5-64.9 4959 (16.0) 2235 (45.1) 1351 (27.2) 954 (19.2) 
65-67.49 6844 (22.0) 3181 (46.5) 2009 (29.4) 1322 (19.3) 
≥67.5 10870 (35.0) 5363 (49.3) 3352 (30.8) 2305 (21.2) 
Smoking*        
Never 17039 (54.8) 7280 (42.7%) 
<0.001 
4481 (26.3) 
<0.001 
2937 (17.2) 
<0.001 Ex-smoker 10344 (33.3) 5145 (49.7%) 3323 (32.1) 2138 (20.7) 
Current 
smoker 
3517 (11.3) 1923 (54.7%) 1136 (32.3) 891 (25.3) 
Alcohol**        
No 10422 (33.5) 4069 (39.0) 
<0.001 
2363 (22.7) 
<0.001 
1596 (15.3) 
<0.001 
Yes 20364 (65.5) 10233 (50.3) 6547 (32.1) 4349 (21.4) 
BMI
#
 
(kg/m
2
) 
       
<25.0 6588 (21.2) 3020 (45.8) 
0.179 
1869 (28.4) 
0.226 
1249 (19.0) 
0.376 
≥25.0 19413 (62.4) 9085 (46.8) 5660 (29.2) 3778 (19.5) 
Deprivation 
Group
##
 
       
1 (most 
deprived 
quintile) 
6215 (20.0) 2765 (44.5) 
<0.001 
 
 
1620 (26.1) 
 
<0.001 
 
 
1201 (19.3) 
0.909 
 
2 6216 (20.0) 2837 (45.6) 1703 (27.4) 1226 (19.7) 
3 6217 (20.0) 2876 (46.3) 1781 (28.6) 1189 (19.1) 
4 6217 (20.0) 2933 (47.2) 1888 (30.4) 1192 (19.2) 
5 (least 
deprived 
quintile) 
6207 (20.0) 3005 (48.4) 1989 (32.0) 1188 (19.1) 
Hub area        
Midlands 9369 (30.1) 4191 (44.7)  
 
<0.001 
 
 
 
2601 (27.8)  
 
<0.001 
 
 
 
1726 (18.4) 
<0.001 
 
 
South 5633 (18.1) 2740 (48.6) 1764 (31.3) 1056 (18.7) 
London 4636 (14.9) 1966 (42.4) 1107 (23.9) 976 (21.1) 
North-East 4864 (15.6) 2375 (48.8) 1540 (31.7) 905 (18.6) 
Eastern 6586 (21.2) 3151 (47.8) 1973 (30.0) 1336 (20.3) 
Table 28- Patient characteristics and proportions of patients with one or more adenomas, advanced 
adenomas or right sided adenomas 
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Patients 
(n=31088) 
number 
(%) 
≥1 adenoma 
(n=14423) 
number (%) 
p 
≥1 
advanced 
adenoma 
(n=5999) 
number (%) 
p 
≥1 right 
sided 
adenoma 
(n=8985) 
number (%) 
p 
Caecal Intubation        
No 1365 (4.4) 244 (17.9) 
<0.001 
151 (11.1) 
<0.001 
57 (4.2) 
<0.001 
Yes 
29723 
(95.6) 
14179 (47.7) 8834 (29.7) 5942 (20.0) 
Rectal retroversion        
No 
3115 
(10.0) 
1433 (46.0) 
0.645 
1001 (32.1) 
<0.001 
589 (18.9) 
0.581 
Yes 
27973 
(90.0) 
12990 (46.4) 7984 (28.5) 5410 (19.3) 
Colonoscopist 
mean nc-CWT 
(minutes) 
       
<10 
19816 
(63.7) 
9020 (45.5) 
<0.001 
5769 (29.1) 
.280 
3609 (18.2) 
<0.001 
≥10 
11272 
(36.3) 
5403 (47.9) 3216 (28.5) 2390 (21.2) 
Bowel preparation 
quality 
  
 
 
 
 
 
 
 
 
Inadequate 
preparation 
1637 (5.3) 620 (37.9) 
<0.001 
360 (22.0) 
<0.001 
277 (16.9) 
0.011 
 Excellent or 
adequate 
29280 
(94.7) 
13775 (47.0) 8610 (29.4) 5708 (19.5) 
Hyoscine use        
No 
20521 
(66.0) 
9129 (44.5) 
<0.001 
5629 (27.4) 
<0.001 
3718 (18.1) 
<0.001 
Yes 
10567 
(34.0) 
5294 (50.1) 3356 (31.8) 2281 (21.6) 
Start time of 
procedure 
       
8-10.59 am or 2-
3.59pm 
19635 
(66.7) 
9244 (47.1) 
0.010 
 
5810 (29.6) 
0.003 
 
3857 (19.6) 
0.125 
 11am-1.59pm or 4-
5.59pm 
9790 
(33.3) 
4453 (45.5) 2732 (27.9) 1849 (18.9) 
Prior colonoscopist 
experience in the 
BCSP (number of 
procedures) 
       
0-299 
27844 
(89.6) 
12858 (46.2) 
0.027 
7972 (28.6) 
0.002 
5290 (19.0) 
<0.001 
≥300 
2344 
(10.4) 
1565 (48.2) 1013 (31.2) 709 (21.9) 
Sedation        
Used 
27012 
(86.9) 
12422 (46.0) 
<0.001 
7750 (28.7) 
0.036 
5149 (19.1) 
0.007 
Not used 
4076 
(13.1) 
2001 (49.1) 1235 (30.3) 850 (20.9) 
Table 29- Colonoscopy characteristics and proportions of patients with one or more adenomas, advanced 
adenomas and right sided adenomas 
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Multivariable analysis  
Table 30 shows the multivariable models for the association between patient factors and 
adenoma detection, advanced adenoma detection and right sided adenoma detection. Most of 
the associations seen in univariable analysis persisted in the multivariable models when 
confounding factors were adjusted for. The Pearson χ2 goodness of fit test gave p values of 
0.077, 0.264 and 0 .478 for each of the models respectively (a p value >0.05 suggests the 
model fits adequately). 
Male gender (odds ratio (OR) for ≥1 adenomas 1.77 (95% confidence interval 1.68-1.86), p< 
0.001) and caecal intubation (OR for ≥1 adenomas 3.71 (3.12-4.33), p< 0.001) had the 
strongest association with the detection of one or more adenomas, advanced adenomas or 
right sided adenomas. Increasing age group was associated with increased detection of one or 
more adenomas or advanced adenomas beyond 65 years of age (OR 1.32  (1.24-1.40) and 
1.23 (1.15-1.31) for those in the ≥67.5 age compared to the youngest age range group 
respectively). However, the risk of one or more right sided adenomas increased in each 
consecutive age group from age 60 years. Current smoking (OR 1.61 (1.49-1.75), p< 0.001) 
is associated with a higher risk of one or more adenomas than non-smoking, this risk is also 
greater than that associated with ex-smoking (OR 1.17 (1.11-1.23), p< 0.001). Current 
alcohol use was associated with an odds ratio of 1.30 (1.24-1.37) for each of the outcome 
variables (p< 0.001) (figure 18). 
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Figure 18- Impact of lifestyle factors and gender on adenoma detection in males and females 
 
Adenoma and advanced adenoma detection was greatest in the least deprived quintile. This 
relationship was not seen for right sided adenomas. A geographical variation in adenoma 
detection is seen even when all available variables are adjusted for. In table 3 the Midlands 
are presented as the reference group (being the largest). The Midlands area and London have 
similar adenoma detection (OR 0.99 (0.92-1.07), p=.517) but Southern, Eastern and North-
East areas have higher adenoma detection (OR 1.21 (1.13-1.31), 1.26 (1.17-1.34) and 1.19 
(1.11-1.27) respectively, all p< 0.001).  
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 Adjusted odds 
Ratio (95% CI) 
for one or more 
adenomas 
p Adjusted odds 
Ratio (95% CI) 
for one or more 
advanced 
adenomas 
p Adjusted odds 
Ratio (95% CI) 
for one or more 
right sided 
adenomas 
p 
Gender       
Female 1.00  1.00  1.00  
Male 1.77 (1.68-1.86) <0.001 1.55 (1.46-1.64) <0.001 1.88 (1.76-2.01) <0.001 
Age (years)       
<62.5 1.00  1.00  1.00  
62.5-64.9 1.08 (1.00-1.16) .048 1.03 (0.94-1.11) .559 1.20 (1.09-1.32) <0.001 
65-67.49 1.17 (1.09-1.25) <0.001 1.15 (1.07-1.24) <0.001 1.22 (1.12-1.33) <0.001 
≥67.5 1.32 (1.24-1.40) <0.001 1.23 (1.15-1.31) <0.001 1.41 (1.31-1.52) <0.001 
Smoking       
Never 1.00  1.00  1.00  
Ex-smoker 1.17 (1.11-1.23) <0.001 1.17 (1.11-1.24) <0.001 1.09 (1.02-1.16) <0.001 
Current smoker 1.61 (1.49-1.75) <0.001 1.34 (1.22-1.45) <0.001 1.57 (1.44-1.72) <0.001 
Alcohol       
No 1.00  1.00  1.00  
Yes 1.30 (1.24-1.37) <0.001 1.38 (1.30-1.46) <0.001 1.27 (1.18-1.35) <0.001 
Deprivation 
Group 
  -    
1 (most deprived 
quintile) 
1.00  1.00  -  
2 1.07 (0.99-1.15) 0.102 1.09 (1.00-1.18) 0.056 -  
3 1.09 (1.01-1.17 0.034 1.15 (1.06-1.25) 0.001 -  
4 1.10 (1.01-1.19) 0.022 1.22 (1.12-1.33) <0.001 -  
5 (least deprived 
quintile) 
1.15 (1.06-1.24) 0.001 1.32 (1.21-1.44) <0.001 -  
Hub area        
Midlands 1.00  1.00  1.00  
South 1.21 (1.13-1.31) <0.001 1.25 (1.15-1.35) <0.001 1.12 (1.03-1.23) 0.012 
London 0.99 (0.92-1.07) 0.517 0.91 (0.83-0.99) 0.026 1.43 (1.30-1.57) <0.001 
North-East 1.26 (1.17-1.34) <0.001 1.35 (1.25-1.47) <0.001 1.17 (1.06-1.28) 0.002 
Eastern 1.19 (1.11-1.27) <0.001 1.17 (1.08-1.26) <0.001 1.26 (1.16-1.37) <0.001 
 
 
 
Table 30- Patient factors- multivariable analysis for one or more adenomas, advanced adenomas or right 
sided adenomas (colonoscopy factors in the same models shown in table 31) 
                      Detection and Management of Colorectal Neoplasia in the NHS Bowel Cancer Screening Programme 
134 
 
Colonoscopy Factors 
Table 29 shows colonoscopy factors and univariable associations with each outcome variable. 
Caecal intubation was achieved in 95.6% of procedures and was significantly associated with 
increased detection of one or more adenomas, advanced adenomas and right sided adenomas 
(all p< 0.001). Rather than exclude incomplete procedures from multivariable analysis, this 
variable was included in the logistic regression to adjust for caecal intubation. Rectal 
retroversion did not affect the detection of adenomas or right sided adenomas (p=0.645 and 
0.581 respectively), and was performed in fewer patients with one or more advanced 
adenomas (28.5% vs 32.1%, p< 0.001). Further analysis was performed to examine the effect 
of rectal retroversion on rectal adenoma detection. In 27973 procedures where rectal 
retroversion was performed, one or more rectal adenomas were detected in 2523 procedures 
(9.0%), compared to 3115 procedures in which rectal retroversion was not performed where 
one or more rectal adenomas were detected in 273 procedures (8.8%, p=0.666). The 
relationship between rectal retroversion and rectal adenoma detection did not change when 
age and gender were accounted for.  
Procedures performed by a colonoscopist whose mean nc-CWT was ≥ 10 minutes were more 
likely to detect one or more adenomas or right sided adenomas (p< 0.001) than those with a 
mean nc-CWT less than 10 minutes. No difference was seen between the two nc-CWT 
groups in advanced adenoma or rectal adenoma detection (p=0.280 and 0.935 respectively).  
 
Multivariable Analysis 
The colonoscopy variables (mean nc-CWT ≥10 minutes, excellent or adequate bowel 
preparation, intravenous antispasmodic use and colonoscopists prior experience >300 
procedures) are all associated with an increase in adenoma detection with statistically 
significant odds ratios between 1.10 (1.05-1.16) and 1.38 (1.23-1.54) (table 31). 
Procedures starting later in a session (11am-2pm or 4-6pm) were associated with a reduction 
in detection of adenomas and advanced adenomas (OR 0.94 (0.90-0.99), p=0.018 and 0.93 
(0.88-0.98) p< 0.001) compared to procedures starting between 8am and 11am or 2pm and 
4pm (figure 19). 
In univariable analysis, procedures in which no intravenous sedation was used were 
associated with lower adenoma, advanced adenoma and right sided adenoma detection 
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however, once other variables were adjusted for in the multivariable models, no significant 
difference in outcome was seen between the two groups. 
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Adjusted odds 
Ratio (95% CI) 
for one or more 
adenomas 
p 
Adjusted odds 
Ratio (95% CI) 
for one or more 
advanced 
adenomas 
p 
Adjusted odds 
Ratio (95% CI) 
for one or more 
right sided 
adenomas 
p 
Caecal 
Intubation 
      
No 1.00 <0.001 1.00 <0.001 1.00 <0.001 
Yes 3.71 (3.12-4.33) 3.34 (2.77-4.02) 5.55 (4.17-74) 
Rectal 
retroversion 
      
No - 
 
1.00 <0.001 -  
Yes - 0.64 (0.59-0.70) - 
Mean nc-CWT 
(minutes) 
      
<10 1.00 <0.001 -  
1.00 <0.001 
≥10 1.10 (1.05-1.16) - 1.28 (1.20-1.36) 
 
Bowel 
preparation 
quality 
      
Inadequate 
preparation 
1.00 
<0.001 
1.00 
<0.001 
1.00 
0.035 Excellent or 
adequate 
 
1.38 (1.23-1.54) 1.39 (1.22-1.57) 1.16 (1.01-1.33) 
Hyoscine use       
No 1.00 <0.001 1.00 <0.001 1.00 <0.001 
Yes 1.29 (1.23-1.36) 1.29 (1.22-1.36) 1.22 (1.15-1.30) 
Start time of 
procedure 
      
8-10.59 am or 2-
3.59pm 
1.00 
0.018 
1.00 
<0.001 
- 
 
11am-1.59pm or 
4-5.59pm 
0.94 (0.90-0.99) 0.93 (0.88-0.98) - 
Prior 
colonoscopist 
experience in 
the BCSP 
(number of 
procedures) 
      
0-299 1.00 <0.001 1.00 <0.001 1.00 <0.001 
≥300 1.20 (1.11-1.30) 1.23 (1.13-1.24) 1.38 (1.22-1.47) 
IV Sedation       
Used 1.00 0.143 1.00 0.210 1.00 0.866 
Not used 1.06 (0.98-1.14) 1.05 (0.97-1.14) 1.01 (0.93-1.10) 
 
 
 
Table 31- Colonoscopy factors- multivariable analysis for one or more adenomas, advanced adenomas or 
right sided adenomas (patient factors in the same models shown in table 30) 
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Figure 19- Relationship between start time of colonoscopy and adenoma detection, withdrawal time, 
caecal intubation and bowel preparation quality 
The ordinal regression model demonstrating the relationship between the total number of 
adenomas detected at each colonoscopy and patient and colonoscopy factors is shown in table 
32. Only significant factors are displayed. The odds ratio refers to the odds of the group 
having more adenomas in total than the reference group. 
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 Odds 
Ratio 
95% 
confidence 
interval 
Significance 
(p) 
Gender    
Female 1.89 1.78-1.99 <0.001 
Male 1.00 - - 
Age (years)    
<62.5 0.75 0.70-0.80 <0.001 
62.5-64.9 0.82 0.76-0.88 <0.001 
65-67.49 0.90 0.84-0.96 0.003 
≥67.5 1.00 - - 
Smoking    
Never 0.55 0.51-0.60 <0.001 
Ex-smoker 0.64 0.59-0.70 <0.001 
Current smoker 1.00 - - 
Alcohol    
No 0.76 0.72-0.81 <0.001 
Yes 1.00 - - 
Caecal Intubation    
No 0.24 0.19-0.27 <0.001 
Yes 1.00 - - 
Rectal retroversion    
No 1.34 0.82-0.68 <0.001 
Yes 1.00 - - 
Mean nc-CWT (minutes)    
<10 0.89 0.84-0.93 <0.001 
≥10 1.00 - - 
Bowel preparation quality    
Inadequate preparation 0.70 0.63-0.79 <0.001 
Excellent or adequate 
 
1.00  - 
Hyoscine use    
No 0.76 0.73-0.80 <0.001 
Yes 1.00 - - 
Start time of procedure    
8-10.59 am or 2-3.59pm 1.08 1.03-1.13 0.003 
11am-1.59pm or 4-5.59pm 1.00 - - 
Prior colonoscopist 
experience in the BCSP 
(number of procedures) 
   
0-299 0.81 0.75-0.88 <0.001 
≥300 1.00 - - 
Table 32- Ordinal regression model of the effect of patient and colonoscopy factors on the total number of 
adenomas detected per procedure. 
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3.3.4-  Discussion 
This is the largest study examining the relative effect of both patient and colonoscopist 
factors on adenoma detection in an FOB test screened population. Patient factors including 
male gender, increasing age, smoking and alcohol use are shown to be associated with 
increased detection of one or more adenomas, advanced adenomas and right sided adenomas. 
Increasing deprivation is shown to have an inverse association with adenoma detection. With 
these variables taken into account, a geographical variation in adenoma detection within 
England is seen. Colonoscopy factors are also shown to have an important effect on adenoma 
detection. Caecal intubation and bowel preparation quality have the strongest association with 
increasing adenoma detection. Longer mean withdrawal time of the colonoscopist, 
intravenous antispasmodic drug use, earlier start time of the procedure and prior 
colonoscopist experience are all shown to significantly increase adenoma detection. Rectal 
retroversion is not associated with an increase in adenomas or rectal adenomas. This study 
also demonstrates the finding that these factors have similar associations with advanced 
adenoma and right sided adenoma detection. 
This study has important implications for colonoscopy practice. We recommend routine use 
of intravenous antispasmodic medication, mean negative complete withdrawal time greater 
than 10 minutes and judicious use of rectal retroversion. Further investigation of the causes of 
reduction in adenoma detection as a session progresses is required to ameliorate this 
phenomenon.  
 
Patient factors 
 Gender, age and lifestyle factors are well recognised risk factors for colorectal neoplasia as 
demonstrated by a recent analysis of lifestyle factors on polyp detection in the USA (Hassan 
et al 2010). 1,321 asymptomatic adults underwent primary screening colonoscopy and same-
day CT colonography showing a positive association between male gender, BMI ≥ 25 kg/m2 
and increasing age with colorectal neoplasia. Other lifestyle factors including smoking and 
alcohol consumption were not shown to be associated with neoplasia detection; this may be a 
result of under-powering due to the relatively small sample size. Our study confirms that 
male gender, increasing age, smoking (or being an ex-smoker) and alcohol use are important 
risk factors for adenoma detection. Figure 18 demonstrates this relationship and the finding 
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that within the study population, females who smoke and drank alcohol had a higher risk of 
adenoma detection (47.8%) than males who didn`t smoke or drink (44.8%, p< 0.001). These 
findings are clinically relevant and should direct clinicians to inform patients of the risks 
associated with lifestyle choices. 
No statistically significant relationship between BMI and adenoma detection was 
demonstrated, however, slightly more adenomas were detected in individuals with a BMI 
greater than 25. This reflects the inconsistent findings on the role of BMI as a risk factor for 
colorectal neoplasia in the existing literature. A study of 3,121 (predominately male) 
individuals in the USA undergoing colonoscopy did not show any association between BMI 
and risk of advanced adenoma detection (Lieberman et al 2000). Other studies however, have 
shown an association between increasing BMI and increased risk of colorectal neoplasia both 
in the general population and in those undergoing screening colonoscopy (Giovannucci et al 
1995; Hassan et al 2010; Betes et al 2003). The findings of the current study regarding BMI 
are potentially limited by the higher rate of missing data for this variable and the reliance on 
self reported measures of height and weight. 
An inverse relationship between deprivation and adenoma detection was seen. In the 
multivariable model, decreasing deprivation was associated with a 15% increase in adenoma 
detection. It is known from the pilot study of CRC screening in the UK that uptake of 
screening is lower in more deprived areas (uptake varied from 61.2% to 37.2% in IMD 
quintiles 1–5 respectively (test for trend p< 0.001) (Weller et al 2004). Similar findings were 
noted in the Nottingham randomised controlled trial of FOB screening (Whynes et al 2003). 
It is also known that colorectal cancer incidence is higher in those who don’t take up the offer 
of screening compared to those who do (Niv et al 2002). A potential explanation therefore, is 
that individuals who take up the offer of screening in more deprived areas differ from those 
who don’t take up the offer of screening but who harbour more neoplasia. In less deprived 
areas, where uptake is higher, this effect is reduced and adenoma detection is not diluted. 
Other possible factors we are unable to account for include differences in diet, physical 
exercise and the potential for there to be more false positive FOB tests in the lower 
socioeconomic groups (perhaps due to differing patterns of non steroidal anti-inflammatory 
medication use). A limitation of this analysis is the use of area-level rather than individual 
measures of socioeconomic status. 
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A geographical variation in adenoma, advanced adenoma and right sided adenoma detection 
was shown to exist even when available patient and colonoscopy variables are adjusted for. 
This variation may be the result of regional variation in the underlying prevalence of colonic 
adenomas in England. A regional variation in colorectal cancer incidence has also been 
observed (Cancer Research UK 2011). Alternatively, it may reflect variations in colonoscopic 
performance or biological risk factors which have not been accounted for.  The geographical 
variation in adenoma detection requires further investigation. 
 
Colonoscopy factors 
Caecal intubation is, unsurprisingly, strongly associated with adenoma detection. An 
alternative approach to our method of analysis would be to exclude incomplete procedures. 
Doing so resulted in minimal change to the outcome of the models but reduced the size of the 
study population. 
 
Adenomas were more likely to be detected where the bowel preparation was better. 
Improving bowel preparation quality is a widely accepted way of improving adenoma 
detection (Froelich et al 2005; Belsey et al 2007). A standardised bowel preparation protocol 
is not used in the NHS BCSP, the bowel preparation used for each individual colonoscopy 
was not available for analysis, therefore we cannot comment on the use or timing of different 
bowel preparations in this study. 
Rectal retroversion is not shown to increase detection of either adenomas or rectal adenomas. 
Surprisingly, it is associated with a reduction in detection of advanced adenomas. A potential 
explanation for this unexpected finding is that rectal retroversion is less likely to be 
performed if significant pathology has already been detected earlier in the procedure. It is 
currently recommended that rectal retroversion is performed during colonoscopy in the NHS 
BCSP (Chilton et al 2011). This recommendation is based on a study of 480 screening 
flexible sigmoidoscopies which showed an absolute increase of 1% in number of adenomas 
detected when rectal retroversion was performed (Hanson et al 2002). A more recent US 
study showed that rectal retroversion did not detect clinically important neoplasia after 
careful forward viewing examination and emphasised the potential discomfort and harm of 
the manoeuvre (Saad et al 2008). Data presented in section 3.1.3 of this thesis suggest a 
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modest positive correlation between rectal retroversion rate and ADR. This may appear at 
odds with the findings in the current study. However, the correlation between RRR and ADR 
is likely explained by the fact that colonoscopists with higher ADR are more likely to 
perform rectal retroversion. The current study examines the relationship at the ‘per 
procedure’ level and demonstrates no increase in adenoma detection with rectal retroversion.    
Rectal retroversion may be a particularly uncomfortable phase of the colonoscopy for the 
pateient and has risks associated with it including bleeding and perforation, particularly if the 
rectum is inflamed. The majority of the distal rectum can be adequately examined with the 
increased field of view of a modern colonoscope in the forward viewing position. Anecdotal 
reports mention the presence of lesions which can only be seen on retroversion though this is 
a rare phenomenon. On the basis of the lack of evidence for increased lesion detection 
compared to the potential for discomfort or harm to the patient, we conclude that 
performance of rectal retroversion should not be used as a quality indicator of screening 
colonoscopy.We agree with the authors of the US study that use of rectal retroversion should 
be at the discretion of the colonoscopist. Thorough colonoscopic inspection of the distal 
rectum remains an essential part of the examination. 
Colonoscopists with a mean (negative complete) colonoscopy withdrawal time (nc-CWT) 
detected one or more adenomas in 10% more individuals than colonoscopists with a mean nc-
CWT of less than 10 minutes. Longer withdrawal time is also associated with increased 
detection of right sided adenomas but no increase in advanced adenoma detection was seen. 
Advanced adenomas, which are likely to be larger than 1cm in size, are likely to be detected 
even with shorter withdrawal times. We encourage screening colonoscopists to aim for a 
mean nc-CWT of around 10 minutes. 
Intravenous hyoscine n-butyl bromide use is associated with a 30% increase in adenoma 
detection. This holds true for advanced adenomas and right sided lesions. It is not clear if the 
administration of the antispasmodic is responsible for the increase in adenoma detection or if 
antispasmodic use is a feature of higher performing colonoscopists. Existing literature is 
conflicting on the role of antispasmodic use during colonoscopy in terms of procedure time 
and patient comfort (Saunders et al 1996; Mui et al 2004). Data on adenoma detection and 
antispasmodic use is limited. A recent small South Korean study of 116 patients showed a  
non-significant increase in adenoma detection in patients with high colonic spasm scores with 
hyoscine use (1.21 polyps per patient in the group given hyoscine vs. 0.41 in the placebo 
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group, p=0.06) (Lee et al 2010). A randomised controlled trial of intravenous antispasmodic 
use in the screening setting is required. 
Time of day of colonoscopy has previously been shown to affect adenoma detection. Two US 
studies have demonstrated that polyp detection decreases in afternoon compared to morning 
colonoscopies and with each subsequent hour of the day (Sanaka et al 2009; Chan et al 2009). 
Analysis of adenoma detection in the BCSP by hour of the day is shown in figure 19. The 
pattern appears to reflect working practice in England where colonoscopy is performed 
during morning (8am or 9am to 1pm) or afternoon (2pm to 5pm) lists and colonoscopists tend 
not to perform all-day lists. When colonoscopies are divided into two groups, those towards 
the start of a list (8-11am and 2-4pm) and those towards the end of a list (11-2pm and 4-
6pm), a decrease in detection of one or more adenomas or advanced adenomas of around 6% 
is demonstrated. Bowel preparation scores, caecal intubation rate and normal complete 
withdrawal time are all adjusted for in this analysis. Although we have no evidence to 
directly support the theory, colonoscopist fatigue may be contributing to this reduction in 
adenoma detection. A recent single centre US study of 20 colonoscopists has observed a 
similar phenomenon of declining polyp detection toward the end of an endoscopist`s shift 
(Long et al 2011).
37
 Screening colonoscopists should reflect on their own practice to 
minimise the effect of fatigue during a colonoscopy list. Further investigation into the 
potential role of operator fatigue during colonoscopy is required. 
 
Previous reports on the effect of colonoscopist experience on adenoma detection are 
conflicting. A number of studies show no relationship or a negative association between 
increasing experience and adenoma detection (Barclay et al 2006; Chen et al 2007; Simmons 
et al 2006). A study of adenoma detection in a large trial of flexible sigmoidoscopy screening 
demonstrated that the adenoma detection rate of some endoscopists increased with experience 
(Atkin et al 2004). Our data suggests that individuals colonoscoped by a colonoscopist who 
had performed ≥300 colonoscopies in the screening programme were 1.2 times more likely to 
have one or more adenomas than if the colonoscopist had performed <300 procedures. It 
should be noted that procedures performed by colonoscopists who had performed less than 50 
procedures were not included in this analysis. It is likely that experience within the screening 
programme is important.  
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Unsedated colonoscopy comprised 13.1% of screening colonoscopies in our study. Two US 
studies have suggested that deeper sedation is associated with increasing detection of colonic 
pathology (Radaelli et al 2008; Wang et al 2008). Our data provide reassuring evidence that 
adenoma detection is not reduced in patients undergoing unsedated colonoscopy. 
Analysis of the total number of adenomas detected echoes the findings when the outcome 
variable is one or more adenomas. The strongest associations between patient factors and 
increasing number of adenomas are for being male and increasing age. Hyoscine use, earlier 
start time and colonoscopist experience (>300) are all associated with increasing numbers of 
adenomas detected. Once again, rectal retroversion not being performed is associated with 
increasing numbers of adenomas detected. As discussed previously, this may be because a 
colonoscopist is less likely to perform retroversion when multiple polyps have been detected, 
Our study has a number of limitations. Firstly, data were not available on some notable 
patient risk factors including family history of colorectal cancer and aspirin use. Secondly, 
this study is retrospective in design and lacks the advantages of a prospective randomised 
controlled trial. However, data for this study were collected prospectively and the size and 
breadth of the dataset offset some of these limitations. 
Finally, many statistically significant relationships are seen in the dataset. This reflects both 
the relationships between the study variables and the size of the dataset. The clinical 
relevance of certain findings is less clear, however, even small odds ratios (such as ≥1 
adenoma detection in late vs. early start time of colonoscopy, OR= 0.94 (0.90-0.99), 
p=0.018) may have important clinical implications, both at a population level and for 
individual patients, colonoscopist and screening centres. 
In summary, this large study of over 31,000 colonoscopies by 148 colonoscopists in the NHS 
Bowel Cancer Screening Programme, demonstrates the importance of both patient and 
colonoscopy factors in determining the risk of an adenoma being detected during screening 
colonoscopy. In particular, the study draws attention to factors which the patient may modify 
in order to minimise their risk of having an adenoma (smoking and drinking alcohol) and also 
to factors which the colonoscopist may modify in order to optimise adenoma detection 
(caecal intubation, mean withdrawal time, bowel preparation quality and start time of the 
colonoscopy). These factors affect not only the risk of detecting one or more adenomas but 
also advanced adenomas and right sided adenomas. Many of the colonoscopy factors shown 
to affect adenoma detection in this study have been proposed as contributing to the risk of 
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missing lesions during colonoscopy, increasing the risk of post colonoscopy colorectal cancer 
(Rex 2000; Rabeneck et al 2010; Bressler et al 2007). This may be particularly relevant to 
right sided lesions which are harder to detect and potentially biologically different to left 
sided lesions (Singh et al 2006; Nawa et al 2008; Arain et al 2010). Awareness of the effect 
of these factors may contribute to reducing the risk of colonoscopy missing adenomas and 
subsequent interval pathology. 
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Chapter 4- Management of colorectal neoplasia in the NHS Bowel 
Cancer Screening Programme 
 
Chapter 4.1- Outcome of 12 month surveillance colonoscopy in high risk 
patients in the NHS Bowel Cancer Screening Programme 
 
4.1.1- Introduction 
Surveillance colonoscopy is recommended for individuals who have previously had 
adenomas removed as the risk of having further adenomas is up to 50% (Waye et al 1992; 
Atkin et al 1992, Winawer et al 1993). The aim of surveillance colonoscopy is to prevent 
subsequent colorectal cancer. Most small adenomas will not progress to malignancy, 
however, adenomas larger than 1cm in size or displaying high grade dysplasia are known to 
have greater malignant potential (Eide 1986). Such lesions are termed ‘advanced adenomas’ 
and the presence of these lesions is widely used as an outcome measure in studies of 
colonoscopic surveillance. 
 The risk of having further adenomas detected at surveillance is dependent on the 
characteristics of the adenomas removed at baseline (Martinez et al 2001). The presence of 
multiple adenomas (greater than 3), especially if one or more is larger than 1cm in size, is 
associated with an increased risk of detecting advanced adenoma or cancer at surveillance 
(Noshirwani et al 2001; Saini et al 2006; Martinez et al 2009). A recent pooled analysis of 
risk factors for finding adenomas at surveillance colonoscopy identified the presence of 
advanced adenoma, 3 or more adenomas, an adenoma ≥10mm in size and age ≥60 years as 
the most important risk factors for detection of adenomas at surveillance (de Jonge at al 
2011).  
The British Society of Gastroenterology guidelines on surveillance following detection of 
adenomas define individuals with 3 or more adenomas of which one is ≥10mm in size or five 
or more adenomas of any size, as being at high risk of having further advanced adenomas or 
cancer detected and recommend that they should undergo surveillance colonoscopy 12 
months following the baseline procedure (Atkins et al 2002; Cairns et al 2010). 
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The NHS Bowel Cancer Screening Programme has adopted the BSG guidelines on adenoma 
surveillance (opting for ongoing biennial FOB screening for the low-risk group rather than 5 
year surveillance colonoscopy). The surveillance programme operates within the auspices of 
the BCSP. All subsequent surveillance procedures are therefore subject to the same quality 
assurance standards of screening colonoscopy (see chapter 1.1) 
This study has two main objectives. Firstly, to describe the findings at 12 month surveillance 
colonoscopy in high risk individuals in the BCSP. Secondly, to identify baseline patient and 
clinical characteristics which may predict an individual’s risk of having advanced adenoma or 
cancer (collectively termed advanced colonic neoplasia; ACN) at surveillance. 
 
4.1.2- Method 
Study Population 
Demographic, colonoscopic and histological data on all individuals undergoing colonoscopy 
in the NHS BCSP were prospectively recorded in a national database. The outcome of 
colonoscopy in individuals found to have adenomas was recorded as either low risk, high risk 
or intermediate risk according to the criteria in the BSG guidelines on adenoma surveillance 
(Atkins et al 2002). We identified individuals who were assigned to the high risk group as a 
result of the baseline screening episode between August 2006 and April 2010. The indication 
for surveillance colonoscopy in this group was detection of 5 or more adenomas smaller than 
10mm or three or more adenomas of which at least one was 10mm or greater in size during 
colonoscopy in the screening episode. Individuals who did not go on to have surveillance 
colonoscopy or who did not fulfil the high risk BSG guideline criteria were excluded. 
All individuals underwent colonoscopy in the baseline screening episode as a result of a 
positive faecal occult blood test. Individuals may have had more than one colonoscopy or 
flexible sigmoidoscopy within a screening episode (if the bowel preparation quality was poor 
or further therapeutic procedures were required).  
 
Study procedures 
Demographic and lifestyle data (date of birth, gender, smoking status, alcohol consumption, 
height (metres), weight (kg), were collected from individuals prior to colonoscopy in the 
                      Detection and Management of Colorectal Neoplasia in the NHS Bowel Cancer Screening Programme 
148 
 
NHS Bowel Cancer Screening Programme. These data were recorded on the BCSP national 
database to which colonoscopy data were added at the time of the procedure. Histological 
data for any lesions detected at colonoscopy were also recorded on the database. Data were 
downloaded from the national database in August 2010 for cleaning and analysis. Where 
possible, missing data were obtained from the screening centre.  
Age was recorded on the date of the first colonoscopy in the screening episode rather than at 
entry to the screening programme. Smoking status was categorised as current smoker, ex-
smoker or never smoked. Alcohol use was categorised as either current use or not. Patient 
body mass index (BMI, kg/m
2
) was calculated from height and weight measurements 
Screening and surveillance colonoscopic findings and histopathological results were also 
obtained from the national database.  
Baseline screening colonoscopic findings were categorized as 3 or more small adenoma of 
which at least one was 10mm or greater in size, 5 or more small (<10mm) adenomas or 5 or 
more adenomas of which at least one was 10mm in size. The presence of one or more 
advanced adenomas, adenomas with a villous component or adenomas displaying high grade 
dysplasia was also recorded.  
Surveillance colonoscopic findings were categorised by the presence of one or more lesions 
displaying advanced colonic neoplasia (ACN). Details of the Dukes Stage and site of cancers 
detected at surveillance colonoscopy were checked with the local screening centre. 
In order to examine whether the colonoscopic quality of the screening colonoscopist affected 
the findings at 12 month surveillance, we included the adenoma detection rate (ADR) of the 
screening colonoscopist as a continuous variable in the univariable analysis. ADR was 
calculated based on all first screening colonoscopies performed by the colonoscopist between 
August 2006 and August 2009. Colonoscopists who had performed less than 50 procedures in 
this period were excluded from this part of the analysis because of the inaccuracy of ADR 
when fewer than 50 procedures have been performed. 
 
Statistical Analysis 
Data were analysed using SPSS (v10.0, Chicago, Illinois, USA). Continuous variables are 
presented as mean (standard deviation (sd)) if normally distributed or median (interquartile 
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range) if their distribution is skewed. Categorical variables are presented as number (%). 
Where two proportions are compared, a two tailed test of two proportions was used. 
Age, BMI, interval to surveillance (days) and ADR of screening colonoscopist were analysed 
as continuous variables. Univariable testing was undertaken with the χ2 test for categorical 
variables and the unpaired T test for normally distributed continuous data. All tests were 2 
tailed and a p value of <0.05 was considered significant. 
Multivariable binary logistic regression modelling was undertaken to examine the 
relationship between baseline colonoscopic findings and presence of advanced neoplasia at 
surveillance colonoscopy. In order to avoid excluding factors with marginal effect, variables 
were included in the model if a p value of <0.1 was present in univariable analysis. Odds 
ratios with 95% confidence intervals were calculated for significant variables in the model. 
 
4.1.3- Results 
Participants 
1760 individuals underwent colonoscopy in the screening episode following a positive FOB 
test and subsequently had surveillance colonoscopy around 12 months later.  
1340/1760 (76.1%) individuals undergoing 12 month surveillance were male compared to 
61.6% of individuals undergoing colonoscopy in the screening programme as a whole 
(p<0.001). This suggests males are more likely to fall into the high risk group at baseline. The 
mean age at baseline colonoscopy of individuals subsequently undergoing 12 month 
surveillance was 65.8 years (sd  3.5).This is similar to the mean age of all patients undergoing 
colonoscopy in the progamme (65.8 years (sd 3.74), p=0.526). 
The mean interval between first colonoscopy in the screening episode and surveillance 
colonoscopy was 387 days (sd 89 days). 1637/1760 (93.0%) of surveillance procedures were 
completed within 3 months of the ‘due date’ (365 days after the baseline screening 
colonoscopy). 1294/1760 (73.5%) patients had more than one procedure during the screening 
episode due to the need for endoscopic therapy or poor bowel preparation necessitating a 
further procedure. 
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Surveillance colonoscopy 
The yield of surveillance colonoscopy at 12 months for cancer was 0.8% (14/1760, 
equivalent to 7.5 cancers per 1000 person years of observation, PYO), the yield for advanced 
adenomas was 6.1% (108/1760, 58.1 cases per 1000 PYO). The yield of advanced colonic 
neoplasia (ACN- a composite of the previous two outcomes) was 6.6% (116/1760, 62.4 ACN 
per 1000 PYO), 6 patients with both an advanced adenoma and cancer at surveillance were 
only counted once. 
866/1760 (49.2%) of individuals had no adenomas and 778/1760 (44.2%) had one or more 
non-advanced adenomas detected at 12 month surveillance. 62/1760 (3.5%) had 5 or more 
adenomas detected at 12 months. 
 
Baseline characteristics 
The demographic and lifestyle factors of those with and without ACN at surveillance are 
shown in table 33. No significant differences were seen between the two groups in age, 
gender, smoking status, alcohol use, BMI, number of screening procedures or interval from 
baseline to surveillance colonoscopy. 
Findings at baseline screening colonoscopy in the two groups were compared. These are 
shown in table 34.  
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Total 
n=1760 
No ACN at 
Surveillance 
n= 1644 
n (%) or mean 
(sd) 
≥1 ACN at 
surveillance 
n=116 
n (%) or mean 
(sd) 
Significance (p 
value) 
Age (years)     
mean (sd) 65.8 (3.5) 65.8 (3.5) 65.9 (3.4) 0.917 
Gender      
Male (%) 1340 (76.1) 1251 (93.4) 393 (93.6) 1.000 
Smoking* (n,%)     
Non smoker 743 (42.2) 697 (93.8) 46 (6.2) 
0.660 Ex-smoker 701 (39.8) 655 (93.4) 46 (6.6) 
Current 311 (17.7) 287 (92.3) 24 (7.7) 
BMI (m/kg
2
)
#
     
mean (sd) 28.0 (5.9) 28.0 (5.9) 28.6 (6.6) 0.353 
Alcohol use
~ 
(n,%)     
No 422 (24.0) 391 (92.7) 31 (7.3) 0.501 
Current 1327 (75.4) 1242 (93.6) 85 (6.4)  
Number of 
procedures in 
screening episode 
 
   
1 1294 (73.5) 1215 (93.9) 79 (6.1) 
0.191 
>1 466 (26.5) 429 (92.1) 37 (7.9) 
Interval between 
last screening and 
first surveillance 
procedure (days) 
 
   
Mean (sd) 384.9 (86.7) 385.4 (85.8) 389.5 (93.4) 0.650 
Table 33- Patient and colonoscopist characteristics in those with no ACN compared to those with one or 
more ACN at 12 month surveillance colonoscopy. 
* Smoking status unknown in 5 patients 
# 
BMI unknown in 218 patients 
~
 Alcohol use unknown in 11 patients 
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Total 
n=1760 
No ACN at 
Surveillance 
n= 1644 
n (%) or mean (sd) 
≥1 ACN at 
surveillance 
n=116 
n (%) or mean (sd) 
 
Significance 
(p value) 
Adenomas detected 
at screening 
colonoscopy 
    
≥3 adenomas, ≥1 
larger than 10mm 
997 (56.6) 938 (94.1) 59 (5.9) 
0.412 
≥5 adenomas (all 
<10mm) 
144 (8.1) 134 (93.1) 10 (6.9) 
≥5 adenomas, ≥1 
larger than 10mm 
619 (35.2) 572 (92.4) 47 (7.6) 
Presence of 
advanced adenoma 
    
None 228 (13.0) 212 (93.0) 16 (7.0) 
0.775 
≥1 1532 (87.0) 1432 (93.5) 100 (6.5) 
Presence of Villous 
adenoma 
    
None 1634 (92.8) 1533 (93.8) 101 (6.2) 
0.023 
≥1 126 (7.2) 111 (88.1) 15 (11.9) 
Presence of large 
adenoma (≥10mm) 
    
None 144 (8.2) 134 (93.1) 10 (6.9) 
0.860 
≥1 1616 (91.8) 1510 (93.4) 106 (6.6) 
Presence of very 
large adenoma 
(≥40mm) 
    
None 1604 (91.1) 1499 (93.5) 105 (6.5) 
0.160 
≥1 107 (6.1) 96 (89.7) 11 (10.3) 
Presence of high 
grade dysplasia 
    
None 1286 (73.1) 1196 (93.0) 90 (7.0) 
0.280 
≥1 474 (26.9) 448 (94.5) 26 (5.5) 
Presence of multiple 
adenomas (≥10) 
    
<10 adenomas 1666 (94.7) 1558 (93.5) 108 (6.5) 
0.395 
≥10 adenomas 86 (5.3) 86 (91.5) 8 (8.5) 
Presence of right 
sided adenoma 
    
None 606 (34.4) 579 (95.5) 27 (4.5) 
0.008 
≥1 1154 (65.6) 1065 (92.3)  89 (7.7) 
Adenoma 
Detection rate of 
screening 
colonoscopist 
    
ADR 48.3 (6.1) 48.0 (6.1) 47.1 (6.6) 0.126 
Table 34- Baseline screening colonoscopy findings in those with and without ACN at 12 month 
surveillance colonoscopy. 
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There appeared to be a trend between the indication for surveillance colonoscopy according 
to the BSG adenoma surveillance criteria and yield of ACN at 12 months. 59/997 (5.9%) 
individuals with 5 or more small (<10mm) adenomas at baseline had ACN at surveillance 
compared to 10/144 (6.9%) individuals with 3 or 4 adenomas of which one ≥ 10mm in size. 
47/619 (7.6%) individuals with both 5 or more adenomas and one or more ≥ 10mm in size 
had ACN at surveillance. This relationship was not significant (p=0.412). 
The following baseline factors were not associated with the presence of ACN at surveillance 
colonoscopy: ≥1 advanced adenomas (p=0.775), ≥ 1 large (≥ 10mm) adenomas (p=0.860), 
high grade dysplasia (p=0.280), ≥ 1 very large (≥ 40mm) adenoma (p=0.160), multiple (≥ 10) 
adenomas (p=0.395). 
The presence of one or more villous adenomas at baseline colonoscopy was associated with 
increased incidence of ACN at surveillance (101/1634 (6.2%) vs. 15/126 (11.9%), p=0.023). 
Also, the presence of one or more right sided adenomas at baseline was associated with ACN 
incidence at surveillance (27/606 (4.5) vs. 89/1154 (7.7%), p=0.008). 
In multivariable analysis, the odds ratio for ACN detection at surveillance if ≥1 villous 
lesions were present at baseline was 1.98 (95% CI 1.11-3.53, p=0.020) and 1.76 (1.13-2.74, 
p=0.012) if ≥1 right sided adenoma were present. 
There was no difference in mean adenoma detection rate per colonoscopist (for the screening 
colonoscopy) between those with and without ACN at surveillance (48.0% vs. 47.1%, 
p=0.126), indicating that within the BCSP, the technical quality of the index screening 
procedure was not a significant factor in the yield of ACN at surveillance colonoscopy. 
 
Cancers detected at surveillance 
Fourteen cancers were detected at surveillance colonoscopy. No synchronous cancers were 
detected. The site and Dukes stage of the cancers are shown in table 35. 6/14 (42.9%) of 
cancers were located in the right colon (proximal to the splenic flexure). 9/14 (64.3%) of the 
cancers were Dukes stage A at diagnosis. There was no association between site and 
increasing stage at diagnosis. One or more adenomas had been removed from the same 
segment of colon in which the cancer was subsequently detected in 9/14 (64.3%) cases. The 
largest adenoma in this segment was 10mm or greater in 5/8 (62.5%) cases. The size of the 
largest lesion at index colonoscopy was not known in one case.  
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 Site 
Dukes 
stage 
Number of polyps 
removed from the 
same segment at 
baseline screening 
colonoscopy 
Size of largest 
polyp removed 
from this 
segment (mm) 
1 Rectum A 2 20 
2 Rectum A 0 - 
3 Sigmoid colon A 1 15 
4 Sigmoid colon A 4 25 
 
5 Sigmoid colon A 2 5 
6 Sigmoid colon A 1 Not known 
7 Sigmoid colon C1 1 10 
8 Sigmoid colon C2 0 - 
9 Transverse colon C2 2 4 
10 Ascending colon A 0 - 
11 Ascending colon A 2 10 
12 Ascending colon A 0 - 
13 Ascending colon B 1 2 
14 Ascending colon C1 0 - 
Table 35- Characteristics of surveillance detected cancers 
 
4.1.4- Discussion 
This study of patients at high risk of future neoplasia based on colonoscopy findings 
following positive FOB screening demonstrated a yield at 12 month surveillance colonoscopy 
of 0.8% for colorectal cancer and 6.1% for advanced adenomas. 
The rate of advanced colonic neoplasia of 6.6% justifies the need for 12 month surveillance 
interval in this high risk group of patients according to the current BSG guidelines for 
surveillance following adenoma detection. 
Comparison of the incidence of advanced colonic neoplasia at surveillance in the current 
study with other published series of colonoscopic surveillance is limited by the highly 
selected nature of this subject population. Noshirwani et al (2000) report the occurrence of 
advanced adenoma (including villous lesions) at surveillance (within 3 years of baseline 
colonoscopy) in 15.3% of average-risk individuals with 4 or more small (<10mm) adenomas 
at baseline and 21.3% of individuals with 3 adenomas of which one was 10mm or greater in 
size. Martinez et al (2001) report advanced adenoma incidence within 3 years of baseline 
colonoscopy in 12.3% of average-risk individuals with 3 or more adenomas and 16.6% of 
individuals with a large (≥10mm) adenoma. Although these studies are not directly 
comparable with our study, the incidence of ACN at 12 months is lower in our higher risk 
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(FOBt positive) population than the incidence of advanced adenomas in the average risk 
populations in the other two studies. It may be concluded that this is a consequence of higher 
quality baseline colonoscopy in our study. It is unlikely that the shorter surveillance interval 
in our study or difference in definition of advanced adenoma would account for the 
differences seen. This argument is countered by the rate of advanced adenomas at 
surveillance in our study being slightly in excess of miss rates of colonoscopy for lesions 1cm 
or greater in size determined by tandem colonoscopy studies (Rex et al 1997; van Rijn et al 
2006).
 
In
 
addition, two recent chemoprevention studies have shown cancer rates during one to 
two years of follow up of 0.3 to 0.4% following colonoscopy (Arber et al 2006; Robertson et 
al 2005). These rates are lower than the 0.8% rate of cancer at 12 months seen in our study.  
The study shows that patient characteristics including age, gender, smoking status, alcohol 
use and BMI are not associated with ACN incidence at 12 months. Within the high risk 
category, increasing number and size of adenomas and presence of high grade dysplasia at 
baseline screening colonoscopy are not associated with outcome at 12 months. The presence 
of one or more villous adenomas however, is associated with a nearly two fold increase in the 
risk of ACN detection at 12 months. Histological subtype (presence of villous architecture) is 
not a criterion for surveillance in the existing BSG guidelines on colonoscopic surveillance 
following adenoma detection. This is in part due to concerns regarding the subjective nature 
of pathological description of villousness for which there is considerable inter-observer 
variability (Constantini et al 2003). Other guidelines however, do include villousness as an 
indication for closer surveillance (Smith et al 2002; Bond et al 2000). 
The presence of one or more right-sided adenomas at baseline colonoscopy was associated 
with a 1.76 fold increase in the risk of ACN detection at 12 months compared to individuals 
with only left sided adenomas. A pooled analysis of seven studies of outcome at surveillance 
colonoscopy suggested a pooled risk ratio of 1.43 (95% CI 1.30-1.57) for adenoma 
recurrence when any proximal adenoma was present (de Jonge 2010). It has been argued that 
colonoscopy is less effective in the proximal colon and as a result may not reduce the 
incidence of or mortality from proximal colorectal cancer (Baxter et al 2009; Brenner et al 
2010). 
The association of the presence of a right sided lesion with subsequent ACN may be 
explained by the propensity for right sided lesions to be more difficult to detect and therefore 
more likely to be missed at baseline colonoscopy (Singh et al 2009; Nawa et al 2008).
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Alternatively, the association may be due, in part, to the differing biology of right sided 
compared to left sided colonic neoplasia (Arain et al 2010). This may account for more de 
novo lesions at surveillance colonoscopy. 
Future studies of the outcome of one and three year surveillance colonoscopy in the Bowel 
Cancer Screening Program should investigate further the predictive role of villous adenomas 
and right sided adenomas as markers of risk for future ACN which may necessitate an 
addition or amendment to the existing guidelines. 
This study has a number of other important conclusions. Firstly, patients who underwent 
repeated procedures during the screening episode did not have a different incidence of ACN 
at 12 months compared to those who had only one procedure in the screening episode. This 
suggests the need for repeated procedures during the screening episode does not confer any 
extra protection, due to repeated mucosal inspection, from ACN detection at 12 months. This 
may be explained by some of the initial procedures being suboptimal (due to poor bowel 
preparation or not reaching the caecum) necessitating a repeat procedure. In addition, 
mucosal inspection may not have been the primary objective of the repeat procedure, for 
instance if the objective of the repeat procedure was to remove a large polyp.  
Secondly, the quality of the screening colonoscopist, as assessed by their overall adenoma 
detection rate, did not appear to affect the incidence of ACN at 12 months. This may be 
because the colonoscopists involved in the study were of a consistently high standard (the 
mean ADR per colonoscopist was 48.3%) and all colonoscopists are required to meet 
predefined standards and complete a directly observed assessment prior to commencing 
practice in the BCSP. An alternative explanation is that colonoscopists with higher ADR are 
more likely to find multiple or large adenomas resulting in a higher proportion of their 
patients requiring surveillance colonoscopy. For this reason, the association between the 
quality of the screening colonoscopist and the incidence of interval pathology will be difficult 
to assess. The use of interval cancer rate, as in a recent Polish study which demonstrated an 
association between lower ADR and higher interval cancer rates, may be more informative 
(Kaminski et al 2010). 
Thirdly, cancers detected at 12 month surveillance colonoscopy had a favourable stage 
profile. 64.3% of these cancers were Dukes Stage A at diagnosis compared to 8.7% in the 
general population and around 45% in the Bowel Cancer Screening Programme (Ellul et al 
2010; National Cancer Intelligence Network 2009). The favourable prognosis of interval 
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cancers has been observed in the colorectal cancer screening previously (Hardcastle et al 
2006). Further research into the outcomes of patients with advanced adenomas at surveillance 
will identify if this group of patients are at ongoing high risk of developing neoplasia or if 
screening and early surveillance confer long-lasting protection. 
A higher proportion of surveillance-detected cancers were located in the right colon 
(proximal to and including the splenic flexure) compared to the general population (42.9% 
vs. 31%) (Toms 2004). The majority of surveillance detected cancers (79%) were located in 
either the ascending or sigmoid colon. This may be explained by the fact that theses areas of 
the bowel are more technically challenging to examine during withdrawal increasing the 
potential for missed lesions in these segments.  
It is hazardous to attempt to determine whether lesions detected at surveillance were missed 
during screening, a result of incompletely resected lesions or de novo lesions arising during 
the surveillance interval. In our study, 9/14 (64.3%) cancers detected at 12 months were 
located in a segment in which an adenoma had been removed previously. According to a 
protocol described in a study by Pabby et al (2005) of colorectal cancers arising during 
surveillance, these would have been classified as arising due to incomplete resection. 4/13 
(30.8%) of cancers in their study were classified in this group. Comparison with our study is 
limited by the higher baseline burden of adenomas in our study. This analysis can be 
extended to include site of the cancer, 3/6 (50%) patients with right sided cancers detected at 
surveillance had a polyp removed from the same segment in which cancer was subsequently 
found compared to 6/8 (75%) of patients with a left sided cancer. This raises the possibility 
that left sided cancers are more likely to have arisen from an incompletely resected lesion 
whereas right sided cancers are more likely to have been missed or new lesions. It is likely 
however, that at the majority of lesions detected at 12 months were present at the time of the 
baseline colonoscopy. There is an argument that the 12 month interval could be shortened to 
minimise the theoretical risk of advanced adenoma progressing to malignancy during the 12 
month interval. A randomised controlled trail of 3 month versus 12 month surveillance in this 
group of patients would be valuable. The current European Union guidelines on colorectal 
cancer screening recommend surveillance colonoscopy within 12 months for individuals with 
5 or more adenomas or an adenoma ≥20 mm to check for missed synchronous lesions 
(Segnan et al 2011). Our study supports the approach adopted by the European guidelines. 
Adoption of the European guidelines in the BCSP would result in numerically more 
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individuals meeting the high risk criteria. In a cohort of 31,088 individuals undergoing 
screening in the BCSP, 4331 (13.9%) met the European criteria for being high risk. In the 
same cohort, 2357 (7.5%) met the current high risk criteria. 
This study has a number of limitations. Firstly, the relatively low incidence of ACN at 12 
months limited the statistical analysis of predictive factors in the current sample size. It is 
possible that in a larger study, significant relationships between baseline characteristics and 
findings at 12 months may emerge.  
Secondly, because the study population was confined to 60 to 69 year old adults with positive 
faecal occult blood testing, the external validity of the study may be limited. It is likely 
however, that individuals with high adenoma burden at index colonoscopy in the non-
screening population have a similar risk of having further advanced adenomas in the future as 
the high risk screened population.  
In conclusion, this study demonstrates that patients with a high adenoma burden at baseline 
screening colonoscopy have a 6.6% risk of advanced adenoma or cancer being detected at 12 
month surveillance colonoscopy. This justifies the need for this surveillance interval in this 
high risk group of patients. The only baseline characteristics associated with increased risk of 
advanced colonic neoplasia being detected at 12 months were the presence of a right sided or 
villous adenoma. The favourable stage profile of cancers detected at 12 months is reassuring.
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Chapter 4.2- Management of Large Sessile or Flat Colonic Polyps in the NHS 
Bowel Cancer Screening Programme 
 
4.2.1- Introduction 
The management of large sessile or flat colonic polyps (LSCP) is of clinical importance due 
to the potential of such lesions to harbour malignancy and their propensity to recur or 
progress to cancer if incompletely removed (Saito et al 2001). In addition, the management of 
LSCPs is associated with an increased risk of major complications to the patient (Heldwein 
2005). 
Such lesions, defined here as sessile or flat lesions (Paris classification 1s, 0-IIa, 0-IIb, figure 
20) of 20mm or greater in size, may be managed endoscopically or surgically. Traditionally, 
surgery has been the mainstay for management of LSCPs (Voloyiannis et al 2008; Onken et 
al 2002), however endoscopic techniques have progressed to allow the removal of such 
polyps. Recent endoscopic techniques such as endoscopic mucosal resection (EMR) and 
endoscopic submucosal dissection (ESD) have facilitated this progress (Swan et al 2009). 
No consensus or formal guidelines exist for the choice of therapeutic modality (Metz et al 
2011). In experienced hands both approaches seem to be acceptable (Church 2003). 
Endoscopic management is associated with cost savings when compared to surgical 
management (Swan et al 2009),
 
however, endoscopic management by non experts may be 
associated with worse outcomes (Brooker et al 2002).  
The advent of laparoscopic colorectal surgery has made surgical management of large polyps 
less invasive and potentially safer than open surgery. The management of large or complex 
rectal lesions has been advanced by the development of Trans-anal Endoscopic Micro-
Surgery (TEMS) which allows the removal of rectal lesions without a skin incision 
(Middleton et al 2005).
 
However, surgery for colonic polyps remains associated with 
significant morbidity and mortality (Young-Fadouk et al 2000).  
The advent of the English NHS Bowel Cancer Screening Programme (BCSP) in 2006 has led 
to an increased awareness of issues surrounding management of LSCPs through increased 
communication between screening endoscopists and the need for quality assurance of all 
steps of the screening pathway. 
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The aim of this study was to determine the incidence of such lesions in the BCSP and 
describe their current management and clinical outcome.  
 
Figure 20- Paris workshop guidelines for the morphological classification of colorectal lesions (Paris 
Workshop Participants 2002) 
 
4.2.2- Methods 
Study Population 
All colonoscopies and flexible sigmoidoscopies performed in the NHS Bowel Cancer 
Screening programme (BCSP) between August 2006 and April 2009 were analysed. Data 
were collected between May and September 2010, thus allowing a minimum 12 month follow 
up period. 
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Study Procedures 
Demographic, colonoscopic and histological data on all patients undergoing colonoscopy in 
the NHS Bowel Cancer Screening Programme are prospectively collected for quality 
assurance purposes. These data are stored in the Bowel Cancer Screening System (BCSS), a 
centrally maintained national database. Details of each polyp removed during colonoscopy in 
the BCSP is recorded in the BCSS, these data include the size, morphology, site and 
histological characteristics of the polyp. These data are recorded at the time of the procedure 
by a trained specialist screening nurse present in the endoscopy room and based on the 
colonoscopist’s assessment of the lesion. Histological data are subsequently uploaded to the 
database. Both the endoscopist`s assessment and the pathological assessment of the size of 
the lesion are recorded in the database. 
The BCSS database was interrogated to identify polyps 20 mm or greater in size with flat or 
sessile morphology. Lesions were included if either the endoscopic or histological 
measurement of size was 20 mm or greater. 20mm was felt to be a clinically relevant cut-off   
as the management of lesions smaller than this is almost always endoscopic and the risk of 
malignancy or complications is smaller (Heldwein 2005). Pedunculated lesions were not 
considered in this study as their management differs to that of flat or sessile lesions. Our 
study focused on lesions which were initially clinically or histologically assessed as benign: 
lesions which were considered initially to be malignant were excluded as the management of 
malignant polyps is subject to other variables such as depth of invasion and risk of loco-
regional spread. Likewise, patients were excluded if they had synchronous cancer, on the 
basis that the cancer rather than the LSCP would determine patient management. Where a 
patient had more than one LSCP, only the largest polyp or the polyp that determined clinical 
management was included in the study. 
Detailed data on the management and follow up of patients with LSCP identified were 
obtained from the BCSS database and from the local screening centre where locally held 
medical records were reviewed to provide this information. Data were collected on the site 
and dysplastic grade of lesions, initial management modality (endoscopic or surgical) and 
subsequent management of the polyp. For surgically managed polyps, the indication for 
surgery, type of operation (including whether the operation was open or laparoscopic), length 
of stay for the operation and any surgical complications were recorded. For endoscopically 
managed polyps, details of the first therapeutic procedure, the total number of endoscopic 
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procedures up to the first surveillance procedure and any endoscopic complications were 
recorded. The majority of lesions managed endoscopically were managed with endoscopic 
mucosal resection (EMR). This technique involves submucosal injection of a saline or colloid 
solution under the lesion to facilitate safe snare resection of the lesion either in on piece (en 
bloc) or by a series of snare resections (piecemeal) (method described in Swan et al 2009). 
Diathermy is employed to remove the polyps, the submucosal cushion is thought to provide a 
barrier to minimise thermal and mechanical trauma to the colonic wall. The term ‘EMR’ 
encompasses a spectrum of endoscopic techniques based on the principle outlined above. We 
have used the term ‘endoscopic’ management to encompass variations in the approach to 
EMR and other methods of polypectomy. 
Within this study, the choice of initial management modality for each polyp was made by the 
clinician responsible for the patient, therefore variations in clinical practice occurred. For 
example, in some cases, lesions were removed when first discovered, whereas some 
endoscopists deferred formal endoscopic resection, taking biopsies from the lesion to provide 
pre-therapeutic histology. For the purpose of this study we have reported the initial histology 
as either the pre-therapeutic histology from biopsies or, where biopsies were not taken, the 
initial resection specimen.  
Approval of this study as service evaluation was obtained from a Regional Ethics Committee. 
Individual patient consent for inclusion in the study and formal ethical approval were 
therefore not sought. 
 
Data Analysis 
Analysis was based on the first therapeutic modality employed for the management of each 
lesion (endoscopic or surgical). Age and gender of patient and site, size and histological 
nature of the lesions in each of these groups were compared.  
The following outcomes were examined for all lesions: 
1. The presence of malignancy in the endoscopic or surgical resection specimen  
The definition of malignancy included adenocarcinoma and polyp cancers (lesions 
with malignant invasion through the submucosa but not beyond the muscularis 
mucosae). 
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2. Incidence of complications (endoscopic or surgical) 
 
In the endoscopically managed group, the following outcomes were also analysed: 
1. Need for surgery 
a. Due to detection of malignancy in the endoscopic resection specimen 
b. Because the lesion was no longer amenable to endoscopic management 
2. Presence of residual or recurrent polyp (RRP) at 12 months  
RRP was defined as endoscopically visible or microscopic evidence of polyp at the 
site of the index LSCP.  
 
Patient factors (age, gender), LSCP characteristics (site, size and histological type) and 
endoscopic technique (en bloc or piecemeal resection) were assessed as potential factors for 
predicting the presence of malignancy, incidence of RRP at 12 months and subsequent need 
for surgery. Differences in management practice between individual screening centres were 
also explored. 
 
Statistical Methods 
Continuous variables are presented as mean (standard deviation (sd)). Categorical variables 
are presented as number (%). Where two proportions are compared, a two tailed test of two 
proportions was used. Categorical variables were compared with the χ2 test. Parametric 
continuous variables were compared with the unpaired T test. Relative risks (RR, 95% 
confidence interval) were calculated for categorical variables and the appropriate outcome 
variable to demonstrate the strength of the association. All tests were 2 tailed and a p value of 
<0.05 was considered significant. Data were analysed using SPSS (v10.0, Chicago, Illinois, 
USA) and Stata (version 10, Statacorp, Texas USA).  
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4.2.3- Results 
Patient and polyp characteristics 
In the study period, 26,552 individuals underwent colonoscopy following a positive FOBt in 
the NHS BCSP, during which 40,704 polyps were detected. 868 lesions were identified in the 
BCSS national database as being 20mm or larger in size and flat or sessile in morphology.  
Further data were obtained from the local screening centre for 807 (93.0%) of these lesions. 
Eighty two of the lesions were not 20mm or greater in size or flat or sessile according to 
locally held data at the screening centre, therefore these lesions were excluded. Thirteen  
lesion were identified as duplicate entries. 121/712 (17.0%) were assessed to be malignant on 
initial clinical or histological assessment and these were also excluded. 591/26552 (2.2%) 
individuals were therefore confirmed to have at least one LCSP.  Thirty three patients were 
excluded due to the presence of a synchronous cancer. One 69 year old male patient was 
found to have a 3 cm sessile lesion in the caecum, pre-therapeutic histology showed a 
tubulovillous adenoma with high grade dysplasia. He declined surgery or further 
colonoscopy. This case was excluded from further analysis. 557/26552 (2.1%) lesions were 
therefore included in the main analyses. 
These lesions were analysed according to the first therapeutic modality employed in their 
management. The characteristics of the patients and the lesions in each group are shown in 
table 36. The groups were similar in terms of age and gender distribution. 
Lesions managed surgically were larger than those managed endoscopically (mean size 
37.9mm vs. 29.5mm, p<0.001). Right sided lesions were defined as those proximal to the 
splenic flexure. Left sided lesions were those at the splenic flexure or distal. 57/174 (32.8%) 
lesions in the right colon were managed surgically compared to 64/383 (16.7%) of those in 
the left colon (p<0.001). 
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 Total 
Endoscopic 
management 
Surgical 
management 
 
Number n, (%) 557 436 (78.3%) 121 (21.7%)  
Mean age years, (sd) 66.4 (3.62) 66.4 (3.62) 66.7 (3.60) P=0.296 
Male n, (%) 384 (68.9%) 299 (68.6%) 85 (70.2%) P=0.408 
Mean size mm, (sd) 31.3 (13.9) 29.5 (11.3) 37.9 (19.4) p<0.001 
Location n, (%)  
Right sided 174 (31.2%) 117 (67.2%) 57 (32.8%) 
p<0.001 
Left sided 383 (68.8%) 319 (83.3%) 64 (16.7%) 
Histology n, (%)  
Tubular adenoma 138 (24.7%) 112 (25.7%) 26 (21.5%) 
p=0.305 
Tubulovillous adenoma 319 (57.3%) 245 (56.1%) 74 (61.1%) 
Villous adenoma 53 (9.5%) 40 (9.1%) 13 (10.7%) 
Serrated polyp 9 (1.6%) 6 (1.4%) 3 (2.5%) 
Metaplastic 15 (2.7%) 15 (3.4%) 0 
Inflammatory 1 (0.2%) 1 (0.2%) 0 
Unknown 22 (3.9%) 17 (3.9%) 5 (4.1%) 
Dysplastic grade n, (%)  
Non-dysplastic 16 (2.9%) 16 (3.7%) 0 
p=0.483 
Low grade dysplasia 360 (64.6%) 283 (64.9%) 77 (63.4%) 
High grade dysplasia 164 (29.4%) 123 (28.2%) 41 (33.8%) 
Not known 17 (3.1%) 14 (3.2%) 3 (2.5%) 
Table 36- Characteristics of patients and lesions classified by initial therapeutic modality 
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Outcomes in endoscopically managed LSCP 
436/557 (78.3%) LSCP were managed endoscopically in the first instance. Outcomes in this 
group are shown in table 37. 
 
Outcome Number , % (n=436) 
Successful resection (no 
recurrence at 3-12 months) 
340 (78.0%) 
Residual or recurrent polyp 
at 12 months 
26 (6.0%) 
Surgery for histologically 
confirmed cancer in LCSP 
19 (4.4%) 
Surgery for failed endoscopic 
therapy in LSCP assessed as 
benign 
51 (11.7%) 
Table 37- Outcome following endoscopic management of LSCP 
  
29/436 (6.7%) LSCP initially managed endoscopically were subsequently found to contain 
malignancy. This was detected in the endoscopic resection specimen in 21 cases and in the 
surgical resection specimen in 8 cases. In 19 of 21 (90.5%) cancers detected in the 
endoscopic resection specimen, subsequent surgery was performed. The remaining two cases 
were managed conservatively as endoscopic excision was complete histologically. 
Recurrent or residual polyp (RRP) was detected in 71/436 (16.3%) patients at 3 month 
surveillance and 26/436 (6.0%) patients at 12 months. 18/26 patients underwent both 3 month 
and 12 month surveillance. RRP was present in 5/18 (27.8%) patients at 12 months where no 
RRP had been detected at 3 months 
70/436 (16.1%) lesions initially managed endoscopically subsequently required surgery (table 
36). The indication for surgery was the presence of malignancy in the endoscopic resection 
specimen in 19/70. In the remaining 51 cases, the lesion was not amenable to further 
endoscopic management, necessitating surgery to completely excise the lesion. Within this 
group, the stated reasons were: Technical limitations to endoscopic management (such as 
involvement of the ileo-caecal valve, size, difficult access or previous attempts at resection) 
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in 38/51 and recurrence or residual polyp which was not manageable endoscopically in 7/51. 
The reason was not given in 6/51 cases. 
In univariable analyses, none of the following variables were associated with incidence of 
RRP at 12 months, subsequent need for surgery or presence of malignancy in the resection 
specimen: age and gender of the patient, histological type or grade of the LSCP, site of the 
LSCP or technique of removal (piecemeal or en-bloc). Only increasing size was shown to be 
associated with these outcomes (table 38). Compared to lesions less than 30 mm in size, a 
lesion 30 to 39mm in size had a relative risk of being malignant of 3.2 (95% CI  1.4-7.4) and 
of 4.1 (2.3-7.3) for subsequently needing surgery. A lesion 40 mm or larger in size had a 
relative risk of being malignant compared to lesions less than 40mm  of 3.7 (1.7-8.2) and of 
2.7 (1.5-4.7) for subsequently requiring surgery (table 39) 
 
Outcome 
Number in which cancer subsequently 
detected, % 
Primary Surgical management of LSCP 25/121 (20.6%) 
Endoscopic resection of LSCP 21/436   (4.8%) 
Secondary surgical management of LSCP 
following initial endoscopic management 
8/51   (15.7%) 
Table 38- Cancer detection in resection specimens 
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Surgical Management 
Surgery was the initial therapeutic modality for 121/557 (21.7%) LSCPs.  All these lesions 
had been assessed, clinically or histologically, as benign. 55/121 (45.6%) were not amenable 
to endoscopic management for the following reasons: 4 (6.6%) involved the ileocaecal valve; 
9 (14.8%) abutted the dentate line; 42 (68.9%) were too large for endoscopic removal (the 
mean size of LCSP in this subgroup was 43.8mm). The indication for surgery was not 
recorded in 66 (54.5%) cases. Despite no pre-surgical evidence of malignancy, cancer was 
present in the surgical resection specimen of 25/121 (20.7%) lesions. There was a non-
significant positive trend between increasing size of lesions managed surgically and cancer in 
the resection specimen: 5/36 (13.9%) of lesions 20-29mm in size, 8/35 (22.9%) 30-39mm in 
size and 12/50 (24.0%) ≥40mm in size were malignant (p=0.484). 
 
Adverse events 
In the group of patients managed endoscopically initially, 18/436 (4.1%) patients required 
admission following the procedure: 13 due to bleeding (11 managed conservatively, 2 
required endoscopy, none required surgery), three were due to pain and two due to 
perforations. Of the two perforations, one was managed conservatively and one required 
surgery. No deaths as a result of endoscopic management of lesions were recorded.  
Size of 
LSCP 
Residual 
or 
recurrent 
polyp at 12 
months 
p 
Rate of 
malignancy 
in LSCP 
p 
Subsequent 
need for 
surgery 
p 
Mean 
number of 
endoscopi
c 
procedure
s 
p 
20-
29mm 
(n=232) 
12 (5.2%) 
0.686 
8 (3.4%) 
0.020 
18 (7.8%) 
<0.001 
1.84 
<0.001 
30-
39mm 
(n=113) 
7 (6.2%) 8 (7.1%) 27 (23.9%) 2.31 
≥ 40mm 
(n=91) 
7 (7.7%) 13 (14.3%) 25 (27.5%) 2.33 
 
 
 
Table 39- Association of size of LSCP with outcome of endoscopic management, presence of malignancy, 
need for surgery and number of endoscopic procedures 
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Screening centres were asked to report surgical complications and whether patients were 
alive 30 days following the surgical procedure in the surgically managed group. Data were 
returned for 108/121 (92.6%) of patients. 1/121 (0.83%) died 4 days following a surgical 
procedure due to myocardial infarction following a postoperative diverticular bleed. 12/121 
(9.9%) surgical complications in this group were reported: 2 anastamotic complications, 6 
wound infections, 1 post-surgical bleed, 3 postoperative ileus and one intra-abdominal sepsis 
were reported. 
Adverse events were more frequent in the surgically managed group compared to the 
endoscopic group (13/121 vs. 18/436, p=0.011). The difference in deaths in each group 
(1/121 vs. 0/436) was not significant (p=0.217) 
The mean length of stay in patients undergoing surgery was 7.0 days (range 1-27 days). 
 
Variation between screening centres 
Rates of surgery as the primary management for LSCP were analysed at 8 centres which had 
managed 20 or more LSCP (table 40). Only one centre had a primary surgical rate out-with 
the 80% confidence interval for the population. This may be explained by the centre also 
having a mean size of LSCP out-with the 95% confidence interval for the population.  
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Screening 
Centre 
Number 
of 
LSCP 
Mean size
#
 
Primary 
surgical 
management 
(n) 
Proportion 
managed 
surgically 
(%) 
Lower 80% 
CI for 
proportion 
managed 
surgically 
(%)
*
 
1 21 29.3 6 28.6 15.9 
2 74 30.4 8 10.8 6.2 
3 37 28.1 8 21.6 12.9 
4 27 34.1 2 7.4 0.9 
5 20 28.8 7 35.0 21.3 
6 24 28.0 5 20.8 10.2 
7 33 32.2 5 15.2 7.1 
8 28 38.6 10 35.7 24.1 
Table 40- Proportion of LSCP initially managed surgically at 8 screening centres with 20 or more LSCP 
 
 
4.2.4- Discussion 
This study demonstrates that endoscopic management of large sessile colonic polyps (LSCP) 
in the NHS Bowel Cancer Screening Programme is safe, effective and avoids the need for 
surgery in the majority of cases. This nationwide study is the largest series of LSCP 
management from Europe or the USA and demonstrates clinical outcomes that compare 
favourably with existing reports (table 40).  
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 BCSP 2011 Moss 2011 Ferrara 2010  Khashab 2009 Arebi 2007  
Number 436 479 182 136 161 
Mean size 29.5mm 35.6mm 24.7mm 32.8mm 32.5mm 
Need for 
surgery 
16.1% 16.3% 8.3% 0 4.3% 
Cancer in 
resection 
specimen 
6.7% 6.9% 7.3% 0.7% 5.5% 
12 month 
recurrence 
6.0% 20.4% 6.9% 17.6% 40% 
Adverse 
events 
4.1% 
admission 
3.0% bleed 
0.5% 
perforation 
7.7% admission 
2.9% bleeding 
1.3% perforation 
All admitted for 24-
72 hours 
12.4% bleeding 
2.2% PPS 
1.1% perforation 
4.5% bleeding 
0 perforation 
5.7% bleeding 
0 perforation 
Table 41- Comparison with other published series of large sessile colonic polyps 
 
Endoscopic management of LSCP in this study was associated with fewer adverse events 
than surgical management. The post-polypectomy bleeding rate of 3.0% is similar to other 
series which report rates of 2.9% - 5.7% (Swan et al 2009; Moss et al 2011; Ferrara et al 
2010; Khashab et al 2009; Arebi et al 2007). This is despite aspirin not being stopped 
routinely in keeping with current anticoagulation management guidelines (Veitch et al 2008). 
Site and size of the LSCP appears to be important in determining the initial therapeutic 
modality with larger and right sided lesions more likely to be managed surgically. This would 
suggest that the expertise of the endoscopist and their previous experience has an effect on 
the initial treatment decision. This is reflected in the centre to centre variation of the 
proportion of LSCPs managed surgically or endoscopically. Availability and extent of local 
expertise influence treatment decisions.  
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Rectal LSCPs were analysed as a subgroup to explore the variation in practice between 
centres in more detail. 205 rectal LSCPs were identified (mean size 33.0mm).  17 were 
managed with TEMS in the first instance (mean size 28.5mm, p=0.42 compared to mean size 
of all rectal LSCPs). Lesions managed by TEMS tended to be smaller than other rectal 
lesions managed with alternative surgical approaches (n=24, mean size 46.0 mm, p=0.02). 
Eleven lesions were managed by TEMS after an initial attempt at EMR, these tended to be 
larger lesions (mean size 39.7 mm, p=0.16 compared to other surgically managed rectal 
lesions). There was no clustering around particular centres in terms of proportion of rectal 
lesions managed by TEMS. Due to the limited data available it was not possible to fully 
evaluate what factors influence whether TEMS was used for rectal LSCPs. Local availability 
is likely to be an important factor. The distance of the LSCP from the anal verge was not 
recorded so this important variable could not be accounted for. 
 
Subsequent need for surgery following initial endoscopic therapy is associated with 
increasing size of the lesion. Polyps 40 mm or greater in size are associated with a 27% need 
for surgery following initial endoscopic management, 7.7% rate of residual or recurrent polyp 
at 12 months, and a 14% risk of the LSCP being malignant. The management of these lesions 
should be carefully considered and prompt referral for management at specialist centres may 
be appropriate.  
Recurrence or presence of residual polyp (RRP) at 12 months is a recognised outcome 
measure for LSCP, however, there is considerable heterogeneity in how this outcome is 
reported (Swan et al 2009; Moss et al 2011; Ferrara et al 2010; Khashab et al 2009; Arebi et 
al 2007). In the present study, RRP at 12 months occurred in 6.0% of endoscopically 
managed lesions. This is in keeping with other series of endoscopically managed large 
colonic polyps (table 40). Late recurrence of lesions (no RRP at 3 months but RRP detected 
at 12 months) occurred fairly frequently (5/18 (27.8%). This may be due to regrowth of 
adenoma from an endoscopically undetectable sub-surface dysplastic focus, from a small 
focus of endoscopically visible but undetected residual adenoma, or due to mis-identification 
of the original polypectomy site. Khashab et al (2009) report a considerably lower rate of late 
recurrence following routine biopsy of the polypectomy scar at 12 months.
14
 They studied 
136 large polyps (≥2cm) removed by EMR. 24 (17.6%) had macroscopic evidence of 
recurrence at follow up. 18 displayed recurrence at first follow up whilst 6 (4.4%) 
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demonstrated ‘late recurrence’ – the presence of recurrence despite initially normal 
surveillance. Negative biopsy of the polypectomy scar was associated with lower recurrence 
rates in long term follow up. 92 of 94 (97.9%) of normal appearing scars with negative scar 
biopsies remained free from recurrence at one year. 6 of 42 (85.7%, p=0.005) polyps with 
macroscopic or microscopic evidence of recurrence were successfully eradicated at long term 
follow up. In our study, it is not known if polypectomy scars were routinely biopsied in cases 
undergoing 3 month endoscopy review. We recommend that, following endoscopic resection 
of LSCP in the BCSP, surveillance of the polypectomy site is conducted both at  3 months 
and at 12 months in keeping with existing guidelines and that  the polypectomy site is 
routinely photographed (or videoed) and biopsied (Atkin et al 2002). Site identification 
should be assisted by placing an endoscopic tattoo at the time of the initial procedure. 
A recent multicentre Australian study of EMR for large sessile colonic polyps produced 
similar results to those seen in our study (table 40) (Moss et al 2011). In their study of 479 
LSCP (mean size 35.6mm), 464 lesions were managed with EMR. Risk factors for failure of 
endoscopic therapy were lesions in a difficult position for EMR, involvement of the 
ileocaecal valve, and a previous attempt by the referring endoscopist. A higher proportion of 
LSCP were managed surgically in the first instance in our study. This reflects the 
observational nature of our study which encompasses broad practice within a national 
screening programme. The Australian study was only of lesions referred to a specialist group 
of colonoscopists with an interest in advanced polypectomy, thus, no data on lesions not 
referred into the service are presented. Two notable comparisons can be made. First, the 
clinical outcomes in the endoscopically managed groups of the two studies are similar. The 
mean size of LSCP in our study was smaller  than in the Australian study (31.3mm vs. 
35.6mm, p<0.001), however, this suggests endoscopic resection of LSCP can be delivered by 
a large national Bowel Cancer Screening Programme at a standard comparable to 
international experience and small groups of experts. It is important to note that all screening 
colonoscopists within the BCSP have passed a detailed screening accreditation exam, 
comprising multiple choice exam, audit of previous 12 months’ practice and assessment of 
colonoscopy technique over 2 colonoscopies by 2 screening examiners. At the time of this 
study, polypectomy technique was not assessed as part of this process. Second, the bleeding 
rates in the two studies are similar. In Australia it has been routine practice to stop aspirin 
prior to polypectomy (Gastrointestinal Expert Group 2011).
 
This is not the case in England 
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where low dose aspirin is usually continued irrespective of therapy to minimise the risks 
associated with cessation of antiplatelet therapy (Veitch et al 2008). This is indirect evidence 
to support the continuation of low dose aspirin during polypectomy, even for large sessile 
lesions. 
A previous study by the same Australian group has suggested a potential cost saving of 
endoscopic therapy compared to surgical management of US$6990 per patient (Swan et al 
2009). Although we have not conducted health economic analysis of our data, it is likely that 
endoscopic management in the country is also associated with a significant cost saving over 
surgery. 
Our study has a number of limitations. Firstly, it was a retrospective observational study 
which introduces the possibility of selection bias. By obtaining data on all LSCP encountered 
in the BCSP from the national database we hoped to minimise this, however, the second 
phase of the data collection process, which involved further data collection from the 
screening centre may have been susceptible to selection bias. However, given the size and 
wide coverage of this study we do not think it would affect our conclusions.  
Second, we were not able to collect more detailed information on the endoscopic technique 
employed for resection of the LSCP. This included details of the endoscopic assessment 
(Paris classification, Kudo pit pattern, use of adjuncts to white light endoscopy such as 
narrow band imaging, ease of access to the polyp), and details of the polypectomy itself 
(EMR technique, type of injection solution used, diathermy settings, need for argon plasma 
coagulation). We have recommended that these data are routinely collected for all LSCP 
resections in the NHS Bowel Cancer Screening Programme for quality assurance and service 
development purposes. An additional consideration we have not been able to examine is the 
patient experience of the different therapeutic modalities. A study of patient acceptability and 
impact on quality of life of surgical vs. endoscopic management of LSCP would be desirable. 
In summary, endoscopic management of LSCPs is effective and provides advantages over 
surgical management in terms of safety and cost. 
There is now a substantial evidence base supporting endoscopic management of LSCP as the 
preferred choice of initial therapy. Endoscopic therapy should only be attempted by 
colonoscopists competent in advanced polypectomy techniques such as EMR and 
comfortable with the endoscopic management of complications. Each lesion should be 
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extremely carefully assessed for evidence of malignancy prior to attempted resection. This 
may necessitate the use of techniques such as narrow-band imaging, assessing lift 
characteristics and chromendoscopy.  Where there is a high suspicion that a lesion may be 
malignant, oncological principles should be followed and a surgical or endoscopic en-bloc 
resection technique should be used. 
 Certain features of an LCSP predict failure of endoscopic therapy, recurrence and need for 
surgery. These features include size greater than 30-40mm, right sided location, involvement 
of the ileocaecal valve, difficult endoscopic access and previous attempts at resection.  A low 
threshold should exist for early referral of lesions displaying such features to an expert 
endoscopist. Consideration should be given to the creation of a network of expert 
colonoscopists to optimise clinical outcomes in difficult cases. 
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5.0- Discussion 
 
5.1.0- Detection of Neoplasia in the NHS Bowel Cancer Screening Programme 
5.1.1- Use of adenoma detection rather than cancer detection as a measure of 
colonoscopic performance 
The aim of Chapter 1 was to examine measures of performance of colonoscopy in the NHS 
Bowel Cancer Screening Programme (BCSP), the main aim of colonoscopy being neoplasia 
detection.  
Neoplasia, as a term, describes any lesion arising due to ‘abnormal or uncontrolled growth of 
cells’. Neoplasia therefore, is an umbrella term that encompasses a range of lesions reflecting 
the adenoma carcinoma sequence (Vogelstein 1988), from small tubular adenomas displaying 
low grade dysplasia to Dukes stage D metastatic colorectal cancer. The clinical significance 
of lesions at the earlier end of this spectrum is less clearly defined than at the advanced end. 
The main aim of the BCSP is to detect lesions that are about to or have already become 
malignant but are pre-symptomatic and at a curable stage. Paradoxically, measuring the 
detection of this group of lesions is not ideal because cancers or advanced neoplastic lesions 
(adenomas ≥10mm in size or displaying high grade dysplasia) are detected relatively 
infrequently (at around 20 to 30% of BCSP colonoscopies) compared to all adenomas (one or 
more adenomas are detected in around 50% of procedures). When assessing the performance 
of individual colonoscopists, the relative infrequency of advanced lesions and in particular, 
cancer, means the confidence intervals around detection rates are wide, limiting the 
usefulness of measures such as cancer detection rate or advanced adenoma detection rate. 
Adenoma detection rate (ADR) tends to have narrower confidence intervals, implying that a 
single point estimate of an individual colonoscopist’s ADR is more reliable than a measure of 
a less frequently occurring lesion for a given number of procedures. 
Work described in Chapter 1.2 demonstrates a ‘ceiling effect’ for colonoscopy withdrawal 
time on adenoma detection rate. Due to the finite number of detectable adenomas in a colon, 
longer withdrawal time and adenoma detection do not have a positive linear association ad 
infinitum. Rather, there is a limit at which increasing withdrawal time is no longer associated 
with increasing adenoma detection. In the BCSP, no such relationship is demonstrated for 
advanced adenoma. Increasing withdrawal time is not associated with increasing detection of 
                      Detection and Management of Colorectal Neoplasia in the NHS Bowel Cancer Screening Programme 
177 
 
such lesions. This is likely to be because the ‘ceiling’ for detection of large lesions (over 90% 
of advanced adenomas are 10mm or greater in size) is below the mean withdrawal time for 
the majority of BCSP colonoscopists (the mean negative complete colonoscopy withdrawal 
time CWT (nc-CWT) was 9.4 minutes, the lowest mean nc-CWT was 5.4 minutes). 
An important function of a measure of colonoscopic performance is to differentiate ‘good’ 
from ‘bad’. It has been shown that ADR correlates with nc-CWT. High ADR and longer nc-
CWT are generally thought of as traits of a good colonoscopist (Milan 2008). Advanced 
adenoma detection rate does not correlate with caecal intubation rate (one can extrapolate that 
cancer detection rate would not correlate with ADR either) and is therefore not as useful as 
ADR in assessing the quality of colonoscopy in the BCSP setting. Advanced adenoma 
detection rate does not reflect the same range of performance as adenoma detection rate. 
A measure of colonoscopic performance should depend on technical factors pertaining to the 
detection of the lesion rather than the underlying prevalence of the lesion itself. Cancer 
incidence rates are known to vary from region to region in England (50 per 100,000 men in 
London compared to 65 per 100,000 men in the North-East, a 30% relative difference) 
(Cancer Research UK 2010). Data from the pilot study of the CRC screening in the UK 
showed a reduction in cancer detection rates in subsequent screening rounds, no such 
variation in adenoma detection rate was demonstrated in either the pilot or the current BCSP 
(Chapter 3.1.3). Epidemiological data on adenoma incidence in different regions of England 
is scarce. It is reasonable to state however, that cancer detection rate is more dependent on the 
underlying prevalence in the group undergoing colonoscopy than adenoma detection rate. 
 
5.1.2- Why are small colonic adenomas important? 
The clinical significance of small colonic adenomas has been questioned. As few as 1% of 
small adenomas may progress to cancer. This risk is higher for advanced adenomas (Brenner 
2007), which progress to malignancy at a rate of around 5% per year. The direct clinical 
benefit of removing a single small adenoma is therefore small. The importance of detecting 
and removing small lesions is justified by three main arguments:  
1. Firstly, detection of small adenomas is a marker of completeness of mucosal inspection 
which is the key objective of colonoscopy. Kaminski (2010) demonstrated that 
colonoscopists with lower adenoma detection rates were more likely to have missed a 
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cancer (which was subsequently diagnosed as an interval cancer) than colonoscopists 
with higher adenoma detection rates. This argument is countered by the risk of adverse 
events incurred by polypectomy. However, the majority of complications arise from 
polypectomy on advanced lesions. Removal of small lesions is generally safe (Heldwein 
2005).  
2. Secondly, studies which have demonstrated a reduction in CRC incidence (Winawer 
1993) and mortality (Mandel 1993; Hardcastle 1996; Kronborg 1996) have all relied on 
removal of all detected adenomas. Within the screening setting therefore, detection and 
removal of all adenomas is presently viewed as being mandatory. 
3. Thirdly, the presence of small adenomas is a marker of future risk of advanced neoplasia 
being detected in an individual. Many studies have quantified this risk (Martinez 2001 
(pooled analysis), Saini 2006 (meta-analysis)). An individual’s future risk of advanced 
neoplasia increases 2.5 fold if three or more small adenomas are detected (Saini 2006). 
Colonoscopic surveillance may be directed at these individuals. Conversely, if an 
individual has had a thorough colonoscopy and only found to have 0, 1 or 2 small 
adenomas, their future risk may be lower than that of the general population.  
4. It is not possible at present to detect which small adenomas will progress to become 
large adenomas or cancer. We assume therefore, that all small lesions have the same 
future risk of progression. 
Outside the screening setting, the context of the colonoscopy must be taken into account. 
Clearly, an elderly patient with multiple comorbidities is unlikely to benefit from the 
detection and removal of small colonic polyps in terms of assessing or reducing their CRC 
risk. However, even in this group, adenoma detection remains a marker of completeness of 
examination 
 
5.1.3- Efficacy of colonoscopy in the NHS Bowel Cancer Screening Programme 
In Chapter 1, adenoma detection rate and other colonoscopy performance indicators are 
shown for the BCSP. Whilst the emphasis of the chapter is on performance indicators, an 
important product of this work was an assessment of the efficacy of colonoscopy within the 
BCSP.  This work contributed to the quality assurance processes of the screening programme 
itself.  The initial work of selecting appropriate performance indicators and defining how they 
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should be calculated has formed the basis of how colonoscopy performance indicators are 
produced in the BCSP. 
The efficacy of colonoscopy in the BCSP compares favourably to performance described in 
other studies of large scale screening colonoscopy (Kaminski 2010) and to previous reports 
of colonoscopy practice in the UK (Bowles 2004; Weller 2006). However, as in previous 
reports of colonoscopic performance (Atkin 2004, Harewood 2005), a wide variation in 
measures such as ADR, withdrawal time and intubation rate was shown. 
The original hypothesis of this chapter was ‘adenoma detection rate is not correlated with 
other measures of colonoscopic performance in the BCSP.’ The data presented in Chapter 1 
refute the null hypothesis. ADR has been shown to correlate with withdrawal time, intubation 
rate, rectal retroversion rate and polyp retrieval rate. This reinforces the position of ADR as 
the key indicator of colonoscopy performance. However, data presented in Chapter 1 show 
that additional consideration must be made of the population in which ADR is calculated 
prior to comparing ADR. Variation in age and gender between populations may account for 
important differences in ADR, requiring standardisation to allow reliable comparisons to be 
made. 
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5.2.0- Management of Neoplasia in the NHS Bowel Cancer Screening 
Programme 
 
Chapter 2.1 explores outcomes at 12 month surveillance colonoscopy in patients with high 
risk adenomas at baseline screening colonoscopy. The headline finding was a yield at 
surveillance colonoscopy of 0.9% for colorectal cancer and 5.7% for one or more advanced 
adenomas. This is a notable finding as it justifies the role of early surveillance colonoscopy in 
this group of patients despite initial high quality screening colonoscopy. Patient factors, 
including age and gender were shown not to be associated with outcome at 12 months. 
Baseline polyp characteristics, including right sided location and presence of villous 
histology, were shown to be associated with the presence of advanced colonic neoplasia at 12 
months. These findings may help to refine surveillance criteria in the future. 
It is important to reflect on why so many lesions were detected at 12 months despite a high 
quality screening colonoscopy. It can be assumed that the majority of advanced lesions 
detected at 12 months must have been missed at baseline colonoscopy. Indeed, the rate of 
such lesions in this study was similar to previous reports of missed lesions 10mm or greater 
in size (Rex 1997; van Rijn 2007). However, this polyp rich population may also be 
susceptible to accumulation of new adenomas and it is difficult to quantify the contribution of 
recurrent lesions at sites of incomplete resection. 
In chapter 2.2 the management of large sessile colonic polyps (LSCP) in the BCSP was 
investigated. This was the largest study of polypectomy practice performed in England. In 
order to gather enough detailed data about the management of each LSCP, additional data 
had to be gathered from local screening centres to supplement the data in the national 
database. This was a large project which required the assistance of many screening 
practitioners around the country. Due to the size of the study and the level of detail needed, 
the data collection period took longer than planned but provided a comprehensive dataset on 
the management of over 550 polyps. Due to the retrospective observational nature of the 
study and the diversity in management of the lesions, rationalising the data was challenging 
but the use of clearly defined outcome measures, derived from the existing literature, 
facilitated this. 
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Size and location of the LSCP were shown to be clear determinants of the initial treatment 
modality. Increasing size was also shown to be associated with failure of endoscopic therapy, 
subsequent need for surgery and presence of malignancy in the resection specimen. 
Endoscopic management was shown to be as safe and effective as other comparable 
published series. Endoscopy had a lower adverse event profile compared to surgery. There 
was a clear variation in the proportion of lesion managed surgically or endoscopically 
between screening centres that could not be accounted for by size of the lesions. It is likely 
that availability of local expertise is an important factor. 
This study has a number of important implications. Firstly, the high failure rates of 
endoscopic management seen in larger LSCP, particularly those over 40mm in size, suggests 
that management decisions in this group should be carefully considered and possibly referred 
to a clinician with experience in their management.  
Higher rates of delayed recurrence were seen in this study compared to rates suggested in the 
literature. This may, in part, be due to the retrospective nature of the study. It seems 
reasonable to suggest that colonoscopists should routinely biopsy polypectomy scars at three 
month check colonoscopy to minimise the risk of missing residual or recurrent adenoma. 
However, the data collected for this study does not answer the question of whether this would 
reduce the rate of endoscopic failure or need for surgery. 
 
 
5.3.0- Improving data quality in the BCSP database 
 
During the process of generating data for chapter 1 of this thesis and subsequently producing 
a report on colonoscopy quality indicators in the NHS Bowel Cancer Screening Programme, 
a number of data quality issues within the BCSP national database were raised. 
Dissemination of these issues within these screening programmes could help to improve the 
quality of future data collection and analysis.  Data quality is critical to the validity of any 
analysis. Specific areas of concern regard missing data, implausible data, duplicate data and 
digit preferences. The overall quality of the data however is of a reasonable standard and 
adequate to allow further statistical analysis. 
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The following recommendations to the BCSP Evaluation Group were made to improve the 
general quality of data in the BCSS national database: 
1. Flags incorporated into BCSS software to alert users that an unexpected value 
has been entered.   
Table 42 below demonstrates suggested limits for the expected range.  
If data entered is outside the expected range, a warning should appear stating ` The 
figure you have entered is outside the expected range for this field. Please check and 
re-enter`. Following re-entry of the item of data, no warning would appear. This 
would give those entering the data the opportunity to double check extreme values. A 
second method, which would be much simpler to quickly implement is to simply 
restrict the range of possible values that can be entered by using a ‘plausible range’ 
i.e. outside this range values are considered implausible.  
 
Data field Expected 
range 
Plausible 
range 
Colonoscopy 
withdrawal time  
5-20 minutes 0-120 minutes 
Midazolam dose 1-5mg 0-50mg 
Fentanyl dose 12-100 mcg 0-500 mcg 
Pethidine dose 12-100 mg 0-500 mg 
Buscopan dose 10-40 mg 0-100mg 
Height 1.5-2.0 m 1.0-2.5 m 
Weight 50-100kg 20-300 kg 
Number of cigarettes 
per day 
0-40 0-150 
Alcohol quantity per 
week 
0-40 units 0-400 
Table 42- Recommended ranges for specific datafields in the BCSS 
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2. Colonoscopists are given unique identifier codes. 
In the original BCSS database, individual colonoscopists could have more than one 
code if they performed colonoscopy at more than one site. This complicated data 
analysis and made calculation of colonoscopist level performance indicators prone to 
error. Assigning a unique identifier to each colonoscopist would avoid this.  
 
3. Entonox use 
This field should be a yes/no option rather than requiring a dose. This reflects the way 
this drug is administered. 
 
4. Standardisation of method for recording timing of colonoscopy  
It was apparent that there was terminal digit preference within the colonoscopy 
withdrawal time dataset. This was demonstrated by the clustering of values at 5, 10 
and 15 minutes. Informal discussions with screening practitioners revealed a number 
of different methods were used to record withdrawal time. As a result of these 
findings a recommendation was made to the BCSP evaluation group to recommend 
that screening practitioners should use a standardised method for recording 
withdrawal time. Recording should commence when colonoscopic evaluation of the 
caecal pole (as identified by anatomical landmarks) commences. Withdrawal time 
should not include time spent attempting to enter the ileocaecal valve. Recording 
should stop when the colonoscope is removed through the anus. Withdrawal time 
should be rounded to the nearest minute. 
 
5. Recording of adverse events  
Comparison of data on adverse events in the BCSS with data obtained from screening 
centres showed that adverse events were infrequently recorded on the BCSS. In 
addition, where an event was recorded, insufficient data to characterise the event or 
stratify it’s severity was present. In light of this, screening centres were reminded of 
the need to record all adverse events on the BCSS and it was recommended that a 
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minimum dataset for adverse events be introduced to allow stratification according to 
the BCSP adverse event stratification tool (Chilton 2010). 
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5.4.0- Can adenoma detection rate be improved upon as a measure of 
colonoscopic quality? 
 
An inherent limitation of ADR is that it does not account for multiple adenomas. 49% of all 
adenomas in the cohort of patients described in section 3.1 were present in addition to the 
index adenoma. Measures of total numbers of adenomas have not previously been widely 
used. The work in this thesis has contributed to the description and validation of two novel 
measures (mean adenomas per procedure (MAP) mean adenomas per positive procedure 
(MAP+)). Both these measures are now routinely reported by the BCSP. Because they are 
more aligned with the ethos of screening colonoscopy as previously described, it is envisaged 
that they will become more widely used by the screening community, and potentially in the 
non screening setting. These measures offer an added insight into colonoscopist performance. 
Figure 14 in chapter 1.1 demonstrated clusters of colonoscopists defined by their ADR and 
MAP. It can be inferred that there is a difference between the two groups of colonoscopists, 
both with good ADR but one with MAP around 1.8 and the other with higher MAP. The 
second group are able to detect not only adenomas in a lot of patients (high ADR) but also 
multiple adenomas in those patients (high MAP). Some colonoscopists are capable of 
attaining MAP values around 3.0 which must reflect attention to use of manoeuvres to 
maximise adenoma detection rate or other non-technical skills. This group of colonoscopists 
have become colloquially known as ‘superdetectors’. Further investigation into their 
colonoscopy performance based on known technical performance indicators and potentially 
their non-technical skills may be useful to identify attributes of best practice. 
These measures of total adenoma detection are not novel. Barclay et al (2006), in their 
important study which confirmed the correlation between ADR and withdrawal time used a 
measure of total adenoma detection. MAP and MAP+ however, are more difficult to measure, 
requiring greater detail of recording than ADR. This is particularly hard to achieve in routine 
colonoscopy practice (outside the screening programme) and illustrates one of the strengths 
of the BCSP in terms of the comprehensiveness of data captured for each colonoscopy. 
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5.5.0- How will the addition of Flexible Sigmoidoscopy impact upon measures 
of colonoscopy performance? 
 
The UK flexible sigmoidoscopy trial (Atkin et al 2010) randomised 170,432 individuals to an 
intervention group (flexible sigmoidoscopy at between 55 and 64 years of age) or a control 
group (which were simply observed). 40,764 individuals underwent flexible sigmoidoscopy. 
Colonoscopy was recommended if any of the following were found: an adenoma 1 cm or 
larger in size; three or more adenomas; tubulovillous or villous histology; severe dysplasia or 
malignant disease or 20 or more hyperplastic polyps above the distal rectum. 5% of 
individuals met one or more of these criteria at sigmoidoscopy and were recommended 
colonoscopy. Median follow up extended to 11.2 years. Colorectal cancer incidence in the 
intervention group was reduced by 23% in intention to treat analysis (hazard ratio 0.77, 95% 
CI 0.70-0.84). Mortality was reduced by 31% (hazard ratio 0.69, 95% CI0.59-0.82). No 
reduction in mortality from proximal cancers was seen suggesting the protection against 
dying from colorectal cancer conferred by flexible sigmoidoscopy is confined to the distal 
colon. Three other trials of flexible sigmoidoscopy screening (Segnan N et al 2002; 
Weissfield J et al 2005; Hoff et al 2009) have reported initial results or are nearing 
completion; none have shown the same degree of benefit as the UK trial, probably due to 
variations in the study protocols. 
On the basis of the evidence from the flexible sigmoidoscopy trials and a re-appraisal of the 
clinical and economic impact of screening options (Whyte et al 2011), the addition of a once-
only flexible sigmoidoscopy between the ages of 55-59 years is to be added to the current 
NHS screening strategy. FOBt will continue from 60-74 years.  
This change in screening strategy will necessitate a range of performance indicators for 
screening colonoscopy to be defined. They will reflect those currently used for colonoscopy 
in terms of incorporating technical measures, safety measures and measures of acceptability. 
Some measure of depth of insertion will be required. This is less easy to define than caecal 
intubation rate as there is no definitive landmark, the use of technologies such as magnetic 
Scopeguide (Olympus, Japan) imaging systems may facilitate this (Painter et al 1999). 
In the longer term, flexible sigmoidoscopy prior to FOB testing is likely to change the 
positivity rate of FOB testing and potentially the yield of colonoscopy in those with a positive 
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FOB test. Minimum standards and targets for pathology based measure of colonoscopy 
performance such as ADR and MAP may have to be modified as a result. 
 
 
5.6.0- How will the advent of optical diagnosis impact on technical measures of 
colonoscopy? 
 
Current practice in colonoscopy necessitates the detection and removal of all adenomas. This 
practice creates a large workload for pathology services which are required to analyse each 
resected adenoma. In addition, each polypectomy exposes the patient to the small risk of a 
complication occurring.  
New technologies such as Narrow Band Imaging (NBI) allow more detailed characterisation 
of colonic lesion than conventional white light endoscopy. NBI (Olympus, Japan) is an 
optical imaging modality which enhances mucosal detail and vascular structures by using a 
short wavelength, narrow-bandwidth blue light. It has been shown to be more effective than 
white light endoscopy in differentiating neoplastic from non neoplastic lesions (East 2007c, 
East 2008b; van de Broek 2008). 
The DISCARD study (Ignatovic et al 2010) was a prospective cohort study comparing optical 
diagnosis with histology. The authors state that ‘the capability to correctly diagnose a polyp 
during colonoscopy (optical diagnosis) would allow recto-sigmoid hyperplastic polyps to be 
left in situ and small adenomas to be resected and discarded without a need for formal 
histopathology, possibly leading to substantial savings in time and cost, and reduction in 
patient risk’. The study demonstrated a sensitivity of 0·94 (95% CI 0·90–0·97) and specificity 
0·89 (0·78–0·95) for adenomas with an overall accuracy of 0·93 (95% CI 0·89–0·96) for 
polyp characterisation. The study was limited by being a single centre study performed by 
expert colonoscopists. A further study (DISCARD 2) is planned with the objective of 
assessing optical diagnosis in a multicentre trial.  
It is likely that in the future, optical diagnosis for lesions less than 10mm in size will become 
standard practice. Further evidence of the efficacy of optical diagnosis in the screening 
setting would be required. The concern would remain that high grade dysplasia or cancer 
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could be missed in a sub-centimetre lesion by discarding it rather than sending it for 
histology. Reassuringly, in a study of polyp cancers in the BCSP, only 103 of 34,959 polyps 
(0.29%) less than 10mm in size were polyp cancers (Lee et al 2010).  
Measures of colonoscopy performance which reflect lesion detection (such as ADR and 
MAP) depend on histological confirmation of the lesion to calculate the ‘numerator’. If 
optical diagnosis were to change, the method of calculating ADR would need to be adapted. 
One option would be to remove the need for histological confirmation of the lesion and 
calculate a polyp detection rate (PDR), whereby the numerator consists of all lesions 
detected, regardless of their nature. Using data from colonoscopists in the BCSP, ADR and 
PDR can be shown to have good positive correlation (r=0.83, p<0.001) as shown in figure 21. 
 
 
Figure 21- Correlation of PDR and ADR for colonoscopists in the BCSP 
 
Francis et al (2011) have suggested that PDR can be accurately converted to ADR using a 
conversion factor (adenoma:polyp detection rate quotient- APDRQ). For the BCSP 
population in Figure 21 the APDRQ would be 0.778. The limitation of PDR is that it can be 
inflated by colonoscopists who remove a lot of non-neoplastic polyps or even biopsy normal 
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tissue. This weakness could be attenuated by regular monitoring or audit of colonoscopists` 
practice. 
If optical diagnosis for lesions less than 10mm in size, measures of adenoma detection and 
total adenoma detection would need to rely on photographic or video confirmation of the 
lesion being an adenoma to remain accurate. Similar adjustments would need to be made 
immunohistochemical FOB testing (iFOBt) was introduced. 
 
 
5.7.0- Use of colonoscopy performance indicators as quality indicators 
 
The evolution of much of this thesis has been driven in part by the requirement for the data 
being generated to be used not just for research but also to inform quality assurance of 
colonoscopy in the BCSP. The data has been used to identify poor performance by using 80% 
confidence intervals around adenoma detection rates to identify outliers against a predefined 
target. The work in Chapter One also contributed towards the development of quality 
assurance guidelines for colonoscopy in the BCSP (Chilton 2011). This process is illustrated 
using a funnel plot (figure 22). 80% confidence intervals are used for quality assurance 
(rather than 95% confidence intervals) because the purpose of the confidence is to detect 
outlying performance rather than certainty about the measure. An 80% confidence limit 
means you can be 80% sure that the true underlying value of the measure is between the 
given limits. 80% confidence limits are used here because pro-active quality assurance should 
not require the same degree of certainty as for example a randomised controlled trial of two 
drugs.  The 95% confidence limits are stricter criteria and whilst indicating a greater level of 
certainty that the true value is below the target, it may mean that the true value has been 
below the target for some time.    
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Figure 22- Funnel plot of ADR against number of procedures showing 80% confidence intervals around a 
minimum standard of 35% 
 
Figure 22 shows an outlier with a low ADR. It was possible, using data generated for chapter 
1, to be satisfied that this value was not an outlier due to missing data or age or gender 
variations in the colonoscoped population. Further action was taken by the BCSP through 
quality assurance channels to investigate and act upon this potential underperformance. 
It became clear during the work for this thesis that whilst ADR was the most widely used and 
referenced performance indicator, quality assessment could not be confined to simply looking 
at adenoma detection. It is important to consider the safety of colonoscopy and the patient 
experience  of colonoscopy at the same time as measuring technical aspects and lesion 
detection. One cannot be optimised at the expense of another. Figure 15 demonstrates a 
model of the components of assessing colonoscopy quality. 
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At present, colonoscopy quality assurance in the BCSP is largely focussed on lesion 
detection. Adverse event incidence is scrutinised at a local level, however, the minimum 
collected dataset for adverse events in the national database has limited analysis of trends in 
adverse events at a national level. Patient experience is poorly considered by the current 
quality assurance structure. This is mainly due to the lack of a validated, widely accepted 
measure of patient comfort during colonoscopy. Prospective validation of a Nurse Assessed 
Colonoscopy Comfort Score (NAPComs) has been undertaken at two centres in the North-
east of England and a collaborating centre in Canada (Ross et al 2011) and results are 
awaited. Incorporation of this into quality assurance mechanisms of the BCSP may allow 
closer scrutiny of the patient experience. It should be considered that the patient experience 
of colonoscopy is not confined to comfort during the procedure itself. 
In economics, Goodhart’s Law states that “once a social or economic indicator or 
other surrogate measure is made a target for the purpose of conducting social or economic 
policy, then it will lose the information content that would qualify it to play such a role” 
(Goodhart 1975). This can be applied to colonoscopy performance indicators. For example, 
the data produced for chapter 1 contributed towards the BCSP Quality Assurance for 
Colonoscopy Guidelines (Chilton and Rutter 2011) defining the target for mean colonoscopy 
withdrawal time to be 10 minutes. This target will now affect the behaviour of colonoscopists 
and limit the use of withdrawal time to differentiate technical performance. 
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5.8.0- Specific recommendations to he Bowel Cancer Screening Programme 
 
The following is a list of specific recommendations to the Screening Programme which have 
arisen from the work included in this thesis. A number of the recommendations have been 
acknowledged by the programme and incorporated into guidelines or routine practice: 
1. Data quality measures: 
a. Flags incorporated into BCSS software to alert users that an unexpected value 
has been entered. 
b. Colonoscopists are given unique identifier codes 
c. Entonox use should be recorded as a yes/no option rather than requiring a 
dose.  
d. Standardisation of method for recording timing of colonoscopy 
e. The definitions for colonoscopy quality indicators described in Appendix A 
ashould be utilized for routine reporting of colonoscopic performance in the 
BCSP. 
2. Recording of adverse events- a standard classification system (Cotton 2010) should be 
employed. 
3. There is no need to adjust for age, gender or screening round when routinely reporting 
measures of adenoma detection 
4. Measures of total adenoma detection  (MAP and MAP+) should be routinely reported 
in addition to ADR. 
5. The proportion of procedures in which rectal retroversion is performed should not be 
used as a quality indicator of screening colonoscopy. 
6. The optimal mean nc-CWT per colonoscopist for screening colonoscopy is around 10 
minutes, this is now a quality target for colonoscopy in the BCSP. 
7. Outlying performance by individual colonoscopists, as identified by measures of 
colonoscopic technical performance identified in this study, was investigated by the 
BCSP Quality Assurance group and local leads. 
8. The following outcome measures should be  audited for management of large sessile 
colonic polyps (LSCP): 
a. The presence of malignancy in the endoscopic or surgical resection specimen  
b. Incidence of complications (endoscopic or surgical) 
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c. In the endoscopically managed group, the following outcomes were also 
analysed: 
i. Need for surgery 
1. Due to detection of malignancy in the endoscopic resection 
specimen 
2. Because the lesion was no longer amenable to endoscopic 
management 
ii. Presence of residual or recurrent polyp (RRP) at 12 months  
 
9. Following endoscopic resection of LSCP in the BCSP, surveillance of the 
polypectomy site is conducted both at  3 months and at 12 months in keeping with 
existing guidelines and that  the polypectomy site is routinely photographed (or 
videoed) and biopsied. 
 
10. Consideration should be given to the creation of a network of expert colonoscopists to 
optimise clinical outcomes in difficult cases. 
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5.9.0- Reflections 
 
I have discussed the strengths and weaknesses of this thesis in the discussion at the end of 
each chapter or subchapter. In this section I will reflect on a number of the general strengths 
and weaknesses of the thesis as a whole. 
 
5.98.1- Data Quality 
The Bowel Cancer Screening Programme commenced in 2006. Centralised data collection on 
all individuals passing through the programme was incorporated into the structure of the 
programme from the outset. The datasets were based on experience from the pilot studies and 
were not specifically designed to allow calculation of colonoscopy quality indicators. The 
user interface of the data collection system enforced very few mandatory fields and did not 
have any warning system if erroneous or unlikely values were entered.  
Data entry was the responsibility of the Screening Practitioners who also had responsibility 
for counselling patients prior to colonoscopy and being present at colonoscopy. For many 
screening practitioners, uploading data was not a priority. As a result, there were concerns 
about the quality of the data and how it could be used to generate colonoscopy quality 
indicators.  
My work with the national database to produce the data for chapter 1 of this thesis was the 
first time the national database had been used for researching colonoscopy quality. This was 
both positive and negative. The disadvantages were that the database was untried and 
untested. There were no processes for retrieving and processing the data. The quality of the 
data (in terms of completeness and accuracy) was not known. The quality indicators 
themselves (such as ADR and withdrawal time) had to be defined and the methods for 
converting raw data into meaningful figures or graphics which could be used both for 
research and as part of the quality assurance process needed describing. These problems were 
also advantages as working with the database for the first time allows a degree of freedom to 
tailor the definitions for the colonoscopy quality indicators and interpret the data in such a 
way that you know to be reliable and sound, as opposed to receiving data that has already 
been processed. 
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The data quality issue was addressed with a number of local audits comparing data from the 
national database with data held locally at a Screening Centre. These small audits showed 
satisfactory completeness and accuracy of the data. This perhaps, is a weakness of my work. 
The data verification and quality audits could have been larger and more rigorous and the 
findings were certainly limited by being confined to one screening centre. However, it was 
reassuring that the datafields necessary for calculating the key colonoscopy quality indicators 
were clearly well populated. The problems in the national database seemed to be with 
datafields where there was a degree of subjectivity (such as morphological shape of the lesion 
or therapeutic modality), or where there was a gap (either temporal or geographic) between 
the patient being screened and the relevant data being available for entry onto the database. 
An example of this is the cancer staging dataset, the use of which has been limited by poor 
data completeness. 
I was also reassured that the data coming out the national database were reliable and reflected 
‘real-life’ for four other reasons. Firstly, the initial work on the national database for Chapter 
2.1, looking at outcomes at 12 month surveillance colonoscopy very closely mirrored 
findings from a pilot study I had performed at a regional level in the North East of England. 
Secondly, when I started to produce colonoscopy quality indicators from the national 
database, the results were similar to (but different on the grounds of variations in definition) 
figures that were already being produced around the country using locally held data. Thirdly, 
it became apparent very quickly when there was problem with the database. For instance, 
when a particular screening centre was shown to have a very low mean adenoma detection 
rate, further investigation of the database revealed missing information for three 
colonoscopists, reflecting poor data entry at the screening centre. Finally, the positive 
response I got from the screening community about the quality indicators that were being 
produced reassured me that there were not any major gaps in the data or major 
methodological flaws. 
 
5.9.2- Data Collection 
Whilst the data collection for chapter 1 was relatively straight forward, gathering data on the 
management of large sessile colonic polyps (LSCP) for chapter 2.2 was a more protracted 
affair. Because the detailed data on management was not available from the central database, 
it was necessary to obtain data from local screening centres. This required staff at the 
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screening centres to manually trawl the patients records for the necessary data. As the study 
was approved by the Evaluation Group of the BCSP, the screening centres were mandated to 
partake in the study, however, some centres with large numbers of polyps to return data on 
struggled to do so in within the planned time period. This was not helped by limited resources 
at some screening centres exacerbated by the increased workload generated by the age 
extension to 74 occurring around the same time. Despite this, thanks to the efforts of many 
screening practitioners, data were received for 93% of polyps. With hindsight, reducing the 
amount and simplifying the format of the data requested from each centre may have 
improved compliance and timeliness. In an ideal world, I would have collected the data from 
each centre personally. This however, would have been costly and time consuming and 
introduced the logistical difficulties of accessing data in different Trusts. If a similar exercise 
were performed in the future, it would be important to keep the requested dataset to a 
minimum and ensure the questions asked were objective and unambiguous. Ideally, the need 
to perform such a retrospective data collection could be avoided by prospectively gathering a 
minimum dataset on particular events, such as LSCP or adverse events. 
 
5.9.3- Outcome Measures 
In Chapter 1, adenoma detection rate is correlated with other measures of colonoscopy 
performance to justify its use as a marker of colonoscopic quality. These however, are 
indirect markers of colonoscopic quality. A direct association between ADR and interval 
cancer rate or adverse event incidence would be harder evidence to support the use of ADR 
as a marker of colonoscopic quality. Kaminski (2010) has demonstrated an association 
between ADR and interval cancer rates in the setting of the Polish screening programme. 
Measuring interval cancer rate is complicated by the difficulties in tracking patients who may 
be diagnosed with cancer outside the screening programme. The use of cancer registry data 
can facilitate this. Research is planned to produce interval cancer rates in the BCSP and 
thence to examine the relationship with baseline colonoscopy quality indicators at a 
colonoscopist level. 
It was a planned component of this thesis to examine the relationship between ADR and 
adverse event incidence. I was unable to perform this analysis for two reasons. Firstly, 
adverse events are fortunately infrequent events. Most colonoscopists will have no or few 
adverse events attributed to them which limits statistical analysis with adverse events as the 
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dependent variable. Secondly, I was unable to produce adverse event data attributable to 
individual colonoscopists in the timeframe of this thesis. Whilst collecting data regarding the 
severity and circumstances of each adverse event was straight forward, it was not possible to 
identify the colonoscopist who performed the procedure at which the adverse event occurred, 
partly because the adverse event data was collected without a unique patient identifier in 
many cases and partly because screening centres were reluctant to provide an identifier of the 
colonoscopist. Further retrospective work to identify the colonoscopist associated with each 
adverse event would allow any association between ADR per colonoscopist and adverse 
event incidence to be examined. Alternatively, an identifier for the colonoscopist should be 
included in the minimum dataset collected for each adverse event. 
 
5.9.4- Retrospective design 
The type of analysis used in this thesis is retrospective and observational in nature. Such 
analysis is inherently at risk of bias due to residual confounding by imperfect measurement of 
confounders or by additional confounders not included in the analysis. To minimise the risk 
of bias, the work uses data prospectively collected for quality assurance purposes, which is 
generally of good quality, and most of the known or suspected confounding variables are 
adjusted for in the analyses. The gold-standard methodology for testing an hypothesis such as 
‘colonoscopy withdrawal time is not associated with adenoma detection rate,’ would be a 
prospective randomised controlled trial (RCT). Blinding in endoscopy trails is difficult for 
obvious reasons. Such trials would need to be large and expensive and would be difficult to 
justify ethically when the positive benefits of longer withdrawal is apparent for observational 
data. 
RCTs are designed to test the effect of a difference between two populations whilst 
prospectively adjusting for known confounding factors. Retrospective studies do not allow 
this luxury and therefore have a tendency to raise as many questions as they answer. 
An example of the difficulty of proving the benefit of endoscopic technique in terms of 
increased adenoma detection is demonstrated by a planned prospective randomised controlled 
trial of Buscopan use with normal saline in the placebo arm. A prospective study was 
estimated to cost a minimum of £250,000 to run. It is therefore much easier to perform a 
retrospective study, as we have done in chapter 1, to answer the question. 
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5.9.5- Non-technical endoscopy skills 
A confounding variable that I have been unable to account for when examining colonoscopic 
performance may be the non-technical skills of the colonoscopist. Currently, colonoscopy 
performance indicators reflect easily measurable, objective aspects of colonoscopic technique 
such as colonoscopy withdrawal time. Non technical skills of endoscopy have been recently 
described by Haycock (2010) and others and reflect the subjective aspects of colonoscopic 
performance. The skills fall into 5 main categories: Communication and teamwork, situation 
awareness, leadership, judgment and decision making. These factors are difficult to measure 
but may contribute to performance measures such adenoma detection. Other factors such as 
fatigue (Harewood 2008), concentration, visual recognition patterns and attitudinal beliefs 
may also contribute. Looking to the future, the ability to measure non-technical skills may 
allow their contribution to adenoma detection to be examined. 
 
598.6- External validity 
A major limitation of the work in this thesis is that the findings are strictly only relevant to 
the population in which the measurements were made, that is FOBt positive English adults 
aged 60 or over. The main reasons the external validity of these findings may be limited are 
firstly, that the population undergoing colonoscopy have a very high neoplastic burden. The 
adenoma detection rates observed in Chapter 1 of this thesis are amongst the highest rates 
reported in the international literature. Some of the conclusions of the thesis, such as 
recommending a mean withdrawal time of around 10 minutes or using measures of total 
adenoma detection, have limited relevance to colonoscopy in an average risk population or a 
symptomatic population such as in day to day practice in the NHS. Colonoscopy in 
symptomatic or average risk populations is associated with much lower adenoma detection 
rates. This limitation has proved an issue with trying to get the findings of the thesis 
published in US Journals. On two occasions the reviewers have noted that findings in an 
FOBt positive population may be of limited relevance to primary screening colonoscopy in 
the USA.  
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5.9.7- Future research 
The following studies would contribute to answering questions raised by the work in this 
thesis: 
1. Correlation of colonoscopy performance indicators with interval cancer rates in the NHS 
Bowel Cancer Screening Programme. 
2. Correlation of measures of adenoma detection (MAP and MAP+) with existing 
measures of colonoscopic performance (CIR, CWT, PRR). 
3. Does ADR improve if CWT increases- an observational study of BCSP colonoscopists? 
4. Is there a learning curve in BCSP colonoscopy? 
5. Randomised control trial of buscopan vs. placebo, outcome measures-ADR and MAP  
6. Randomised trial of endoscopic vs. surgical management of large sessile colonic polyps. 
7. A systematic review and metanalysis of the effect of time of day on adenoma detection 
at colonoscopy. 
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General Summary 
1. The NHS Bowel Screening Programme National Database contains quality data 
which can be used to calculate colonoscopy performance indicators. 
2. Adenoma detection rate per colonoscopist correlates positively with other measures of 
colonoscopy performance such as colonoscopy withdrawal time and caecal intubation 
rate. 
3. These measures of performance can also be used as quality indicators. The NHS 
Bowel Cancer Screening Programme offers high quality colonoscopy. 
4. Measures of total adenoma detection such as MAP (mean number of adenomas per 
procedure)   and MAP+ (mean number of adenomas per positive procedure) can 
enhance quality assurance of colonoscopy in the BCSP. 
5. The optimum mean withdrawal time per colonoscopist is around 10 minutes. 
6. Patient age, gender, smoking status, alcohol use, socioeconomic status and 
geographical location are associated with the risk of adenoma, right sided adenoma 
and advanced adenoma detection in multivariable analysis. 
7. In the same analysis, colonoscopy factors including withdrawal time, caecal 
intubation, bowel preparation quality, antispasmodic use, colonoscopist experience 
and time of day are associated with adenoma, right sided adenoma and advanced 
adenoma detection. 
8. Prolonging withdrawal time, using antispasmodics and optimising bowel preparation 
quality are easily modified factors that may improve adenoma detection rate but this 
would need prospective studies to prove. 
9. 12 month surveillance of patients with ‘high risk’ adenomas at baseline screening is 
associated with a yield of advanced adenomas or cancers that justify this surveillance 
interval. 
10. The presence of right sided or villous adenomas at baseline screening is associated 
with increased risk of advanced neoplasia at 12 month surveillance. Analyses of these 
factors in larger datasets and those undergoing 3 year surveillance may allow 
surveillance criteria to be refined. 
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11. Larger and right-sided large sessile or flat colonic polyps (LSCP) are more likely to 
be managed surgically in the first instance. Increasing size of the LSCP is associated 
with failure of endoscopic therapy, subsequent need for surgery and presence of 
cancer in the resection specimen. 
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Appendix A- Definitions of Colonoscopy Quality Indicators 
 
The following variables are commonly used indicators of colonoscopic quality. They were 
assessed (where appropriate) at the following levels: 
 Screening centre 
 Endoscopy Unit 
 Individual colonoscopist.  
Data were predominately gathered by analysing the BCSS database. Further details of this are 
provided in the Methodology section. Specific definitions of the variables and consideration 
of the raw data held in the database are given below. 
 
A.1- Adenoma detection rate 
Adenoma detection rate (ADR) was defined as: 
 Numerator : The number of colonoscopies at which one or more histologically 
confirmed adenomas were found (in a given time period). 
 Denominator: Total number of colonoscopies performed (in the same time period). 
 
Within the context of the BCSP the following rules will apply: 
 Only histologically proven adenomas, the details of which have been uploaded onto 
the BCSP database will be counted. 
 Only first screening colonoscopies will be counted. Surveillance and therapeutic  
procedures will not be included in the analysis. 
 Incomplete (not reached caecum) colonoscopies will be included in the analysis. 
 All colonoscopies fitting the 2 criteria above, regardless of outcome, will be included 
in the denominator count. 
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ADR was calculated (for a predefined time period and colonoscopist or location) using the 
following data fields from the BCSS database: (text in square brackets refers to specific data 
fields in the database). 
 Numerator: Count of colonoscopies where [Count of Adenomas] ≥ 1 
 Denominator: Count of colonoscopies performed. 
 Only adenomas were counted-  [Count of Adenomas] = Number of polyps with 
[Polyp_Type] = adenoma. 
 Only screening colonoscopies were counted-  
[Investigation.Confirmed_Type_of_Test] = Colonoscopy AND 
[Investigation.Episode_Type] = Screening 
 
The following fields were used to define the timeframe, location or colonoscopist. 
 Date of procedure - [Investigation.Confirmed_Date_of_Test} 
 Site of procedure - [Investigation.External_Test_Site_ID] 
 Colonoscopist - [Investigation.External_Test_Consultant_ID] 
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A.2- Colonoscopy withdrawal time 
Colonoscopy withdrawal time (CWT) is defined as the average time taken by a particular 
endoscopist withdrawing the colonoscope from the caecum to extubation from the anus. Only 
procedures which were ‘normal’ (i.e. no therapeutic procedures were undertaken) and at 
which the caecum was reached were be counted in the analysis. Screening or surveillance 
procedures (but not therapeutic procedures) wee included. 
The following data fields are routinely recorded by the Screening Practitioner during the 
procedure and uploaded onto the BCSS database: 
 [Investigation_Colonoscopy.QA_Start_Time] 
 [Investigation_Colonoscopy.QA_Finish_Time] 
 [Investigation_Colonoscopy.QA_Withdrawal_Time]- This field will be used to 
calculate the mean CWT. 
 
The following rules will apply to which colonoscopies are included: 
Screening or Surveillance subject episodes only – [Investigation.Episode_Type] = Screening 
or Surveillance. 
 Subjects who had a colonoscopy - [Investigation.Confirmed_Type_Of_Test] = 
Colonoscopy. 
 
 Where the colonoscopy was complete - [Investigation_colonoscopy.QA_Extent] = 
Caecum, Ileum or Appendix. 
 
 Where the result of the colonoscopy was normal – 
[Investigation.Diagnostic_test_result] = Normal 
 
 Confirm that the result of the colonoscopy was normal – [Investigation_colonoscopy. 
Number_Polyps_Resected] = 0 or blank 
 
The following fields were used to define the timeframe, location or colonoscopist. 
 Date of procedure - [Investigation.Confirmed_Date_of_Test} 
 Site of procedure - [Investigation.External_Test_Site_ID] 
 Colonoscopist - [Investigation.External_Test_Consultant_ID] 
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A.3- Caecal intubation rate 
Caecal intubation rate (CIR) was defined as: 
 Numerator – Number of colonoscopies at which the caecum or terminal ileum was 
reached in a stated period. 
 Denominator – Total number of colonoscopies performed in the same period. 
 
Screening practitioners record the completeness of the colonoscopy during the procedure and 
upload this onto the Database. An ‘intention to reach caecum’ approach was used. All failures 
were counted regardless of the reason. 
Both screening and surveillance colonoscopies were be included. Only subjects who had one 
test in each screening round were included (to avoid counting repeat procedures). 
The following fields on the BCSS database were used: 
Extent of procedure – [Investigation_Colonoscopy.QA_Extent] = caecum, appendix or ileum. 
 
The following rules will apply to which colonoscopies are included in the analysis: 
 Screening and surveillance subject episodes – [Investigation.Episode_Type] = 
Screening or Surveillance. 
 
 Subjects who had a colonoscopy- [Investigation.Confirmed_Type_Of_Test] = 
Colonoscopy 
 
 Where the subject only had 1 procedure in the episode  - Where count of 
[Confirmed_Type_Of_Test] = 1 per [Episode_ID] 
 
The following fields will be used to define the timeframe, location or colonosocpist. 
 Date of procedure - [Investigation.Confirmed_Date_of_Test} 
 Site of procedure - [Investigation.External_Test_Site_ID] 
 Colonoscopist - [Investigation.External_Test_Consultant_ID] 
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A.4- Rectal retroversion 
Rectal retroversion is a recommended procedure to ensure lesion at the anorectal junction are 
not missed. It is a marker of completeness of the colonoscopic examination. 
All screening and surveillance colonoscopies were included in this analysis. Only subjects 
undergoing one colonoscopy in each round were included to avoid double counting repeat 
procedures. 
Rectal retroversion rate was defined as: 
 Numerator – Number of colonoscopies during which rectal retroversion is performed 
 Denominator – Total number of colonoscopies performed. 
 
The following database field was used for the numerator; 
 Was retroversion performed? - [QA_Retro] = Yes 
 
The following rules will apply to which colonoscopies are included in the analysis: 
 Screening and surveillance subject episodes – [Investigation.Episode_Type] = 
Screening or Surveillance. 
 Subjects who had a colonoscopy- [Investigation.Confirmed_Type_Of_Test] = 
Colonoscopy 
 Where the subject only had 1 procedure in the episode  - Where count of 
[Confirmed_Type_Of_Test] = 1 per [Episode_ID] 
 
The following fields were used to define the timeframe, location or colonoscopist. 
 Date of procedure - [Investigation.Confirmed_Date_of_Test} 
 Site of procedure - [Investigation.External_Test_Site_ID] 
 Colonoscopist - [Investigation.External_Test_Consultant_ID] 
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A.5- Sedation practices 
Sedation doses used and patient comfort during each colonoscopy are recorded by the 
Screening Practitioner and uploaded on the database. 
All colonoscopies will be included in the analysis in the section. 
The following database fields will be used: (text in square brackets refers to specific data 
fields in the database, text in curly brackets –{}, refers to the variables): 
 Nurse assessment of patient comfort during procedure – [QA_Comfort_Exam] = { No 
or minimal discomfort, Mild discomfort, Moderate discomfort, Severe discomfort} 
 Mean doses of the following drugs used by each colonosocpist 
o Midazolam 
o Fentanyl 
 Number (and proportion) of procedures in which no sedation was used  (ie no 
benzodiazepines or opiates were recorded as having been used). 
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A.6- Patient Comfort 
Nurse reported patient comfort score is recorded contemporaneously by the screening 
practitioner at two points during the patient’s journey through colonoscopy. Firstly ‘during 
the examination' and secondly, ‘in recovery'. 
Patient comfort (or discomfort) is scored on a modified Likert scale as one of 4 options {none 
or minimal discomfort, mild discomfort, moderate discomfort, severe discomfort}. 
Although this is not a validated method of recording patient comfort and the data is limited 
by being nurse- (rather than patient-) reported, the proportion of patients in each category will 
indicate comfort levels in each colonoscopist’s cohort of patients. 
All procedures will be included in the analysis for this quality indicator. 
The following fields will be used: 
 [QA_Comfort_Exam] 
 [QA_Comfort_Recovery] 
 
Patient comfort is graded on the following scale at each time point: 
 {No or minimal discomfort} 
 {Mild discomfort} 
 {Moderate discomfort} 
 {Severe discomfort} 
 
Data will be presented as the percentage of patients in each category per colonoscopist. 
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A.7- Bowel preparation quality 
Adequate bowel preparation is a prerequisite for a high quality colonoscopy. Quality of 
bowel preparation is recorded at the time of colonoscopy and uploaded onto the BCSP 
database. 
The following data field and variables are used: 
 [QA_Bowel_Prep]  
o {Excellent} 
o {Adequate} 
o {Complete examination despite inadequate preparation} 
o {Incomplete examination due to inadequate preparation} 
 
All colonoscopies including screening, surveillance and therapeutic procedures will be 
included. 
Data will be analysed at the following levels: 
 Site of procedure - [Investigation.External_Test_Site_ID] 
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A.8- Adverse events 
Complications are recorded on the BCSP database and classified as either being early or late. 
The following complications are recorded: 
 
Early Complications Late Complications 
Pain Pain 
Hypoxia Haemorrhage 
Bradycardia Perforation of colon 
Iatrogenic hypotension Aspiration pneumonia 
Cardiac arrhythmia Death 
Cardiac arrest Fever and sweats 
Respiratory arrest Bleeding 
Haemorrhage Bleeding requiring 
transfusion 
Perforation of colon Anaphylactic reaction 
Consent refused   
Aspiration pneumonia   
Death   
Withdrawal of consent   
Bleeding   
Bleeding requiring transfusion   
Anaphylactic reaction   
Use of reversal agent  
  
Table 43- Classification of colonoscopy adverse events in the BCSP 
 
The following data fields will be used: 
 [Complication_early] 
 [Complication_late] 
 Was the patient discharged home after the procedure or kept in hospital? - 
[QA_Outcome] – {Discharge Home} or {Unscheduled emergency  hospital 
admission}. 
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Data will be presented as follows: 
 Number of Early complications 
 Number of Late complications 
 Number of times reversal agents (flumazenil or naloxone) were used 
 Number of colonic perforations 
 Number of bleeding episodes ( Number requiring transfusion) 
 30 day mortality. 
 
The classification of adverse events described above has largely been superceded by the 
stratification according to severity described in figure 10. 
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A.9- Polyp Retrieval Rate 
As many polyps as possible should be retrieved once they have been removed to allow 
histological examination to establish the nature of the polyp as this will impact on subsequent 
management. Polyp retrieval relies on adequate technical skills of the colonoscopist and thus 
is a marker of the technical quality of the colonoscopy.  
Polyps which are not retrieved are recorded on the screening database as such. 
Polyps retrieval rate is calculated as follows: 
Numerator:  Number of polyps retrieved  
Denominator: Total number of polyps removed 
 
The following fields are used: 
 Was the polyp retrieved?   [Polyp_Therapy_Success] 
o {Biopsy specimen not retrieved} 
o The number of polyps retrieved (ie the numerator) will be calculated by 
subtracting the number of polyps not retrieved from the total number of polyps 
discovered. 
 
The following rules will apply to which colonoscopies are included in the analysis: 
 Screening and surveillance subject episodes – [Investigation.Episode_Type] = 
Screening or Surveillance. 
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Appendix B- Ethical approval 
 
 
National Research Ethics Service 
 
County Durham & Tees Valley 2 Research Ethics Committee 
The Tatchell Centre 
University Hospital of North Tees 
Piperknowle Road 
Stockton-on-Tees 
TS19 8PE 
 
Telephone: 01642 624164  
Facsimile: 01642 624164 
Email: leigh.pollard@nhs.net 
 
17 September 2009 
 
Dr T Lee 
Endoscopy Research Fellow 
University Hospital of North Tees 
Piperknowle Road 
Stockton-on-Tees      TS19 8PE 
 
Dear Dr Lee 
 
Full title of project:Detection and management of colorectal neoplasia in the 
NHS Bowel Cancer Screening Programme 
 
Thank you for seeking the Committee’s advice about the above project. 
You provided the following documents for consideration: 
Covering letter dated 15 September 2009 
Project Plan dated September 2009 
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This document has been considered by the Chair, who has advised that the project 
does not require ethical review by a NHS Research Ethics Committee.   
This letter should not be interpreted as giving a form of ethical approval to the project 
or any endorsement of the project, but it may be provided to a journal or other body 
as evidence that ethical approval is not required under NHS research governance 
arrangements. 
However, if you, your sponsor/funder or any NHS organisation feels that the project 
should be managed as research and/or that ethical review by a NHS REC is 
essential, please write setting out your reasons and we will be pleased to consider 
further. 
Yours sincerely 
Leigh Pollard 
Committee Co-ordinator
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Appendix C- Dissemination 
 
Efficacy and safety of colonoscopy in the UK NHS Bowel Cancer Screening Programme 
 Published by GUT, 2011 [Epub ahead of print] 
Plenary oral presentation – BSG March 2011 
 Poster – DDW May 2011 
 Oral Presentation – International Coloproctology Forum, Verbier, January 2011  
 
Colonoscopy withdrawal time and adenoma detection rate in screening colonoscopy: 
The optimum average withdrawal time is 10 minutes 
 Pending revisions for Endoscopy February 2012 
Rejected after review by NEJM on January 2011 and Gastrointestinal Endoscopy 
August 2011 
Oral presentation - BSG March 2011 
 Oral presentation - DDW May 2011 
 
Patient and colonoscopy factors influencing adenoma detection in patients undergoing 
colonoscopy in the NHS Bowel Cancer Screening programme 
 Poster – BSG March 2011 
Awarded Best paper presented by a trainee in the surgical section at the BSG 
 Oral presentation - DDW May 2011 
 
12 month surveillance colonoscopy for high risk adenomas in the NHS Bowel Cancer 
Screening Programme 
 Oral presentation - Institute of Health and Society Research Day July 2010 
Oral presentation - Royal Society of Medicine (Coloproctology Section) Overseas 
Meeting, Krakow, Poland, June 2010 
 Poster – BSG March 2010 
 
Management of large colonic polyps in the NHS Bowel Cancer Screening Programme 
Under review, Endoscopy, February 2012 
Oral presentation - BSG March 2011 
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Can we improve on ADR as a measure of colonoscopic quality- MAP and MAP+? 
Oral presentation - BSG March 2011 
 Poster – DDW May 2011 
 
Colorectal Polyp Cancers in the NHS Bowel Cancer Screening Programme.  
Poster - NCRI November 2010  
Shortlisted for the British Oncology Association Young Investigator award. 
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Appendix D- Abbreviations 
ACN Advanced colonic neoplasia 
ADR Adenoma detection rate   
AE Adverse events 
APC Adenomatous polyposis coli 
AS-ADR Age standardised adenoma detection rate 
BCSP Bowel Cancer Screening Programme  
BCSS Bowel Cancer Screening System 
BMI Body mass index 
CI Confidence intervals  
CIR Caecal intubation rate 
COX 2  Cyclo-oxegenase 2 
CRC Colorectal cancer  
CWT Colonoscopy withdrawal time 
EMR Endoscopic mucosal resection  
ESD Endoscopic submucosal dissection 
EUS Endoscopic ultrasound 
FAP Familial adenomatous polyposis 
FOBt Faecal occult blood testing  
GS-ADR Gender standardised adenoma detection rate 
HD High definition 
HGD High Grade dysplasia 
HNPCC Hereditary non polyposis colorectal cancer 
I1-ADR First incident round ADR 
I2 ADR Second incident round ADR 
IBD Inflammatory Bowel Disease 
ICC Intra class correlation coefficient 
IMD Indicies of multiple deprivation 
JAG Join advisory group on endoscopy 
kg kilogram 
LGD Low grade dysplasia 
LSCP Large sessile or flat colonic polyps  
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LSoA Lower Super output Area 
MAP Mean number of adenomas per patient 
MAP+ Mean number of adenomas per positive procedure 
NapComs Nurse assessed patient comfort score  
NBI Narrow band imaging 
NC-CWT Negative complete colonoscopy withdrawal time  
NHS  National Health Service 
N/R Nor recorded 
NSAID Nonsteroidal anti-inflammatory drug 
OR Odds ratio 
P-ADR Prevalent round ADR 
PDR polyp detection rate (PDR)  
PIAG Patient Information Advisory group 
PJS Peutz-Jeghers Syndrome 
PRR Polyp retrieval rate 
PYO Person years of observation 
RCT Randomised control trial 
RR Relative risk 
RRP Residual or recurrent polyp  
RRR Rectal retroversion Rate 
sd Standard deviation  
TEMS Trans-anal Endoscopic Micro-Surgery 
TNM Tumour, Node, Metastases 
uCIR unadjusted Caecal intubation rate 
UK United Kingdom 
USA United States of America 
WHO World Health Organisation 
 
 
 
 
 
